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Chapter 1
INTRA-ABDOMINAL INFeCTION
Abdominal pain
Of all visits to the emergency department 10-15% of patients present with acute 
abdominal pain1,2. A large proportion (38-72%) of patients with acute abdominal pain 
are admitted to the hospital3-5. The cause of abdominal pain can range from self-limiting 
to life threatening disease. Other complaints in the presence of abdominal pain are 
usually anorexia, vomiting, diarrhoea and constipation. Clinical findings include fever or 
hypothermia, tachycardia, tachypnea, decreased bowel sounds, abdominal tenderness 
or guarding. Diffuse abdominal pain and generalised tenderness are often symptoms of 
intra-abdominal infection. Approximately in half of patients abdominal pain, as presented 
in the emergency department, is caused by infection4. 
Peritonitis
The abdominal cavity is a sterile compartment which is covered by a mesothelial 
membrane surrounding the abdominal viscera: the peritoneum. Intra-abdominal infection 
refers to the inflammatory responses of the body in response to inflammation (without 
bacteria) or infection (with bacteria) within the abdomen. Whether bacterial contamination 
will transform to intra-abdominal infection depends on bacterial pathogenicity and host 
defence mechanisms6. Many different diseases can cause the activation of the immune 
system leading to inflammation of the peritoneum (peritonitis). 
Primary peritonitis describes infection of the peritoneum caused by bacteria from a source 
outside the abdomen, usually bacteria from the bloodstream entering the peritoneal 
cavity. 
More common is secondary peritonitis which results from an infection inside the 
abdominal compartment. Common causes of secondary peritonitis are perforation of the 
gastrointestinal tract (58%), postoperative anastomotic leakage (27%), ischemia (6%) and 
inflammation (4%). Perforation is localised in the lower gastrointestinal tract (64%), upper 
gastrointestinal tract (25%), or appendix (2%)7. When anatomical disruption of an organ is 
present it is considered a complicated intra-abdominal infection. 
Classification of peritonitis
Peritonitis is mainly classified depending on the extent of contamination of the peritoneal 
cavity. A unique defence mechanism is present in the peritoneal cavity designed to 
confine the infection which can lead to intra-abdominal abscess formation. When only 
a part of the peritoneum is affected due to nearby inflammation of an organ or abscess 
this will cause mild symptoms. In cases of inflammation of the total abdominal cavity 
(generalised peritonitis), as a rule patients will experience more complaints. In most 
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1classifications purulent peritonitis is discriminated from faecal peritonitis. This because the latter can only be explained by perforation of the bowel with accessory high 
bacterial load. Available classification systems are the Mannheim Peritonitis Index, the 
left colonic Peritonitis Severity Score (PSS) and the Hinchey classification for perforated 
diverticulitis8-10. Classification of peritonitis can be useful because it may guide treatment 
and enables research. 
Abdominal sepsis 
The immune response to invasion of the abdominal cavity by micro-organisms is a 
complex network of pro-and anti-inflammatory cascades. When the immune system 
does not resolve the infection progression of the infection to the systemic circulation can 
progress to sepsis. Common signs are fever, tachycardia, tachypnea, decreased urine 
production and confusion. Due to decreased systemic vascular resistance hypotension 
and subsequent shock can occur. When shock is not treated adequately this can lead to 
multi organ failure and even death.
Primary treatment of sepsis consists of intravenous fluids and antibiotics followed by 
elimination of the source of infection. In case of abdominal sepsis contained abscesses can 
be drained percutaneously. When peritoneal contamination has lead to purulent or faecal 
peritonitis surgical treatment is warranted. Depending on the condition of the patient 
surgery can comprise short damage-control surgery or lengthy complex surgery with 
anastomosis of the bowel after resection. Despite considerable improvement in antibiotic 
treatment, intensive care capacity and treatment options mortality is still between 9% and 
30% in patients with abdominal sepsis11,12.
DIVeRTICULITIS
Apart from appendicitis, one of the most frequent causes of abdominal infection is 
represented by diverticulitis. In the Netherlands colonic diverticular disease leads to over 
18.000 hospital admissions per year13. This disease comprises many different conditions: 
from asymptomatic diverticulosis to perforated diverticulitis with systemic sepsis.
Pathogenesis of diverticular disease
Diverticula arise at the point where the vasa recta penetrate the colonic wall to supply 
blood to the mucosa of the colon14. This weak point is where the mucosa and submucosa 
protrude through the muscle layer of the colonic wall. Pathogenesis of diverticulosis has 
not been conclusively established. Many theories on the development of diverticulosis 
have been proposed, including dietary habits, medicine use, motility disorders of the 
colon and collagen abnormalities of the colonic wall15. The prevalence of diverticulosis 
is estimated at 5% by the age of fourty years and increases with age up to 50-70% in 
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octogenarians16,17. Most people with diverticulosis remain asymptomatic18,19. Symptoms 
of diverticular disease include change of bowel habit, abdominal pain, symptoms of 
inflammation, diverticular bleeding and fistula formation. 
Diverticulitis is the result of diverticular inflammation. There are several theories about 
the pathogenesis. It was believed that fecalith obstruction leads to an increased pressure 
of the diverticular sac with bacterial overgrowth, resulting in necrosis and perforation 
of the diverticulum. More recent studies suggest low-grade inflammation as a form 
of inflammatory bowel disorder and possible changes in colon flora in patients with 
diverticulitis20. Of all patients with an episode of acute diverticulitis only 25% present 
with complicated disease including abscess formation, fistula, obstruction or perforated 
disease with peritonitis.
Classification and diagnosis of diverticulitis
Several grading systems exist for acute diverticulitis of which the Hinchey Classification 
is still mostly used. Edward Hinchey proposed to differentiate according to the intra-
operative degree of abdominal contamination8. In current practice clinical evaluation 
alone seems inadequate to make a diagnosis of diverticulitis and adequately grade 
diverticulitis therefore radiological investigation is performed in most cases21-23. Based on 
radiological finding patients may be selected for conservative treatment of complicated 
diverticulitis. It is of great importance to differentiate between uncomplicated and 
complicated diverticulitis in patients because of the high morbidity and mortality in case 
of perforation24,25. 
In Chapter 2 the accuracy of preoperative staging of perforated diverticulitis by CT 
scanning is investigated. 
Operative treatment of diverticulitis
The treatment of diverticular disease depends on the severity of the disease. In case 
of complicated diverticular disease operative treatment is mostly the treatment of 
choice. Since the beginning of the previous century, a three-stage operation strategy 
was common practice. A preliminary transverse colostomy was advised with a period of 
three to six months delay before resection of the inflamed sigmoid. The rationale for this 
strategy was that primary resection was too difficult and hazardous during the acute stage 
of the disease. After several months, the second stage - resection of the involved bowel - 
could be performed to treat and prevent relapse. The third stage involved reconstruction 
of the bowel with reversal of the colostomy after several months of recovery. Mortality 
rates were high when using this complex treatment strategy. The conviction arose that 
the colonic segment with the perforation had to be resected immediately eliminating the 
remaining source of infection in the peritoneal cavity. Subsequently a two-stage operation 
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1i.e. Hartmann’s procedure, became the preferred surgical strategy, although Henri Hartmann had only developed his operation for rectal carcinoma originally. During the 
Hartmann’s procedure sigmoid colectomy with subsequent colostomy is considered the 
first step, the second stage being represented by the colostomy closure. This treatment 
strategy remained the treatment of choice for decades.
Improvement in surgical and radiological intervention techniques and progress in the 
management of peritoneal sepsis have resulted in increasing interest in colonic resection 
with direct construction of bowel continuity since the 1990s. However, fear of anastomotic 
leakage often deters many surgeons from performing a one-stage procedure with primary 
anastomosis under conditions of generalised peritonitis.
In 1996, a new nonresectional laparoscopic approach was described26. In patients with 
purulent peritonitis without gross fecal contamination (Hinchey III), only laparoscopic 
peritoneal lavage, inspection of the colon, and the placement of abdominal drains 
appeared to diminish morbidity and improve outcome26-28. 
In Chapter 3 a narrative review on treatment options for perforated diverticulitis is 
presented. 
In 2008 the results of a first large series was published on patients treated by laparoscopic 
lavage and drainage of the abdominal cavity without colonic resection in case of purulent 
peritonitis29. 
In Chapter 4 the early experience of Dutch surgeons with laparoscopic peritoneal lavage 
for complicated diverticulitis in a historical series is investigated. 
To confirm the published success rates of laparoscopic lavage a multicentre randomised 
controlled trial on operative treatment strategies for perforated diverticulitis was initiated. 
The LADIES-trial is a joint initiative between the LOLA-trial, which compares laparoscopic 
lavage and drainage with resectional surgery in purulent peritonitis, and the DIVA-trial, 
which compares Hartmann’s procedure with sigmoid resection with primary anastomosis 
in purulent or faecal peritonitis. 
In Chapter 5 the study protocol of the LADIES-trial is described. 
In Chapter 6 the clinical results of the surgical treatment with laparoscopic lavage of this 
randomised trial are reported. 
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Guidelines on treatment of diverticulitis
The diagnosis and treatment of diverticulitis are marked by many speculatives and 
dogmas. In recent years research on diverticulitis is extensively performed and published. 
In Chapter 7 the Dutch National Guidelines for diagnosis and treatment of acute colonic 
diverticulitis is summarised. The guidelines are based on an evidence-based review of 
the literature by a multidisciplinary workgroup initiated by the Dutch Society of Surgery. 
TReATMeNT OF COMPLICATIONS FOLLOWING INTRA-
ABDOMINAL INFeCTION
Abdominal surgery
If patients require surgical treatment for perforated diverticulitis they are mainly operated 
via open surgery, although experience with laparoscopic surgery is increasing. Open 
surgery is mostly performed by opening the midline of the abdominal wall through the 
linea alba. Following surgery the wound edges of this avascular plane of the abdominal 
wall are sutured back together. 
Incisional hernia
When healing of this incision fails an incisional hernia will develop. This is defined as 
an abdominal wall gap with or without a bulge in the area of a postoperative scar30. 
Incisional hernia is one of the most frequent complications following abdominal surgery 
with an incidence of 10-20% after a ten year follow-up31-34. Perforated diverticulitis leads 
to purulent or faecal peritonitis with high bacterial load with increased risk of surgical site 
infection and compromised wound healing35.
Incisional hernia repair
Due to the experienced pain or discomfort, risk of strangulation of herniated bowel and 
negative impact on quality of life, repair of incisional hernia is often performed36,37. Primary 
suture repair of large abdominal defects resulted in a recurrence rate of up to 63%38.When 
a mesh is used during hernia repair to reinforce the abdominal wall recurrence rates of 
herniation is reduced by 50%39. Mesh repair is considered the gold standard, however the 
performed technique and mesh material are far from standardised until now. 
Complications following incisional hernia repair
Implantation of meshes can be complicated by mesh infection, erosion, shrinkage and 
adhesion formation. Mesh infection is a feared complication and reported in up to 16% 
of patients after hernia repair40. Failure of the hernia repair is influenced by many factors 
such as mesh material. Therefore many modifications to the mesh have been made to 
optimize biocompatibility and reduce complications.
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1Currently non-resorbable synthetic materials are the most commonly used prosthesis for reinforcement of ventral hernias. Advantages of synthetic meshes are low recurrence 
rates, ease of use and relatively low costs. Infection of the mesh might be reduced in 
macroporous meshes because large pores permit infiltration of macrophages and allow 
rapid fibroplasia and angiogenesis, with reduced infiltration and growth of bacteria41,42. 
The drawback of macroporous meshes is the increased risk of visceral adhesions to the site 
of the repair41,43,44. To reduce adhesion formation antiadhesive coatings have been added 
to synthetic meshes with positive results44-46. Mesh infection often necessitates removal 
of the mesh, which leaves the patient with a contaminated field and an abdominal wall 
deficit that is often larger than the original hernia which makes the use of synthetic mesh 
debatable47,48.
In case of high risk of infection at the surgical site a biological mesh is recommended 
for ventral hernia repair49. The risk is significantly increased in incisional hernias type 
III and IV (Working Group Incisional Hernia of the European Hernia Society) as often 
is the case after operations for perforated diverticulitis of the colon. Biological meshes 
are extracellular scaffolds, processed from animal (bovine or porcine) small intestine 
submucosa, pericardium, or dermis. The donor tissue is said to be cleared of cells and 
immunogenic particles, after which a scaffold of extracellular matrix (ECM) remains. 
After implantation the scaffold is gradually vascularized and remodeled into the host 
tissue while degradation of the ECM takes place50,51. To increase biomechanical strength 
chemical crosslinking of the biological mesh can be conducted. Crosslinking stabilizes the 
3-dimensional structure of the ECM. This improves withstanding of the ECM’s enzymatic 
degradation, which can be accelerated by inflammation or infection at the implantation 
site52-54. 
In Chapter 8 infection rate, adhesion formation, incorporation and shrinkage of synthetic 
and biological meshes after implantation in a contaminated environment are compared.
In Chapters 9 and 10 the infectious complications and functional outcome of crosslinked 
and non-crosslinked biological meshes in a contaminated environment and clean 
environment are investigated, respectively.
Adhesion formation
Intraperitoneal adhesion formation remains a major clinical problem with an incidence 
up to 93% after abdominal surgery55. Adhesions are considered a physiologic response 
to surgical trauma or infection like perforated diverticulitis56,57. However postoperative 
adhesions result in an increased risk of small bowel obstruction, chronic abdominal pain, 
infertility and inadvertent bowel injuries at future operations58. To prevent formation of 
adhesions surgical techniques are adjusted to reduce tissue injury, such as the introduction 
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of laparoscopic surgery. Furthermore intra-abdominally positioning of various barriers 
have been studied. 
In Chapter 11 the influence of a new adhesion barrier on the formation of adhesions in a 
peritonitis rat model is evaluated. 
In Chapter 12 the results of the studies in this thesis are discussed and future perspectives 
are described.
In Chapter 13 and 14 the results of the studies are summarised in the English and Dutch 
language, respectively.
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ABSTRACT
Background
Treatment of perforated diverticulitis depends on disease severity classified according to 
Hinchey’s preoperative classification. This study assessed the accuracy of preoperative 
staging of perforated diverticulitis by computerized tomography (CT) scanning.
Methods
All patients were included who presented with perforated diverticulitis between 1999 
and 2009 in two teaching hospitals of Rotterdam, the Netherlands, and in addition had a 
preoperative CT scan within 24 h before emergency surgery. Two radiologists reviewed all 
CT scans and were asked to classify the severity of the disease according to the Hinchey 
classification. The CT classification was compared to Hinchey’s classification at surgery.
Results
Seventy-five patients were included, 48 of whom (64%) were classified Hinchey 3 or 4 
perforated diverticulitis during surgery. The positive predictive value of preoperative 
CT scanning for different stages of perforated diverticulitis ranged from 45 to 89%, and 
accuracy was between 71 and 92%. The combination of a large amount of free intra-
abdominal air and fluid was strongly associated with Hinchey 3 or 4 and therefore 
represented a reliable indicator for required surgical treatment.
Conclusions
The accuracy of predicting Hinchey’s classification by preoperative CT scanning is not 
very high. Nonetheless, free intra-abdominal air in combination with diffuse fluid is a 
reliable indication for surgery as it is strongly associated with perforated diverticulitis 
with generalized peritonitis. In 42% of cases, Hinchey 3 perforated diverticulitis is falsely 
classified as Hinchey 1 or 2 by CT scanning.
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INTRODUCTION
Diverticular disease has become more prevalent in Western countries1. About 10–25% 
of individuals with diverticulosis will develop symptomatic diverticulitis, and of these, 
15% will develop significant complications, such as perforation2. Although the absolute 
prevalence of perforated diverticulitis complicated by generalized peritonitis is low, its 
importance lies in the significant postoperative mortality, ranging from 4 to 26% regardless 
of the surgical strategy selected3,4. The optimal treatment for perforated diverticulitis is 
still a matter of debate5.
Optimal treatment strategies are based on disease severity as classified by Hinchey (Table 
1)6. Today, a conservative treatment with antibiotics (and abscess drainage) is advocated 
for Hinchey 1 and 2 perforated diverticulitis7. Patients presenting with perforated 
diverticulitis with generalized peritonitis (Hinchey 3 and 4) should undergo emergency 
surgical treatment. Laparoscopic peritoneal lavage without resection of the affected 
bowel segment in patients with purulent peritonitis (Hinchey 3) appears to diminish the 
morbidity and improve outcome8-10, whereas acute resection should be performed in 
patients with gross fecal peritonitis (Hinchey stage 4)9.
Unfortunately, (the modified) Hinchey’s classification is based on clinical findings during 
surgery. Ideally, one should be informed about the severity of the disease to optimize 
treatment strategy. Today, computed tomography (CT) scanning is the modality of 
choice in the assessment and management of diverticulitis with its high sensitivity and 
specificity11-15. With CT-guided percutaneous abscess drainage (PCD), it has also become 
an important therapeutic modality11-16. The CT-based classification by Hansen– Stock can 
be used as a classification system and accounts for asymptomatic diverticulosis as well 
as complicated diverticulitis in different stages, including perforation17. Nevertheless, the 
degree of peritonitis—and hence the severity of disease—in perforated diverticulitis can 
be represented best by the modified Hinchey’s classification.
The aim of this study was to assess the accuracy of preoperative CT scanning in predicting 
the stage of severity of perforated diverticulitis. The CT findings are compared with the 
clinical findings during surgery classified according to the Hinchey classification6.
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MATeRIALS AND MeThODS
All patients who underwent emergency surgery for perforated diverticulitis between January 
1999 and January 2009 at the Erasmus University Medical Centre and Maasstad Hospital 
in Rotterdam, the Netherlands, were selected from computerized surgery registration 
databases. After patient selection was completed, predetermined parameters were 
extracted from medical records and the computerized patient’s registration databases. 
The indication for surgery was based on clinical and radiological findings. Only patients 
who underwent preoperative CT scanning within 24 h before emergency surgery were 
included in this study, because clinical evolution could disturb comparability between 
radiologic and surgical findings, when the interval is longer. Patient characteristics, 
preoperative findings, for example, Hinchey classification, Mannheim Peritonitis Index, 
specific findings on CT scan, and postoperative outcome were registered and analyzed.
A total of 158 consecutive patients underwent emergency surgery for perforated 
diverticulitis during the study period. Forty-six patients were excluded from analysis 
because they underwent emergency surgery without the performance of a preoperative 
CT. These patients were operated on based on clinical assessment only (n=24), free 
intraperitoneal air on plain radiography (n=16), or specific findings during ultrasound 
(n=6). Another 37 patients were excluded because time of scanning was more than 24 
h before surgery (median 3 days, range 2–50 days). The remaining 75 patients were 
included in the study, and the characteristics of these patients are listed in Table 2.
All preoperative CT scans were independently reviewed by a consultant radiologist and 
a senior radiology resident. Both were asked to classify disease severity according to the 
Hinchey classification (Table 1). Features recorded by the radiologist were, among others, 
thickness of bowel wall, number of diverticula, pericolic inflammation, stenosis, amount 
and location of free intraperitoneal air, fluid, and/or abscesses. Based on these features, 
Table 1. The modified Hinchey classification of perforated diverticulitis.
Hinchey classification Clinical features
0 Mild clinical diverticulitis
1 a Confined pericolic inflammation or phlegmon 
   b Confined pericolic abscess
2 Pelvic, intra-abdominal, or retrocolic abscess
3 Generalized purulent peritonitis
4 Generalized fecal peritonitis
In the original Hinchey classification, Hinchey 1a and 1b were combined
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they were asked to grade the severity of disease subjectively according to Hinchey’s 
classification. Both radiologists were blinded to the patients’ surgical and pathological 
findings at the time of CT review. If there was any discrepancy in the radiologists’ 
evaluations, a consultation between them took place so that they could come to a final 
agreement. Different types of CT scanners were used ranging from single-slice to 64-slice 
dual-source scanners. CT-examinations performed after 2001 at the Erasmus University 
and after 2006 at the Maasstad Hospital could be digitally analyzed. Different imaging 
protocols were used, and slice thickness varied between 3 and 8 mm. The contrast agent 
used was intravenous, oral, and/or rectal.
ReSULTS
Sixty-six patients (88%) received intravenous contrast, and 15 of them (20%) received 
rectal contrast at the same time. Nine patients (12%) underwent CT scanning without 
contrast. The location of the diverticular diseases was located in the sigmoid colon in 72 
patients (96%), in the descending colon in 16 patients (21%), and in the transverse colon 
in 2 patients (3%). Extra luminal air was found in 47 patients (64%), and abscesses were 
found in 41 (55%) patients. CT scanning showed bowel obstruction in one patient. No 
fistula formation was observed. Median colonic thickness was 9 mm (range 2–20 mm).
Comparison of findings during surgery (gold standard) and CT findings regarding Hinchey 
classification is shown in Table 3. The inter-observer agreement for scoring Hinchey was 
high with a discrepancy rate of 7% (5/75). Final agreement was reached in the 5 cases that 
initially were differently scored by the radiologists. In all cases, the initial conclusion of the 
consultant radiologist was chosen.
Table 2. Patient characteristics.
Characteristics
Gender (male/female) 30/45 (40/60%)
Hospital (Erasmus/ Maasstad) 38/37 (51/49%)
Age Median 63 years (range 23-89) 
ASA I 13 (17%)
        II 25 (33%)
        III 27 (36%)
        IV 10 (13%)
MPI Median 19 (range 5-39)
Values in parentheses are percentages unless indicated otherwise. 
ASA American Society of Anaesthesiologist classification, MPI Mannheim Peritonitis Index 
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Forty-eight of the 75 patients (64%) were correctly staged by CT scanning in accordance 
with the Hinchey classification. Based on the results, sensitivity, specificity, positive 
predictive values (=precision of CT), and accuracy of CT were calculated for all stages 
of disease (Table 3). The use of rectal contrast did not significantly increase the accuracy 
of CT scanning (correctly staged with rectal contrast: 62%, without rectal contrast: 73%; 
P=0.55). Stratifying the patients according to time intervals (within 12 h and between 
12 and 24 h before surgery) did not change the result (correctly staged with 12 h: 62%, 
between 12 and 24 h: 66%: P=0.81). In Table 4, distribution of specific CT features is listed 
for the different Hinchey stages found during surgery. Signs of diffuse intraperitoneal 
fluid on CT scans are not seen in Hinchey 1 and 2 patients (both 0%). Nevertheless, free 
intraperitoneal fluid is not pathogmonomic for Hinchey 3 or 4 perforated diverticulitis, 
as it is only seen on CT scans in 38 and 56% of cases, respectively. Intraperitoneal air 
in different amounts is found in almost all stages of perforated diverticulitis (75–100%). 
The combination of diffuse free air and intra-abdominal fluid is strongly associated with 
Hinchey 3 and 4 (positive predictive value: 80 percent). The positive predictive value of 
CT scanning for perforated diverticulitis that requires surgical treatment (e.g., Hinchey 3 
and 4) is 94%. Unfortunately, the negative predictive value is only 61%.
Table 3. Hinchey classification according to CT imaging compared to the true findings during 
surgery for perforated diverticulitis.
Hinchey classification 
according to CT-scan
Hinchey classification 
at surgery
1 2 3 4
1 13 1b 7b --
2 2a 9 9b --
3 2a -- 16 --
4 -- -- 6a 10
Performance of CT-scan
Sensitivity (%) 76 90 42 100
Specificity (%) 86 83 95 91
Positive predictive value (%) 62 45 89 63
Negative predictive value (%) 93 98 61 100
Accuracy (%) 84 85 71 92
a overstaged | b understaged | The numbers that are underlined refer to the patients that are 
correctly classified by preoperative CT | The numbers that are italicized refer to the patient that are 
incorrectly classified by preoperatieve CT | CT computed tomography
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DISCUSSION
The optimal treatment strategy for perforated diverticulitis depends on the severity of 
disease classified according to Hinchey’s classification18. Ideally, perforated diverticulitis is 
adequately staged before surgery in order that the optimal treatment strategy (antibiotics, 
abscess drainage, surgery) can be chosen. In recent years, CT scanning has become the 
imaging modality of choice to determine the extent of the disease and surgeons tend to 
rely more frequently on the CT findings to decide upon further treatment.
The present study shows that CT scanning has a high specificity for Hinchey 3 and 4 
perforated diverticulitis (95 and 91%, respectively). This means that when the radiologist 
diagnoses Hinchey 3 or 4 diverticulitis, this compares well with the true findings, and 
hence, emergency surgery is indicated. The positive predictive value for surgery is 
94%, which is excellent. Nevertheless, sensitivity for Hinchey 3 is low (42%), meaning 
that a significant number of patients with Hinchey 3 diverticulitis are understaged (as 
Hinchey 1 or 2) by retrospective assessment of the CT scan. The main reason for this 
discrepancy was the relatively small amount of free intra-abdominal pus found during 
surgery. This can easily be missed on an emergency CT scan (Figure 1). Another reason 
for the relatively high number of misclassifications of Hinchey 3 perforated diverticulitis 
by preoperative CT scanning could be rupture of a diverticular abscess, in which Hinchey 
2 perforated diverticulitis found on the CT scan has proceeded toward Hinchey 3 at the 
time of surgery19. It is therefore possible that future patients who undergo CT scanning 
are classified as Hinchey 1 or 2 perforated diverticulitis and are treated according to 
these CT findings (that is conservatively), are in reality Hinchey 3 patients (n=16/41; 39% 
of Hinchey 1 and 2 cases; Table 3), and should have been treated surgically. It seems 
that only Hinchey 4 perforated diverticulitis is excellently staged by CT scanning. The 
conclusion after the radiologists’ report will always be that emergency surgery is indicated 
in these patients. Due to the low sensitivity of CT scanning in Hinchey 3 patients, the 
predictive value of CT for conservative treatment is only 61%.
Table 4. Specific computed tomography findings compared to true findings during surgery 
(Hinchey classification) in patients with perforated diverticulitis.
hinchey 
classification 
at surgery
Free 
intraperitoneal 
air (%)
Loculated 
gas bubbles 
(%)
Diffuse 
intraperitoneal 
fluid (%)
Abscess 
(%)
Pericolic fluid 
collection (%)
1 25 50 0 30 15
2 35 65 0 100 50
3 66 33 38 47 56
4 100 0 53 30 29
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The inter-observer agreement for scoring Hinchey was high. In 5 cases, the consultant 
radiologist convinced the resident to revise her conclusion. In daily practice, and especially 
during night shifts, the CT scan is first read by the radiology resident. If necessary, the 
original reading is changed by the consultant radiologist, who will see the CT only the 
day after. The relative inexperience by the residents could lead to over- or undertreating 
a patient with perforated diverticulitis who undergoes a CT scan. Although in this study 
overtreatment or undertreatment was not caused by this phenomenon, we recommend 
a dedicated consultant radiologist to read all CT scans performed on patients in this 
category.
Lohrmann et al. previously investigated the value of CT scanning in diverticular disease14. 
They stated that CT scanning correctly determined Hinchey stage in 93% of patients. 
Unfortunately, only 7 patients were found to have Hinchey 3 or 4 perforated diverticulitis 
(CT sensitivity of 71% in this subgroup). This suggests that the study was based on a 
heterogeneous group of patients, only a few of whom had perforated diverticulitis with 
peritonitis.
Ritz et al. conclude in their study on 204 patients who had undergone surgery for 
diverticular disease that CT scanning is an accurate modality for staging this disease15. 
The positive predictive value of CT scanning compares well with the results of this present 
study, especially the positive predictive value of perforated diverticulitis Hinchey 3 and 
4 (100 and 94%). Unfortunately, surgery was performed within 24 h after CT scanning in 
only 42 patients (21%). In all other patients, elective surgery was performed after a mean 
of almost 7 days of initial conservative therapy with antibiotics or percutaneous abscess 
drainage. No new CT scan was performed prior to elective surgery; hence, clinical 
evolution could have disturbed comparability between radiologic and surgical findings.
Figure 1. Preoperative CT image without evident signs of free fluid or generalized peritonitis of 
a patient who appeared to have Hinchey 3 perforated diverticulitis during surgery. A free air; B 
bladder; C colonic diverticulum
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The present study exclusively covers patients with perforated diverticulitis. Nevertheless, 
36% of the patients studied who underwent surgery appeared to have Hinchey 1 or 2 
during surgery (Table 4; n=27). Twenty-five of these patients were ‘proven’ Hinchey 1 
or 2 by preoperative CT scanning, but the indication for emergency surgical treatment 
was set by the surgeon on call who probably doubted the CT report in combination 
with the clinical symptoms (sepsis, acute abdomen). These patients could conceivably be 
treated conservatively instead if preoperative (CT) assessment had 100% accuracy. Even 
if subjective ‘clinical’ signs of acute abdomen are present or objective findings of small 
amounts of free air are present on CT (75% of Hinchey 1 patients and 90% of Hinchey 
2 patients; Table 3), true Hinchey 1 and 2 patients can be treated conservatively with 
antibiotics and analgesics18. If this conservative treatment fails, surgical intervention is 
indicated.
The combination of free air and intra-abdominal fluid seen on the CT scan correlated 
well with Hinchey 3 and 4 perforated diverticulitis as found during surgery, and these are 
the main findings the radiologists used to for the CTbased diagnosis of Hinchey 3 or 4. 
Only very few patients with a CT scan diagnosis of Hinchey 3 or 4 diverticulitis appear 
to have a stage of disease during surgery that might have been treated successfully 
without surgery. In other words, large amounts of free air and free fluid are indications for 
emergency surgery.
Preoperative differentiation between Hinchey stage 3 and 4 is not very important, as 
both need emergency surgical treatment. Nevertheless, it could be useful in deciding 
on the surgical approach5. In case of purulent peritonitis (Hinchey 3), laparoscopic 
peritoneal lavage and drainage without resection of the affected bowel segment has 
shown excellent results10. In case of fecal peritonitis, laparotomy is recommended for 
resection of the affected bowel segment5. Unfortunately, the present study shows that 
preoperative differentiation between Hinchey 3 and Hinchey 4 is not possible with CT 
scanning. It is therefore advisable to perform diagnostic laparoscopy, when the CT scan 
shows large amounts of free air and fluid (CT Hinchey 3/4). When purulent peritonitis 
is found, laparoscopic treatment could be performed. In case of fecal spill, conversion 
toward laparotomy is indicated.
CT technology has evolved rapidly in the past decades and will continue to do so in the 
future. In previous studies, CT scanning could only visualize bowel wall discontinuity in a 
minority of patients with proven bowel perforation14. Thanks to advances in technology, 
multidetector row CT scanners are able to visualize the site and size of the perforation 
more accurately20-22. This additional information would be helpful in deciding on the 
appropriate surgical technique. In Hinchey 3 perforated diverticulitis, most of times the 
perforation has been sealed by omentum. In case of Hinchey 4 diverticulitis, an overt 
perforation is found, causing a fecal spillage. 
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CONCLUSIONS
Current CT scanning does not seem to suffice to accurately predict the severity of 
perforated diverticulitis according to Hinchey’s classification21. Nevertheless, specific 
findings on CT like the combination of a large amount of free intraperitoneal air and 
diffuse intraperitoneal fluid are a good predictor for Hinchey 3 or 4 diverticulitis and 
mandate surgical intervention. Diagnostic laparoscopy is advised in these patients to 
distinguish between purulent or fecal peritonitis. To date, distinction between Hinchey 
3 and 4 with preoperative CT scanning is not possible. Diagnosis of Hinchey 1 or 2 
perforated diverticulitis after CT assessment is not reliable, as 39% of these patients 
are in fact Hinchey 3 patients for whom surgery is indicated. In the absence of free 
intraperitoneal air, conservative treatment is justifiable. A prospective study is warranted 
to confirm our statements.
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INTRODUCTION
Diverticular disease is one of the most common diseases of the gastrointestinal (GI) 
tract requiring in-hospital treatment in Western countries. Despite its high incidence, 
controversies remain about the optimal treatment of the different stages of this disease.
Most people with diverticular disease remain asymptomatic; however, approximately 
15% develop symptoms, and of these, 15% will develop significant complications 
such as perforation1. Although the absolute prevalence of perforated diverticulitis 
(PD) complicated by generalized peritonitis is low, its importance lies in the significant 
postoperative mortality rate, ranging from 4–26%2-4. Owing to the low prevalence of 
generalized peritonitis due to perforated diverticulitis (GPPD), strategies for the treatment 
of this stage of diverticulitis are even less thoroughly investigated. There are two major 
reasons for this.
Firstly, in the pathogenesis of diverticular disease, diverticulitis and perforation seem to 
have multifactorial origins, including lifelong dietary habits, medicine use, coexistence of 
other bowel or collagen-related diseases, and genetic influences. This complex interaction 
of factors makes it very difficult to investigate. Nevertheless, fundamental epidemiological 
research is warranted to assess the etiology of this disease and subsequently to develop 
prevention strategies.
Secondly, although uncomplicated diverticulitis is a common GI disease, the incidence 
of PD is relatively low (fewer than four cases per 100 000)3. Owing to this low incidence, 
it is difficult to design and successfully complete randomized controlled trials to assess 
optimal treatment strategies. Operations for PD are classified as emergency and may be 
performed outside office hours, rendering it even more difficult to start such trials.
Nevertheless, the consequences of this disease for general healthcare and for the patients 
in particular are enormous, as it is accompanied by high morbidity and mortality rates 
and poor quality of life having survived the event. Healthcare costs are significant owing 
to long periods of intensive care and overall hospital stay, the high rate of additional 
interventions or operations to treat complications, and outpatient stoma care5. 
eTIOLOGy
The prevalence of diverticulosis is estimated at 5% by the age of 40 years and up to 50–
70% at 80 years of age1,6. Its exact prevalence is difficult to assess because most people 
remain asymptomatic1. Only about 15% of patients with diverticulosis will manifest any 
related clinical symptoms1,7. Approximately 80% of patients presenting with PD do not 
have a previous history of diverticular disease8.
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The pathogenesis of this disease process is probably multifactorial involving dietary 
habits (low fiber), changes in colonic pressure, motility, and wall structure associated 
with ageing, along with other factors9. The reason why a subgroup of individuals with 
diverticulosis progresses from asymptomatic to symptomatic or even to complicated PD 
remains poorly understood. Dietary shifts during the past century have likely not only 
influenced colonic motility and intraluminal pressure, but also altered colonic flora10. 
The change in the colonic microbial environment may be an important element in the 
transformation of asymptomatic diverticular disease into diverticulitis, but its exact role 
has not been adequately defined11.
Like the pathophysiology of diverticula, the etiology of diverticular inflammation is also 
speculative. The development of diverticulitis has been described as similar to that 
of appendicitis. Perforation of variable extent may result, accounting for a range of 
symptoms12,13.
In general, patients with diverticular disease show raised intracolonic pressures, especially 
in the sigmoid colon14. As almost all diverticular perforations occur in the sigmoid 
colon, these pressure changes must be an important etiological factor. Furthermore, 
the properties of the colonic wall are likely important because diverticula consist 
predominantly of mucosa lacking a smooth muscle layer. The mucosal barrier is vulnerable 
and may be impaired by various exogenous factors, such as the use of nonsteroidal anti-
inflammatory drugs (NSAIDs), corticosteroids or opiate analgesics, smoking, and alcohol 
consumption15.
The etiology of perforation remains unknown, but it is thought to be a result of an 
excessive increase in intradiverticular pressure and focal necrosis16. This local perforation 
may form pericolic phlegmones and pus collections (Hinchey I)17. If this process 
progresses further, localized abscesses may form between loops of the small bowel or 
in the pelvic peritoneum (Hinchey II). If the pus cannot be contained, the abdominal 
peritoneum becomes contaminated, producing generalized purulent peritonitis (Hinchey 
III). The same is found when a large intraperitoneal diverticular abscess ruptures into the 
abdominal cavity18. If the initial perforation is large, fecal contamination of the abdominal 
cavity can occur (Hinchey IV)17.
Since the incidence of diverticulosis increases with age, the majority of patients presenting 
with symptoms are elderly. Complicated diverticulitis is also observed predominantly 
in older patients. This problem is caused by an obscure presentation of diverticular 
complications in the elderly patient, with a consequent delay in diagnosis. Polypharmacy 
(e.g. with NSAIDs or corticosteroids) may further exacerbate this problem and may even 
increase the risk of developing complications19.
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PReVeNTION
The possible role of diet and lifestyle offers strategies for prevention. Large, prospective 
studies have identified a preventive effect of both vegetable and high fiber intake and 
physical exercise in the development of diverticular disease, as well as diverticulitis20-22. 
Fiber as a dietary supplement may be beneficial in prevention. Nevertheless, it is 
remarkable that the incidence of diverticular disease has not been reduced, given the fact 
that several studies have shown an increased intake of fiber in Western populations over 
the last three decades23. The exact role of fiber in the pathophysiology of diverticulosis 
and its prevention remains unclear. Furthermore, when symptoms have developed, 
evidence of a benefit of fiber intake is even less convincing23.
One of the latest therapies for the prevention of recurrent diverticulitis is the use of 
mesalazine, rifaximin, or a combination of the two24,25. The rationale for mesalazine use 
is that it inhibits some key factors of the inflammatory cascade26. Another very recent 
therapeutic strategy is the use of probiotics27. Probiotics diminish changes in the 
spectrum of intestinal microflora and the adherence and translocation of pathogens. They 
also regulate the production of antimicrobials and interact as competitive metabolites 
with pro-inflammatory organisms. Importantly, the combination of the Lactobacillus spp. 
with rifaximin seems effective in reducing severe forms of diverticulitis and preventing 
recurrences, hence reducing surgical treatment significantly28,29.
The role of surgery in the prevention of complicated diverticular disease is unclear. 
Advances in diagnostic modalities, medical therapy, and surgical techniques over the 
past two decades have changed both the management and outcomes of diverticulitis30. 
Patients treated nonoperatively would be expected to do well without elective colectomy 
since most patients will not have further episodes of diverticulitis31,32. Recurrent episodes 
of diverticulitis do not lead to more complications or failure of conservative treatment3,33. 
At present, it is thought that elective resection for uncomplicated diverticulitis does not 
alter outcome, nor does it decrease mortality or prevent severe complications of the 
disease (e.g. perforation)32,33. Moreover, the prevalence of persistent symptoms after 
surgery for diverticular disease (up to 25%) may be an additional reason to discuss the 
indication for prophylactic surgery34.
PeRFORATeD DIVeRTICULITIS WITh LOCALIzeD PeRITONITIS: 
TReATMeNT STRATeGIeS
The optimal treatment strategy for PD depends on the degree of peritonitis. The 
introduction of computed tomography (CT) has improved preoperative assessment 
of diverticular disease. The CT-based classification by Hansen–Stock is the primary 
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classification system and accounts for asymptomatic diverticulosis as well as complicated 
diverticulitis in different stages, including perforation35. Nevertheless, the degree of 
peritonitis – and hence the severity of disease – in PD can be represented best by Hinchey’s 
classification (Figure 1). Hinchey I and II represent localized peritonitis with phlegmon or 
abscess near the affected sigmoid and abscess elsewhere, respectively. Even localized PD 
can present as acute abdominal pain, frequently resulting in emergency surgery when a 
preoperative CT scan for diagnosis is not performed.
The high specificity of CT has allowed this modality to become a surrogate for the 
perioperative assessment made by the Hinchey classification36. Furthermore, CT has 
become an important therapeutic aid. It is now recognized that patients with small, 
contained perforations, who are not systemically ill, can be treated initially with antibiotics 
alone or by CT-guided percutaneous drainage36,37. Although mechanical control of the 
source of infection remains important, several studies have found that abscesses up to 4 
cm seem to respond better to antibiotics alone37,38.
Therefore, in general, Hinchey I and II PD can be treated conservatively with fluids, 
analgesics, and antibiotics, with or without percutaneous drainage of abscesses. It must 
also be noted that in Hinchey I and II, small amounts of free air are shown on CT scan, 
but this does not imply the need for surgical treatment per se. If conservative treatment 
fails, surgical intervention is indicated, in which resection with primary anastomosis (PA) 
is preferred above sigmoid colectomy with subsequent colostomy, also referred to as 
Hartmann’s procedure (HP). The performance of a diverting loop-ileostomy to “protect” 
the anastomosis should be considered, especially in patients with a number of comorbidity 
factors39.
PeRFORATeD DIVeRTICULITIS WITh GeNeRALIzeD PeRITONITIS: 
TReATMeNT STRATeGIeS
Hinchey III and IV (GPPD) are characterized by generalized purulent and fecal peritonitis, 
espectively. Both represent indications for emergency surgery. Since the beginning of the 
previous century, a three-stage operation strategy was common practice for the treatment 
of complicated diverticular disease. A preliminary transverse colostomy was advised with 
a period of 3–6 months delay before resection40,41. The rationale for this strategy was that 
primary resection is too difficult in the acute stage of the disease. After several months, 
the second stage – resection of the involved bowel – could be performed to treat and 
prevent relapse of the disease.
Since the 1960s, combinations of antibiotics were used for the treatment of Gram-
negative bacteria and anaerobic bacteria, and these resulted in improved survival in 
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septic patients42. Unfortunately, mortality rates in patients with GPPD remained high. 
It was thought that the basic cause of this high mortality was the remaining source of 
infection in the peritoneal cavity. Based on this “expert opinion evidence”, the conviction 
arose that the colonic perforation had to be removed immediately42,43.
A two-stage operation (e.g. HP) subsequently became the preferred surgical strategy 
in these patients44. The second stage was represented by the colostomy closure. This 
change in strategy was mainly based on the results of two reviews published in 1980 and 
1984 by Greif et al.45 and Krukowski and Matheson46, respectively. Unfortunately, these 
reviews were not systematic, containing a wide range of different surgical techniques and 
covering more than 25 years during which substantial improvements in antibiotic and 
other perioperative supportive therapies had taken place. Furthermore, it is not known 
whether the patients were comparable for a number of essential variables, such as age, 
American Society of Anesthesiologists (ASA) classification, and Hinchey scores.
Figure 1. The Hinchey Classification of perforated diverticulitis.
Reprinted with permission from N Engl J Med 2007;357:2057-2066
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Between 1993 and 2000, two randomized controlled trials assessing primary versus 
secondary resection were published47,48. These randomized controlled trials drew 
opposing conclusions. Kronborg47 concluded that three-stage nonresectional surgery 
(suture and transverse colostomy) in PD was still superior to primary resection because of 
a lower postoperative mortality rate; however, mortality was not different in Hinchey IV 
who underwent primary resection or patients who were treated according to the three-
staged surgical strategy. Unfortunately, the study was stopped early because of low 
recruitment (an average of four patients each year) and hence underpowered. A total 
of 62 patients were included and operated on by 27 different surgeons over a period of 
14 years. Zeitoun et al. concluded that primary resection was superior to nonresectional 
surgery because of less postoperative peritonitis and fewer reoperations48. However, 
postoperative mortality after primary resection was higher compared with nonresectional 
surgery (24% vs. 19%). Nontheless, HP became the advocated surgical strategy.
Improvements in surgical and radiological intervention techniques and progress in the 
management of peritoneal sepsis has resulted in increasing interest in colonic resection 
with PA since the 1990s. Several systematic reviews have concluded PA to have a better 
clinical outcome than HP for patients with GPPD22. However, fear of anastomotic leakage 
often deters many surgeons from performing a one-stage procedure (e.g. PA) in GPPD, 
although it is becoming more widely accepted that anastomotic leakage does not seem 
to be related to the grade of contamination of the abdomen.
Restoration of bowel continuity after HP is a technically challenging operation and is 
associated with significant morbidity and mortality49. These rates can be as high as 25% 
and 14%, respectively, after colostomy reversal in patients who have undergone HP for 
PD2,4. The performance of a diverting loop-ileostomy has been reported to decrease 
the rate of symptomatic anastomotic leakage in patients operated on for diverticular 
peritonitis. The risk of a permanent ileostomy is recognizably less than that of HP, with 
fewer complications50,51.
In 1996, a new nonresectional laparoscopic approach was described52. In patients with 
peritonitis without gross fecal contamination, laparoscopic peritoneal lavage, inspection 
of the colon, and the placement of abdominal drains appeared to diminish morbidity and 
improve outcome52-54. In a series of 100 patients with GPPD, Myers et al. showed excellent 
results after laparoscopic lavage and drainage of the peritoneal cavity, with morbidity and 
mortality rates <5%55.
In a second elective stage, definitive surgery can take place (e.g. laparoscopic resection 
and PA)53,54, although subsequent elective resection is probably unnecessary55,56. 
Nevertheless, the number of studies are rather limited and mostly based on small groups 
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of patients. Furthermore, the rates of additional radiological interventions and conversion 
to an open procedure are high57. Finally, for many hospitals, it will not be possible to have 
a surgical team with expertise in colorectal laparoscopic surgery present at all times.
Some authors have expressed their concerns regarding laparoscopic nonresectional 
treatment of GPPD. They state that the decision to perform nonresectional surgery is 
influenced by the surgical access to the abdomen (i.e. laparoscopy), rather than based 
on evidence in literature58. Unfortunately, the evidence to which these investigators refer 
(primary resection favoring three-stage procedures) is equivocal or contradictory, as 
stated above46-48.
The major criticism of the nonresectional laparoscopic lavage technique is the continued 
presence of the perforated colon as a septic focus and the column of feces in the colon 
as potential ongoing sources of contamination. This was also the main criticism towards 
the three-stage procedure that was used to treat GPPD until the 1970s. However, GPPD 
is accompanied by ileus, hence it is not likely that the fecal column is propelled towards 
the perforation. Moreover, a patent communication between the colonic lumen and the 
peritoneal cavity usually cannot be found during laparoscopy because the site of the 
original perforation has become sealed by the inflammatory process and omentum, 
and seems efficient to control the source of contamination. In patients who are found to 
have fecal peritonitis or who fail to improve after lavage, acute resection should still be 
performed57,59.
The suggestion that nonresectional surgery in combination with more advanced antibiotics 
has never been proven to be an inferior strategy could explain the excellent results after 
laparoscopic lavage in combination with modern management of peritoneal sepsis with 
improved antibiotics and intensive care medicine.
In the case of Hinchey III peritonitis, laparoscopic treatment by lavage and drainage 
without resection has shown such excellent results that this new approach cannot be 
ignored53-55,57. The problem is that Hinchey’s classification represents the severity of 
disease during surgery. Preoperative CT scanning is essential to differentiate between 
Hinchey I, II, and generalized peritonitis (Hinchey III and IV), but exact differentiation 
between purulent of fecal peritonitis is not possible with today’s radiological modalities. 
It is therefore advised that all patients with GPPD on CT scan undergo diagnostic 
laparoscopy. In cases of purulent peritonitis, laparoscopic lavage and drainage can 
then be performed. Alternatively, resectional surgery can be considered, for which PA 
is preferred. In cases of fecal peritonitis, conversion to laparotomy is advised to perform 
sigmoid resection with PA (or HP), as laparoscopic lavage and drainage have shown not 
to be successful in Hinchey IV PD.
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The abovementioned statements still need to be confirmed in randomized, controlled 
trials. Currently, a nationwide randomized trial (Ladies [Laparoscopic Peritoneal Lavage 
or Resection for Generalized Peritonitis for PD] trial) is running in The Netherlands under 
the auspices of the Dutch Diverticular Disease (3D) Collaborative Study Group60. While 
awaiting the results of randomized trials assessing laparoscopic lavage, the open approach 
(PA or HP) presently remains the standard procedure in patients with generalized (purulent 
of fecal) peritonitis from a free macroperforation in diverticulitis.
FUTURe STRATeGIeS
Currently, the only patients who require surgery (laparoscopically or open) are those who 
fail conservative treatment and those with generalized peritonitis who require emergency 
surgery38,61. It seems that a more minimally invasive surgical treatment could be a safe 
and feasible option in GPPD. To ensure good results, it is essential that these procedures 
are performed by dedicated colorectal surgeons who have laparoscopic lavage in their 
armamentarium of procedures. Minimally invasive nonresectional treatment of GPPD has 
the highest probability of success53.
If nonresectional laparoscopic lavage and drainage to treat GPPD is found to be a safe 
and better alternative for resectional surgery in the future, why should this be different 
from nonresectional nonsurgical (e.g. CTguided) percutaneous lavage and drainage? As 
yet, the literature does not report this treatment strategy. Is it possible that this will be the 
next step in the ever more conservative management of different stages in diverticular 
disease?
Fluid resuscitation and modern antibiotic strategies will not be different from 
laparoscopically lavage procedures. In order to gain control of the septic focus using 
percutaneous techniques, it is important that large size catheters are used for adequate 
drainage of thick and viscous purulent contents62. The main problem is the inability 
for inspection of the abdominal cavity to localize the site and size of the perforation. 
Such a careful inspection of the abdominal cavity, to look for or exclude other causes of 
generalized purulent peritonitis, is not possible using today’s radiographic modalities. 
Furthermore, in cases of a large perforation causing fecal peritonitis, source control 
by percutaneous lavage and drainage is impossible; hence, surgical treatment will be 
necessary to achieve source control and restore premorbid anatomy and function. It is, 
therefore, not likely that percutaneous (nonsurgical) nonresectional lavage and drainage 
will play a prominent role in the treatment of GPPD in the near future, because it cannot 
yet meet the principles of abdominal infection treatment.
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PROPOSAL FOR A TReATMeNT STRATeGy FOR PeRFORATeD 
DIVeRTICULITIS
Further basic and clinical investigations need to be performed in order to fill the several 
gaps in our knowledge of the pathophysiology of diverticulitis, as well as its treatment and 
prevention. For the same reason, there is a need for further good quality epidemiological 
research to identify risk factors in diverticular perforation. Whether new insights into the 
etiology will lead to new surgical strategies for prevention and treatment of PD remains 
to be seen.
Abdominal CT scanning is essential in patients suspected of having PD, because only 
patients with generalized peritonitis (free fluid and large amount of peritoneal free 
air) need to undergo emergency surgery. Unfortunately, CT scans cannot presently 
differentiate between Hinchey III or IV PD. The differentiation between the two is essential 
because the treatment strategy is different. It is therefore advised that patients who have 
GPPD on CT scan will undergo diagnostic laparoscopy, followed by definitive surgery. 
Hinchey III patients should undergo laparoscopic lavage and drainage, while Hinchey IV 
patients need to undergo conversion towards laparotomy for resection of the affected 
colon segment. Future randomized controlled trials must assess whether laparoscopic 
lavage for Hinchey III, and PA with ileostomy for Hinchey IV, are indeed the preferred 
surgical strategies. In cases of Hinchey I and II, a conservative treatment is advocated.
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ABSTRACT
Background
Laparoscopic lavage has recently emerged as a promising alternative to sigmoid resection 
in the treatment of perforated diverticulitis. This study examined an early experience with 
this technique.
Methods
The files of all patients with complicated diverticulitis were searched in 34 teaching hospitals 
of the Netherlands. Patients with perforated diverticulitis treated with laparoscopic lavage 
between 1 January 2008 and 31 December 2010 were included.
Results
Treatment with laparoscopic lavage was performed in only 38 patients in ten hospitals. 
Lavage was successful in controlling sepsis in 31 of the 38 included patients, with 32% 
morbidity (10 of 31 patients) and fast recovery. Overall, 17 of 38 patients developed 
complications, of whom two had a missed overt sigmoid perforation. Two patients died 
from multiple organ failure and one from aspiration pneumonia; one other patient died 
after palliative management of inoperable lung carcinoma. Three patients in whom 
lavage was successful underwent subsequent sigmoid resection for recurrent diverticulitis. 
Patients in whom lavage was unsuccessful tended to have more co-morbidities, a higher 
preoperative C-reactive protein concentration and a higher Mannheim Peritonitis Index. 
Conclusion
Laparoscopic lavage for perforated diverticulitis was feasible in the majority of patients, 
but identification of an overt sigmoid perforation and patient selection are of critical 
importance.
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INTRODUCTION
Perforated diverticulitis is a serious condition that can present as either purulent (Hinchey 
III) or faeculent (Hinchey IV) peritonitis1. Regardless of this classification, sigmoid resection 
with either end colostomy or primary anastomosis has been the standard treatment. 
However, these operations are associated with high morbidity and mortality rates, the 
latter being 27% in a national study of patients with both purulent and faecal peritonitis2,3. 
In addition, the stoma is never reversed in many patients2,3.
Laparoscopic lavage, originally described in Ireland in 1996, has emerged as a promising 
alternative to sigmoid resection4. A systematic review has shown that, for Hinchey III 
diverticulitis, lavage leads to low morbidity and mortality rates, while avoiding the creation 
of a stoma5. However, the available data are derived from small nonrandomized studies.
Hinchey II diverticulitis is defined as diverticulitis with a pelvic abscess of at least 5 cm in 
diameter. Percutaneous drainage is recommended for this condition; surgery is required 
only when the abdominal abscess is not amenable to percutaneous treatment and signs 
of sepsis are present6-9. Lavage does not seem to be sufficient for Hinchey IV diverticulitis 
(faeculent peritonitis). As there is overt communication between the intestinal lumen and 
the peritoneal cavity, sigmoid resection is recommended to prevent further dispersion 
contamination5.
Laparoscopic treatment, as promoted by the Irish group, has been received with both 
enthusiasm and scepticism in the Netherlands10. Convinced by the existing evidence, 
some hospitals have implemented lavage as a new standard for Hinchey III diverticulitis; 
others have been more reluctant, fearing failure of the new strategy. Before the start of the 
Ladies trial (a large randomized trial investigating the safety and efficacy of laparoscopic 
lavage for perforated diverticulitis), some surgical units had already started to apply this 
novel strategy11. The aim of the present study was to report on the results of laparoscopic 
lavage performed in these centres before the start of the Ladies trial.
MeThODS
Eligible for this study were patients treated with laparoscopic lavage for perforated 
diverticulitis in Dutch teaching hospitals before the start of the Ladies trial in the interval 
from 1 January 2008 to 31 December 2010. Medical records in the 34 hospitals were 
screened for the diagnosis ‘diverticulitis’ or ‘acute abdomen’. The medical files of these 
patients were checked for the type of surgery they had undergone. Patients were included 
if they underwent laparoscopic lavage as the primary treatment for diverticulitis with either 
free air (Hinchey II or III) and/or with purulent peritonitis (Hinchey III). Demographic data, 
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co-morbidity, American Society of Anesthesiologists (ASA) grade, preoperative white 
blood cell count, Creactive protein (CRP) concentration, and results of plain abdominal 
X-ray and computed tomography (CT) were recorded. The following information was 
obtained from the operation records: presence of abdominal pus and its location, 
presence of faeces, presence of overt sigmoid perforation, closure of overt perforation, 
amount of saline used for lavage and placement of drains. Survival, length of time in the 
intensive care unit (ICU), antibiotic regimen, and number of complications, diagnostic 
measures, reinterventions, reoperations and readmissions were recorded. Treatment 
failure was defined as ongoing abdominal sepsis.
The Mannheim Peritonitis Index (MPI) was used as a predictor of the mortality risk (Table 1). 
The Hinchey classification was used to stratify the patients according to the intraoperative 
findings: Hinchey II for a large pelvic abscess, and Hinchey III when purulent peritonitis 
was present.
Data on the following co-morbidities were extracted from the patient’s history: 
cardiovascular morbidity (myocardial infarction, ischaemic attack, aneurysm, atrial 
fibrillation, thrombosis), pulmonary morbidity (chronic obstructive pulmonary disease), 
malignancies, organ failure (renal insufficiency, pulmonary insufficiency) and other 
morbidities (hypertension, diabetes, hypercholesterolaemia).
ReSULTS
Thirty-eight patients treated with laparoscopic lavage were identified in ten hospitals. All 
had clinical evidence of diverticulitis with obvious signs of local or generalized peritonitis. 
Patient characteristics are shown in Table 2. A total of 24 men and 14 women were 
included, of median age 59 (range 23–79) years. Eighteen patients had one or more co-
morbidities. Stratified by the most severe co-morbidity, eight patients had cardiovascular 
disease (myocardial infarction, stroke, atrial fibrillation and thrombosis), five were 
previously diagnosed with malignancy, two had pulmonary disease (chronic obstructive 
pulmonary disease) and three had hypertension. One patient had respiratory insufficiency 
before surgery. Four patients had undergone previous abdominal surgery not related to 
diverticular disease. None of the patients had had a previous episode of diverticulitis, 
although one had been admitted for uncomplicated diverticulitis 7 days before surgery. 
None of the patients used systemic corticosteroids.
Twenty-eight of the 38 patients had surgery on the day of arrival at the emergency 
department (Table 2). Preoperative imaging revealed free intra-abdominal air in 32 of 35 
patients who had CT. At operation a pelvic or retroperitoneal abscess was found in five 
patients; local or generalized purulent peritonitis was present in 33 patients, of whom two 
had overt sigmoid perforation.
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The amount of irrigation fluid was reported in 14 patients, in whom a median of 4 (range 
3–6) litres of saline was used. The placement of drains was reported in 36 patients: no 
drains were placed in three, one drain was used in 17 patients, and two in 16. One of 
the patients required conversion to an open procedure because the left lower quadrant 
could not be visualized. In both patients with overt sigmoid perforation, the perforation 
was closed primarily.
Table 1. Mannheim Peritonitis Index. 
Risk factor Weight
Age (years) <50 0
>50 5
Sex M 0
F 5
Organ failure* No 0
Yes 7
Malignancy No 0
Yes 4
Preoperative duration of peritonitis (h) ≤24 0
>24 4
Diffuse generalised peritonitis No 0
Yes 6
Exudate Clear 0
Cloudy, purulent 6
Faeculent 12
The origin of sepsis was always colonic: 0 of 4 points.*Includes kidney failure (creatinine over 
177 µmol/L, urea more than 167 µmol/L, oliguria less than 20 ml/h), lung failure (partial pressure 
of oxygen less than 50mmHg, partial pressure of carbon dioxide greater than 50mmHg), shock 
(hypodynamic or hyperdynamic) and profound intestinal obstruction (paralysis for more than 24 h 
or complete mechanical ileus).
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Table 2. Risk factors for treatment failure.
Overall
(n=38)
Sepsis 
controlled 
(n=31)
Sepsis not 
controlled 
(n=7)
Sex ratio (M:F) 24:14 20:11 4:3
Age (years)* 59 (23-79) 58 (23-79) 66 (39-77)
ASA fitness grade
I
II 
III 
IV
 
12
11
12
3
11
9
10
1
1
2
2
2
Comorbidities
none
1
2
≥2
20
6
6
6
18
4
5
4
2
2
1
2
Mannheim Peritonitis Index†
3
13.3 (5.0) 12.6 (5.1) 15.0 (4.3)
Preoperative CRP (mmol/l)† 203 (143) 180 (123) 322 (187)
Preoperative WBC count (x103/mm3)† 15.4 (5.3) 15.8 (4.8) 13.5 (7.4)
Preoperative hospital stay 
0
1
2
>2
 
28
5
2
3
21
5
2
3
7
0
0
0
Free air 
No imaging 
No
Pericolic 
Distant
3
3
4
28
3
2
4
22
0
1
0
6
Operative findings
Pelvic abscess, diffuse free air on CT (Hinchey II)
Localised cloudy or purulent exudate (Hinchey III)
Generalised cloudy or purulent exudate (Hinchey III)
5
29
4
3
25
3
2
4
1
Overt perforation
Yes
No
2
36
2
29
0
7
Values are *median (range) and †means (s.d.). ASA, American Society of Anesthesiologists; CRP, 
C-reactive protein; WBC, white blood cell; CT, computed tomography
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The median duration of operation was 68 (range 30–220) min. There were no intraoperative 
complications. A postoperative antibiotic regimen of cefuroxime and metronidazole 
was reported in 12 patients. The regimen used in the other patients was unclear or not 
specified.
Postoperative outcomes are summarized in Table 3 and Figure 1. The median length of 
postoperative hospital stay was 10 (range 4–77) days. Six patients required admission to 
the ICU, with a median stay of 6 (range 2–46) days. Four patients required readmission to 
the surgical ward after discharge.
Laparoscopic lavage failed to control sepsis in seven of the 38 patients. Two patients died 
from multiple organ failure after operation. A laparotomy was performed in five other 
patients: sigmoid resection and end colostomy in three, a diverting stoma in one and 
closure of the sigmoid perforation in one. At laparotomy, faeculent peritonitis was found 
in two patients and purulent peritonitis in one. Intraoperative data were lacking for the 
other two patients. Abdominal sepsis was controlled in all five patients after the second 
operation. Nonetheless, one patient died from aspiration during the postoperative 
course. All patients in whom lavage was unsuccessful developed complications within 30 
days (Table 3). No carcinoma was found on histopathological examination of specimens 
of resected sigmoid.
Lavage was successful in controlling the abdominal sepsis in 31 patients, including two 
who had an overt sigmoid perforation closed primarily. One patient with a pre-existing 
bronchial carcinoma developed persistent small bowel obstruction after surgery; because 
of the poor prognosis, parenteral feeding was stopped and the patient died. Ten of 31 
patients developed complications within 30 days (Table 3).
Follow-up visits were reported in 28 patients, a median of 69 (range 12–529) days after 
surgery. Follow-up was carried out for more than 3 months only when late complications 
occurred. Two patients underwent elective sigmoid resection for recurrent symptomatic 
diverticulitis at 6 and 9 months after operation, and one patient required emergency 
sigmoid resection for recurrent perforated diverticulitis at 12 months.
In 17 of 30 patients who were treated successfully and recovered, follow-up colonoscopy 
was performed to exclude colonic malignancy; in none of these malignancy was found.
Patient characteristics were analysed to determine predisposing factors for uncontrolled 
abdominal sepsis (Table 2). Patients in whom lavage was unsuccessful were more likely to 
have co-morbidities, had a higher mean CRP concentration and a higher MPI. 
Processed on: 22-2-2017
507513-L-bw-Mulder
60
Chapter 4
DISCUSSION
Treatment with laparoscopic lavage in the Netherlands was less successful than in the Irish 
experience; the Irish group reported very promising results with a mortality rate of 4% in a 
series of 92 patients10. The present study analysed a retrospective series of patients from 
ten hospitals. It suffers from all the limitations of retrospective research, especially the risk 
of patient selection bias. Because of this and the small study size, the results should be 
interpreted with caution. In this series, two patients (5%) treated with lavage died after 
Table 3. Outcomes of surgery.
Overall 
(n=38)
Sepsis 
controlled 
(n=31)
Sepsis not 
controlled 
(n=7)
Laparotomy 5 Hartmann’s 
procedure 3
Diverting stoma 1
  Closure of 
perforation 1
Hospital stay (days)* 10 (4-77) 10 (4-42) 16 (6-77)
ICU admission 6 2 4 
Readmission 4 3 1
In-hospital death
Multi organ failure
Aspiration
Persistent bowel obstruction
4
2
1
1
1
1
3
2
1
30 day morbidity†
Bowel obstruction
Abdominal abscess 
Enterocutaneous fistula
Wound infection 
Incisional hernia
Pneumonia
Pulmonary embolism
Burst abdomen
Atrial fibrillation
17
5
4
3
2
2
2
1
1
1
10
3
2
1
1
0
1
1
0
1
7
2
2
2
1
2
1
0
1
0
Recurrent diverticulitis
Elective sigmoid resection 
Emergency sigmoid resection
3
2
1
3
2
1
*Values are median (range). †Number of patients with complications. The breakdown describes all 
complications; some patients had more than one complication. ICU, intensive care unit. 
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surgery and five other patients required further surgery because of ongoing abdominal 
sepsis. The 31 patients in whom lavage was successful had low mortality and morbidity 
rates, and a quick recovery.
Selection of patients who would benefit from laparoscopic lavage is probably of utmost 
importance, with faeculent peritonitis and the presence of overt perforation being 
absolute contraindications to lavage. The extent of peritonitis could not be analysed in the 
present study as this was not reported consistently in the operation records. Unsuccessful 
treatment was associated with higher ASA grade and co-morbidities. Although the MPI 
has been designed as a predictor of postoperative death in patients with peritonitis, 
certain elements of the index (higher age, organ failure, concomitant disease, generalized 
peritonitis, faeculent peritonitis) have been reported to predict reintervention for 
secondary peritonitis, as was found here12,13. The preoperative CRP concentration was 
higher in the group in whom sepsis was not controlled. This is a known predictor of 
perforated appendicitis and perforated diverticulitis14,15; however, it remains unclear 
whether CRP can predict the success of laparoscopic lavage for perforated diverticulitis.
No randomized studies have been published on this topic. The available evidence is 
therefore limited to uncontrolled studies with a high risk of selection and publication 
bias. Most studies have analysed patients with both Hinchey II and Hinchey III and have 
considered Hinchey II patients as candidates for lavage treatment, without discrimination 
within this group of patients based on the presence of free abdominal air. This might 
make the results appear considerably better because Hinchey II diverticulitis is known to 
be associated with fewer complications than true perforated diverticulitis16. The present 
Figure 1. Flow chart of clinical outcome. 
Laparoscopic lavage
 N=38
Sepsis controlled
N=31
Sepsis not controlled, 
reintervention required
N=7
Death 
Multiorgan failure
N=2
Reintervention
Resection + end-colostomy N=3
Loop-ostomy N=1
Closure of perforation N=1
Sepsis controlled 
N=5
Death 
Aspiration N=1
Complete recovery 
N=4
 
Death 
Bowel obstruction, 
palliation N=1
Complete recovery 
N=30
 
Recurrent diverticulitis, 
sigmoid resection N=3
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study included patients with purulent peritonitis and/or distant free air only. Laparoscopic 
treatment does not seem to be appropriate for patients with Hinchey II diverticulitis 
without free air. These patients can be treated either conservatively or by percutaneous 
drainage of the pelvic abscess6. Laparoscopic lavage is considered to be unsafe for 
faeculent peritonitis or when an overt perforation is present.
Laparoscopic lavage is a promising novel treatment for perforated purulent diverticulitis. 
The high morbidity and stoma rates associated with sigmoid resection can be avoided. 
However, in the present series, mortality and morbidity were high among patients in 
whom the abdominal sepsis was not controlled. When no clinical improvement is 
observed within 48 h, (laparoscopic) reintervention is indicated for additional lavage or 
resection. The study suggests that laparoscopic lavage might not benefit all patients 
with Hinchey III diverticulitis. It appears that patients with multiple co-morbidities, a high 
CRP concentration and a high MPI are at risk of failure of lavage. Sigmoid resection as a 
first step might be the best intervention for these patients, but the mortality rate is high 
anyway. It remains unproven which risk factors predispose to failure of lavage; the results 
of four randomized trials addressing this topic are eagerly awaited11,17-19.
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ABSTRACT 
Background
Recently, excellent results are reported on laparoscopic lavage in patients with purulent 
perforated diverticulitis as an alternative for sigmoidectomy and ostomy. 
The objective of this study is to determine whether LaparOscopic LAvage and drainage 
is a safe and effective treatment for patients with purulent peritonitis (LOLA-arm) and to 
determine the optimal resectional strategy in patients with a purulent or faecal peritonitis 
(DIVA-arm: perforated DIVerticulitis: sigmoid resection with or without Anastomosis).
Methods
In this multicentre randomised trial all patients with perforated diverticulitis are included. 
Upon laparoscopy, patients with purulent peritonitis are treated with laparoscopic lavage 
and drainage, Hartmann’s procedure or sigmoidectomy with primary anastomosis in a 
ratio of 2:1:1 (LOLA-arm). Patients with faecal peritonitis will be randomised 1:1 between 
Hartmann’s procedure and resection with primary anastomosis (DIVA-arm). The primary 
combined endpoint of the LOLA-arm is major morbidity and mortality. A sample size of 
132:66:66 patients will be able to detect a difference in the primary endpoint from 25% in 
resectional groups compared to 10% in the laparoscopic lavage group (two sided alpha 
= 5%, power = 90%). Endpoint of the DIVA-arm is stoma free survival one year after initial 
surgery. In this arm 212 patients are needed to significantly demonstrate a difference of 
30% (log rank test two sided alpha = 5% and power = 90%) in favour of the patients with 
resection with primary anastomosis. Secondary endpoints for both arms are the number 
of days alive and outside the hospital, health related quality of life, health care utilisation 
and associated costs.
Discussion
The Ladies trial is a nationwide multicentre randomised trial on perforated diverticulitis 
that will provide evidence on the merits of laparoscopic lavage and drainage for purulent 
generalised peritonitis and on the optimal resectional strategy for both purulent and 
faecal generalised peritonitis.
Trial registration
Nederlands Trial Register NTR2037
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BACkGROUND 
Diverticular disease is an important condition in terms of healthcare utilisation and it is 
one of the five most costly gastrointestinal disorders in westernised countries1. Despite 
this high prevalence, treatment of all different stages of diverticular disease is still hardly 
evidence based, hence containing a lot of controversies. 
Perforated diverticulitis is a perforation of an inflamed diverticulum of the large bowel, 
mostly the sigmoid, resulting in either purulent or faecal peritonitis (Hinchey stadia III 
or IV). Both conditions require emergency surgery2,3. Regardless of selected strategy 
emergency operations for acute perforated diverticulitis are associated with substantial 
morbidity (up to 50%) and mortality (15 to 25%)3-8. Primary sigmoidectomy with or without 
anastomosis has become the standard practice for patients with generalised peritonitis 
complicating diverticulitis and for many surgeons the Hartmann’s procedure remains the 
favoured option6-10. Restoration of bowel continuity after this procedure is a technically 
difficult operation, with high morbidity and mortality rates11,12. Therefore stoma reversal 
after HP is only performed in 50 to 60% of the patients, thereby compromising quality of 
life and increasing costs13,14. 
Recently laparoscopic lavage (LL) emerged as an effective alternative for patients with 
perforated diverticulitis with purulent peritonitis15. This nonresectional procedure has 
first been described by O’Sullivan in 199616. In 2009, a systematic review on all studies 
on laparoscopic lavage with a total number of 231 patients was performed. Mortality 
was less than 2% and a (permanent) colostoma was avoided in the majority of these 
patients15-22. So laparoscopic lavage for perforated purulent diverticulitis has a great 
potential in improving health and reducing costs.
Nevertheless, since sigmoidectomy is still considered the standard of care for perforated 
diverticulitis, implementation of LL might be variable. Some surgeons will embrace lavage 
because of its technical simplicity; other might be reluctant fearing failure of this novel 
strategy. Only a head to head comparison of both surgical strategies will provide an 
evidence based surgical approach of patients with perforated diverticulitis with purulent 
peritonitis (LOLA-arm).
In case of faecal peritonitis there is no evidence that LL is a valid alternative for a 
resectional strategy. But again, the optimal surgical treatment is still a matter of debate. 
The available literature suggests equality of Hartmann’s procedure (HP) and resection 
with primary anastomosis (PA) regarding postoperative mortality and morbidity5,8,9,23,24. 
The likelihood of stoma closure seems higher after PA with ileostomy (85%) compared 
to HP (60%), but robust evidence is lacking13,25. Therefore, HP and PA are compared to 
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determine the optimal resectional treatment for perforated diverticulitis with generalised 
purulent or faecal peritonitis, regarding stoma free survival (DIVA-arm).
Study objectives
For this two-armed randomised trial two objectives can be defined to determine the 
optimal strategy for the treatment of perforated diverticulitis. First, is laparoscopic lavage 
for patients with purulent peritonitis superior compared to sigmoidectomy, in terms of 
mortality, morbidity, quality of life, health care utilisation and associated costs (LOLA-
arm)? Secondly, is HP or PA the superior approach for patients with purulent or faecal 
generalised peritonitis in terms of stoma free survival, quality of life and cost-effectiveness 
(DIVA-arm)? 
MeThODS/DeSIGN
The Ladies trial is designed as a nationwide multicentre randomised trial in which patients 
with generalised peritonitis caused by perforated diverticulitis are randomised to undergo 
either laparoscopic lavage and drainage or resectional surgery by laparotomy.
Patients presenting with clinical signs of diverticulitis with diffuse peritonitis can be 
included upon the finding of free gas on plain abdominal radiography, upon the finding of 
free gas on CT, or upon the finding of peritonitis with diffuse fluid or gas on CT. Exclusion 
criteria include dementia, pelvic irradiation, steroid treatment, prior sigmoidectomy and 
preoperative shock with inotropic requirement. All patients need to fulfil the selection 
criteria and will need to give written informed consent.
Eligible patients undergo diagnostic laparoscopy to exclude other causes of generalised 
peritonitis. If the diagnosis perforated diverticulitis is confirmed, the patient can be 
enrolled and randomised. Block-randomisation is performed during laparoscopy via the 
trial website according to Figure 1. In case of purulent peritonitis (Hinchey III) patients are 
randomised to LL, HP or PA (LOLA-arm). The best evidence indicates that the latter two 
resectional strategies are equal in terms of postoperative morbidity and mortality in case 
of generalised peritonitis8. For this reason a three way 2:1:1 randomisation is performed.
In case of an overt perforation with faecal peritonitis (Hinchey IV) patients will undergo 
laparotomy and are randomised 1:1 to either undergo HP or PA.
Patients who are either ineligible for trial entry, who show other causes of peritonitis 
than diverticulitis at laparoscopy or who do not wish to take part in the study are treated 
at the discretion of the surgeon on call. These patients will be registrated by the trial 
coordinator.
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endpoints
Primary endpoint of the LOLA-arm is the combined number of mortality and major 
morbidity, twelve months after initial surgery. Secondary endpoints of the LOLA-arm 
are quality of life, health care utilisation and associated costs. Mayor morbidity includes 
reintervention, fascial dehiscence, incisional hernia, myocardial infarction, urosepsis, 
respiratory failure and renal failure. Respiratory failure is defined as a SOFA score of less 
than 300. Renal failure is defined as a threefold creatinine increase or a GFR decrease 
over 75% or a urinary output of less than 0.3/kg/h for 24 hours or anuria for twelve hours.
Primary endpoint of the DIVA-arm is the stoma free survival within twelve months after 
initial surgery. Secondary endpoints are quality of life and cost-effectiveness.
Participating centres
More than thirty-five teaching hospitals in the Netherlands are participating in this trial, 
including six academic centres.
Study population
This study consists of patients eligible for surgical treatment of perforated diverticulitis. 
Inclusion criteria are age between 18 and 85 years, a clinical suspicion for perforated 
diverticulitis and free gas on plain abdominal radiography, free gas on CT, or peritonitis 
with diffuse fluid or gas on CT.
Figure 1. Flow chart of the trial. 
Patients suspected for perforated diverticulitis 
18-85 years 
Dementia
Preoperative shock
Pelvic irradiation
Steroid treatment
Prior sigmoidectomy
Diagnostic laparoscopy 
Perforated diverticulitis 
unconfirmed
Perforated diverticulitis
Purulent peritonitis 
Perforated diverticulitis 
Faecal peritonitis / overt 
sigmoid perforation
2:1:1 1:1
Laparoscopic 
lavage Hartmann
Resection + 
anastomosis Hartmann
Resection + 
anastomosis 
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ethics
This study will be conducted in accordance with the principles of the Declaration of 
Helsinki and Good Clinical Practice guidelines. Medical ethics approval has been obtained 
by the medical ethics committee from the Academic Medical Centre in Amsterdam, 
dated September 30th, 2009. Prior to randomisation, written informed consent must be 
obtained from all patients.
Study outline
Diagnostic laparoscopy: a careful inspection of the stomach, duodenum and sigmoid is 
performed to localise the site of perforation. In case of peritonitis due to a perforated 
diverticulum it must be attempted gently to locate the site of perforation. Careful removal 
of adherent omentum or bowel is tried. If clearly adherent, it should be left in place.
If no obvious perforation is apparent and faecal content is absent, the patient is 
randomised online between treatment with LL, HP or PA in a ratio 2:1:1.
In case of an overt perforation or intra-abdominal contamination with faeces, the patient 
is not eligible for LL and is randomised between HP and PA.
LL: the abdominal cavity is irrigated with six litres of warm saline. At the end of the 
procedure a Douglas drain is inserted via the right lateral port.
HP: The perforated diseased part must be resected. There is no need of having the distal 
transsection line on the proximal rectum. An end-colostomy is performed according to 
the preference of the operating surgeon, the same accounts for closing the rectal stump.
PA: Sigmoidectomy is done according to the guidelines of the American Society of Colon 
and Rectal Surgeons26,27. The distal transsection margin has to be on the proximal rectum, 
the proximal margin is determined by the absence of wall thickening due to diverticulitis. 
The type of anastomosis and the decision to perform a defunctioning loop-ileostomy are 
to the discretion of the surgeon on call.
Leaving a Douglas drain after resectional surgery is at the discretion of the operating 
surgeon. The resected tissue is sent for histological investigation to exclude malignancy.
Antibiotics are administered for seven days in both groups. Postoperatively, oral diet and 
mobilisation are advanced as soon as possible. Within four to six weeks after surgery 
a sigmoidoscopy is performed to exclude malignancy as the underlying cause of the 
perforation.
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After the sigmoidoscopy is performed, the patient will be offered reversal of the stoma, 
when he or she is found eligible for surgery by the surgeon and anaesthesiologist.
Statistical analysis
The analysis will be performed in accordance with the intention to treat principle.
In the LOLA-arm of the study, the assumpted difference in the combined number of 
mortality and major morbidity between laparoscopic lavage and resection is 15%. With a 
two sided likelihood ratio test and a significance level of 0.05, a sample size of 132:66:66 
will be necessary to detect this difference. With a group size of a hundred patients per 
arm it is also possible to find a significant difference (alpha = 0.05, beta = 0.1) of at 
least 10% in subscales of the SF-36, a validated quality of life questionnaire, at two, four, 
thirteen, 26 and 52 weeks after initial surgery.
In the DIVA-arm 212 patients are needed to significantly demonstrate a difference in 
stoma free survival between both treatment arms, using log rank statistics with a power 
of 90% and a type I error of 5%. The suspected postoperative mortality for HP and PA 
is equally high (+ 15%)8. About 60% of the patients that underwent HP have their stoma 
reversed11,12. When corrected for the expected mortality before reversal, the reversal rate 
will be 50%. Patients with a protective loop-ileostomy after PA will have their enterostomy 
reversed in over 85%12. After correction for expected mortality before reversal, this will 
result in a 72% stoma reversal rate in the initial patient population. 
economic evaluation
Comparisons of the different surgical strategies in the economic evaluation will be 
analogous to the analyses of the clinical endpoints. The economic evaluation will be 
performed from a societal perspective, with the costs per unit improvement on the 
primary clinical endpoints, defined as combined mortality and morbidity for the LOLA-
arm, and stoma free survival for the DIVA-arm.
We hypothesise that a more effective intervention will be associated with less health 
care utilisation as well as absence from paid work (productivity costs). Therefore, the 
primary analysis will be a cost-effectiveness analysis that evaluates costs associated with 
an improved surgical outcome.
In addition, a secondary analysis will evaluate cost differences in relation to differences 
in quality-adjusted life-years (QALYs). This cost-utility analysis, resulting in an incremental 
cost-effectiveness ratio expressed in costs per QALY, will be included to allow comparison 
with other health-related interventions or programs. With a study horizon of twelve 
months, no discounting will be applied. We will differentiate between direct medical, 
direct non-medical and indirect costs.
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Data collection and monitoring
An electronic Case Report Form (CRF) will include general patients data: sex, age, medical 
history, POSSUMscore, preoperative APACHE-score, surgical parameters, Hinchey score, 
data concerning type of intervention, complications, mortality, duration of hospital and 
intensive care stay and the patients response to the questionnaires.
Patients will be followed for a period of twelve months. During this follow-up period 
patients will complete a set of questionnaires (SF-36, EQ-5D and GIQLI) two, four, thirteen, 
26 and 52 weeks after the initial surgery. The questionnaires will be sent to the patients by 
mail accompanied by a stamped return envelope. Collection of the questionnaires will be 
safeguarded by the trial coordinator.
At four, thirteen, 26, 39 and 52 weeks after initial surgery, the patients will be asked to 
complete questionnaires to assess complications, additional interventions, readmissions, 
duration of hospital and intensive care stay, visits to the outpatient clinic, number of days 
of sick leave and to ensure completions of the questionnaires. 
Patient safety
An independent data monitoring and safety committee has been established to interpret 
the data from the current trial, to monitor any early significant differences between the 
groups of treatment and to make interim analyses to decide on continuation of the study 
after every 25 included patients.
An independent trial monitor will monitor the study procedure and the data of included 
patients.
A data management agency created the online database of the study to guard the entry 
of data by the local investigators. The same organisation has trained all trial coordinators, 
all local investigators and some local coinvestigators on the guidelines of Good Clinical 
Practice.
The trial coordinators have trained all other personnel on the protocol, on asking informed 
consent, on reporting Serious Adverse Events and on data entry.
According to the Good Clinical Practice guidelines, a list of Serious Adverse Events is 
defined. All events on this list have to be reported by the local investigators to the trial 
coordinators within 24 hours after the event. These events will be reported to the central 
Medical Ethics Committee (CCMO) within 24 hours afterwards. With this measure, the 
central Medical Ethics Committee compares the incidence of complications between the 
arms of the trial and can decide on continuation of the trial. 
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DISCUSSION 
Since the introduction of laparoscopic lavage and drainage for purulent peritonitis for 
perforated diverticulitis in 1996, the number of patients treated with this new method 
had gradually inclined. However, there have been no publications of high methodological 
quality on this topic28. Therefore we do not know whether laparoscopic lavage is in fact 
a safe and effective treatment. Since the existing publications do promise a significant 
reduction in mortality and major morbidity, a randomised trial is appropriately warranted. 
A data monitoring committee will guard the methodological quality of the study, the 
safety of the patients, and monitor any early significant differences between the different 
surgical strategies.
We have not found any evidence that laparoscopic lavage is a safe treatment for 
perforated faecal peritonitis. Therefore in this group of patients randomisation will only 
take place between the two resectional strategies.
In the presented study all patients suspected for perforated diverticulitis are included, 
and a midline laparotomy can be avoided in selected patients with other pathology.
We do not know whether the lavage itself is important for the treatment of the peritonitis, 
since there are no publications on the treatment of purulent perforated diverticulitis 
with diagnostic laparoscopy and antibiotic treatment alone. Laparoscopic lavage in 
combination with antibiotic treatment however, has been examined in a systematic review 
with very promising results28.
The stoma reversal rate is the primary endpoint for the DIVA-arm of the trial. Questions 
could be raised about the benefits of this reversal for a patient that is incontinent for 
faeces. A definitive colostoma for this specific group of patients might be preferable 
considering daily care. However this group of patients will be small and no studies have 
compared quality of life for incontinent patients with or without a stoma. The colostoma 
and ileostoma show equal impact on the patients quality of life, and quantification of 
incontinence problems is unpractical in the emergency setting29. Therefore incontinence 
is not established as an exclusion criterion. All resections will be performed with the 
intention of stoma reversal.
In the Netherlands the standard of care for perforated diverticulitis is either HP or 
PA. Resection with primary anastomosis is a type of treatment not mastered by every 
gastrointestinal surgeon. In the emergency setting, some surgeons might prefer HP, 
fearing anastomotic leakage. However, there is no clear evidence available showing a 
difference in mortality and major morbidity between HP and PA. Therefore we decided to 
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include treatment with PA in the randomisation process of the LOLA-arm as well.
Our hypothesis is that PA leads to a 22% higher stoma free survival, and that this procedure 
might be advocated as the new standard of care in selected patients with generalised 
peritonitis caused by perforated diverticulitis. 
LIST OF ABBReVIATIONS 
LOLA-arm: Laparoscopic lavage and drainage or sigmoidectomy with HP or PA for 
purulent peritonitis for perforated diverticulitis; DIVA-arm: Sigmoidectomy with HP or PA 
for generalised peritonitis for perforated diverticulitis; SF-36: Quality of Life Questionnaire 
Short Form 36; GIQLI: Gastro Intestinal Quality of Life Index; EQ-5D: Euro Quality of Life 
Questionnaire; LL: Laparoscopic lavage; HP: Hartmann’s procedure; PA: Sigmoidectomy 
with primary anastomosis.
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ABSTRACT 
Background
Case series suggest that laparoscopic peritoneal lavage might be a promising alternative 
to sigmoidectomy in patients with perforated diverticulitis. We aimed to assess the 
superiority of laparoscopic lavage compared with sigmoidectomy in patients with purulent 
perforated diverticulitis, with respect to overall long-term morbidity and mortality.
Methods
We did a multicentre, parallel-group, randomised, open-label trial in 34 teaching 
hospitals and eight academic hospitals in Belgium, Italy, and the Netherlands (the Ladies 
trial). The Ladies trial is split into two groups: the LOLA group comparing laparoscopic 
lavage with sigmoidectomy and the DIVA group comparing Hartmann’s procedure with 
sigmoidectomy plus primary anastomosis. The DIVA section of this trial is still underway 
but here we report the results of the LOLA section. Patients with purulent perforated 
diverticulitis were enrolled for LOLA, excluding patients with faecal peritonitis, aged older 
than 85 years, with high-dose steroid use (≥20 mg daily), and haemodynamic instability. 
Patients were randomly assigned (2:1:1; stratified by age [<60 years vs ≥60 years]) using 
secure online computer randomisation to laparoscopic lavage, Hartmann’s procedure, 
or primary anastomosis in a parallel design after diagnostic laparoscopy. Patients were 
analysed according to a modified intention-to-treat principle and were followed up after 
the index operation at least once in the outpatient setting and after sigmoidoscopy and 
stoma reversal, according to local protocols. The primary endpoint was a composite 
endpoint of major morbidity and mortality within 12 months. This trial is registered with 
ClinicalTrials.gov, number NCT01317485.
Findings
Between July 1, 2010, and Feb 22, 2013, 90 patients were randomly assigned in the 
LOLA section of the Ladies trial when the study was terminated by the data and safety 
monitoring board because of an increased event rate in the lavage group. Two patients 
were excluded for protocol violations. The primary endpoint occurred in 30 (67%) of 45 
patients in the lavage group and 25 (60%) of 42 patients in the sigmoidectomy group 
(odds ratio 1.28, 95% CI 0.54–3.03, P=0.58). By 12 months, four patients had died after 
lavage and six patients had died after sigmoidectomy (P=0.43).
Interpretation
Laparoscopic lavage is not superior to sigmoidectomy for the treatment of purulent 
perforated diverticulitis.
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INTRODUCTION
Diverticular disease is the fourth most costly gastrointestinal disorder in developed 
countries with an estimated annual hospital admission rate of 209 per 100 000 adults in 
Europe1,2. The prevalence of this disorder increases with age and is estimated at 5% of 
people in their forties and can be as high as 80% in those aged older than 80 years2,3. Of 
patients with acute diverticulitis, 8–35% presented with perforated disease with abscesses 
or peritonitis2,4. Perforated diverticulitis is graded according to the Hinchey classification, 
with abscess formation scored as Hinchey I or II, purulent peritonitis as Hinchey III, 
and faecal peritonitis as Hinchey IV5. Laparoscopic peritoneal lavage has emerged as 
a promising alternative to sigmoidectomy in patients with purulent peritonitis owing to 
perforated diverticulitis. This non-resectional strategy was first described in 19966,7. In 
2008, Myers and colleagues reported a 95% success rate of laparoscopic peritoneal lavage 
in 92 patients8. 2 years later a systematic review of case series showed a mortality rate of 
less than 5% and a colostomy was avoided in most patients9. Since these publications, 
laparoscopic lavage for purulent perforated diverticulitis has gained popularity because 
of its great potential to improve outcomes and reduce costs. Despite the absence of 
robust evidence from randomised trials, laparoscopic lavage has been embraced by 
many surgeons. Even some national and international guidelines state that it is a safe 
approach in purulent perforated diverticulitis10,11. The laparoscopic lavage (LOLA) group 
of the Ladies trial postulated that laparoscopic lavage compared with sigmoidectomy 
for purulent perforated diverticulitis would lead to a reduction in composite outcome of 
major morbidity and mortality in a randomised multicentre trial12.
MeThODS
Study design and participants
The Ladies trial is a multicentre, parallel-group, randomised, open-label superiority 
trial done in 34 teaching hospitals and eight academic hospitals in Belgium, Italy, and 
the Netherlands. It was designed to compare laparoscopic lavage and sigmoidectomy 
for purulent perforated diverticulitis in the LOLA group and to compare Hartmann’s 
procedure versus sigmoidectomy with primary anastomosis in both purulent and faecal 
perforated diverticulitis in the DIVA group. Patients with signs of general peritonitis and 
suspected perforated diverticulitis were eligible for inclusion. Radiological examination by 
radiography or a CT scan had to show diff use-free intraperitoneal air or fluid for patients 
to be classified as having perforated diverticulitis. Exclusion criteria were dementia, 
previous sigmoidectomy, pelvic irradiation, chronic treatment with high-dose steroids 
(>20 mg daily), being aged younger than 18 years or older than 85 years, and having 
preoperative shock needing inotropic support. Patients with Hinchey I and II perforated 
diverticulitis were excluded from the study and patients with Hinchey IV peritonitis or 
Processed on: 22-2-2017
507513-L-bw-Mulder
84
Chapter 6
overt perforation could only be included in the DIVA group. The study protocol12 was 
approved by the ethical review board and written informed consent was obtained from 
all patients before randomisation. This study was investigator initiated and designed in 
accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
Randomisation and masking
After preoperative informed consent was obtained by the surgeon or surgical resident, 
diagnostic laparoscopy was done to confirm the diagnosis of perforated diverticulitis and 
to distinguish between purulent and faecal peritonitis or overt perforation. Only patients 
with purulent perforated diverticulitis without overt perforation were randomly assigned 
within the LOLA group with secure online computer randomisation, either directly in 
the operating room or by the trial coordinator on the phone. Patients were randomly 
assigned (2:1:1) to receive either laparoscopic lavage, sigmoidectomy without primary 
anastomosis, or sigmoidectomy with primary anastomosis (with or without defunctioning 
ileostomy), allowing for a 1:1 comparison between lavage and sigmoidectomy in the 
LOLA group (figure, Appendix). Patients with an overt perforation or faecal peritonitis 
were included in the DIVA group of the study and not analysed within the LOLA group. 
We used a random and concealed block size of 2, 4, or 6 for randomisation and stratified 
for age (younger or older than 60 years). Treatment allocation was not masked to patients, 
physicians, or researchers at any timepoint.
Procedures
The procedures for surgery, reintervention, and stoma reversal have previously been 
described12. To determine the presence of a sigmoid perforation, adherent tissues were 
carefully removed, but when firmly adherent, they were left in place. Laparoscopic lavage 
was done by irrigation with up to 6 L of warm saline throughout the abdominal cavity. 
A Douglas drain was inserted in the right lateral port site. Sigmoidectomy with primary 
anastomosis was done according to the guidelines of the American Society of Colon and 
Rectal Surgeons and the creation of a defunctioning ileostomy was at the discretion of 
the surgeon13. 4–6 weeks after laparoscopic lavage, sigmoidoscopy was done to exclude 
malignancy as the underlying cause of perforation. In the sigmoidectomy group, patients 
were offered stoma reversal if they were fit enough and willing to undergo surgery. 
Routine sigmoidectomy was not recommended for patients after laparoscopic lavage. 
Patients were followed up after the index operation at least once in the outpatient setting 
and after sigmoidoscopy and stoma reversal, according to local protocols. If the patient 
was not in active follow-up by the surgeon at 12 months, the patient was contacted to 
verify the remaining follow-up.
Outcomes
The primary endpoint of the LOLA group was a composite endpoint including major 
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morbidity and mortality within 12 months. Major morbidity was defined as the occurrence 
of the following events or conditions: surgical reintervention, abdominal wall dehiscence, 
abscesses needing percutaneous drainage during the full period and urosepsis, myocardial 
infarction, renal failure, and respiratory insufficiency within 30 days after operation or in 
hospital12. Elective stoma reversal surgery was not defined as morbidity or reintervention 
for either group, whereas elective sigmoidectomy after lavage was scored accordingly. 
Secondary outcomes were operating time, length of hospital stay, days alive and outside 
the hospital, shortterm morbidity and mortality, incisional hernia, reinterventions within 
12 months, and health-related quality of life (measured with Short Form-36 version 2 
[SF-36v2], Gastrointestinal Quality of Life Index [GIQLI], and EuroQol 5D 3 level [EQ-
5D-3L] questionnaires at 2, 4, 13, and 26 weeks)14. These timepoints were chosen to 
address both short-term and long-term postoperative recovery. Short-term morbidity 
and mortality were defined as within 30 days after operation or until discharge, if the 
patient was still admitted at that time. We did a post-hoc analysis of the incidence of 
recurrent diverticulitis and the incidence of underlying perforated colorectal carcinoma 
diagnosed during follow-up. Failure of treatment was defined as persisting abdominal 
sepsis, resulting in surgical reintervention or death15. 
Statistical analysis
We calculated that a sample size of 264 patients for the LOLA group was needed to 
detect a 15% difference in the composite endpoint of major morbidity and mortality, 
with an expected rate of 25% in the sigmoidectomy group and 10% in the laparoscopic 
lavage group at 12 months. We used a two-sided likelihood ratio test and a power of 
90%12. The assumption of 10% major morbidity and mortality is based on the reported 
morbidity and mortality by Toorenvliet and colleagues, whereas 25% major morbidity 
and mortality was based on adjusted data from the scientific literature because we only 
included patients with a Hinchey III score and excluded those with Hinchey IV or other 
risk factors for postoperative morbidity and mortality according to our set exclusion 
criteria9,16,17. We designed a monitoring plan for source data verification on the basis 
of the assumption that the trial was a moderate-risk study. The first three participating 
patients in each centre, followed by a 50% sample control of the following included 
patients, were verified by an independent clinical research associate. The clinical research 
associate verified informed consent, inclusion criteria, adverse events, and adherence 
to Good Clinical Practice guidelines, with the resources available (eg, patient charts 
at the participating hospital). In regular interim analyses, an independent data and 
safety monitoring board (DSMB) assessed the progress of the trial and examined safety 
variables after inclusion of every 25 patients. Although no stopping rules were defined in 
the protocol, a formal DSMB charter was developed and approved by the central ethical 
committee. This charter allowed the DSMB to stop the study for safety or early superiority 
without any prespecified definitions. According to this charter, the DSMB assessed the 
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progress and analysed outcomes on the basis of the data supplied by the researchers—
eg, for early morbidity (<30 days) and major morbidity as defined in the study protocol. 
The DSMB was granted access to individual data for those patients with study-related 
severe morbidity and mortality. We analysed patients according to a modified intention 
to- treat principle. We tested the primary endpoint using binary logistic regression 
analysis with post-hoc correction for the planned stratified age groups (<60 years and 
≥60 years) with a two-sided significance level of 5%. We tested secondary outcomes with 
linear and binary logistic regression analysis with post-hoc correction for the planned 
stratified age groups (<60 years and ≥60 years) to compare groups. For categorical 
data and binary data with no events in one of the groups, we calculated numbers and 
percentages and compared these between groups with unadjusted Fisher’s exact test. 
We reported data with effect sizes, mean differences (MD), odds ratios (OR) and 95% CI, 
or with 1000 samples bias corrected and accelerated bootstrapped 95% CIs in the case of 
non-parametric data. We tested continuous variables for normality using the Shapiro-Wilk 
test and Q-Q plots. We summarised data as either means with SDs or medians (IQRs), 
depending on normality. We did post-hoc subgroup analysis for the American Society 
Anesthesiologists physical status classification (ASA) grade because ASA grade differed 
significantly between the two treatment groups at baseline. Subgroup analyses have been 
done with logistic regression analysis. We used a complete case analysis approach apart 
from the quality of life questionnaires (SF-36v2, GIQLI, and EQ5D), assuming random 
missing data. All questionnaires were scored according to the relevant manuals and 
presented as domains and summarised scores. In cases of missing items within domains 
of the SF-36 and GIQLI, missing items were substituted with the mean value if at least 
half of the items in the subscale were known. When questionnaires were not returned 
for any of the four timepoints, missing data were imputed by linear interpolation if the 
borderline timepoints (eg, 2 weeks and 6 months) were available. Missing observations 
in the first or last timepoint were imputed with the first observation carried backward 
and last observation carried forward method. At least one returned questionnaire was 
needed for imputation of the missing timepoints. Questionnaire outcome comparisons 
were corrected for multiple testing with the Benjamini-Hochberg method, although 
this correction was not prespecified in the protocol. The trial was registered with the 
trialregister.nl, number NTR2037 and ClinicalTrials.gov, number NCT01317485.
Role of the funding source
The funder of the study critically reviewed and adjusted the study design, but had no role 
in data collection, data analysis, data interpretation, or writing of the report. All authors 
had full access to all data in the study and had full responsibility for the decision to submit 
for publication.
Processed on: 22-2-2017
507513-L-bw-Mulder
87
Laparoscopic peritoneal lavage or sigmoidectomy for perforated diverticulitis with purulent peritonitis
6
ReSULTS
Between July 1, 2010, and the early termination of the trial on Feb 22, 2013, we randomly 
assigned 90 patients in the LOLA group; 47 patients were assigned to laparoscopic 
lavage and 43 to the sigmoidectomy. Patients were followed up for 12 months (figure 1). 
Two patients were excluded because of protocol violations of the inclusion criteria; one 
used high-dose steroids and the other was randomly assigned despite a known diagnosis 
of perforated rectal carcinoma at the time of surgery. One patient in the lavage group was 
lost to follow-up at 12 months because he could not be located after he moved house. 
Patients in this trial were included from 30 hospitals (28 from the Netherlands, one 
Belgian, and one Italian). Because the registration of non-included patients seemed to be 
incomplete, a chart review was done in all participating hospitals in the Netherlands to 
verify the number of excluded and missed patients within the study period. In these 
hospitals, 563 patients with acute surgery for perforated diverticulitis were identified of 
whom 186 were eligible and underwent diagnostic laparoscopy, 77 were excluded with 
Hinchey I or II diverticulitis. Of 247 eligible patients with Hinchey III perforated diverticulitis, 
84 were included in the LOLA group. Another six patients were included from foreign 
participating hospitals (Appendix, Table 1). The baseline characteristic of patients included 
in this trial (Table 1) did not differ from the eligible but not included patients (Appendix). 
The mean age in the 88 analysed patients was 63 years (SD 12.5) and 51 (58%) were men. 
The proportion of patients with ASA grade III or IV was lower in the lavage group. The 
physiological score and operative severity score (POSSUM-OS) reported in the 
sigmoidectomy group was higher than that in the lavage group, but can be attributed to 
the two point higher procedure score for sigmoidectomy (Appendix). Within the 
sigmoidectomy group, 20 patients were allocated to sigmoidectomy with end colostomy 
and 22 to sigmoidectomy with primary anastomosis, of whom one was converted to a 
Hartmann’s procedure and one crossed over to laparoscopic lavage (because this patient 
could not be placed in the stirrups, needed to use the circular stapler because of recent 
knee surgery). 14 patients were diverted with an ileostomy. One patient in the lavage 
group was converted to open Hartmann’s because of faecal contamination of the pelvis 
identified during lavage. Seven sigmoidectomies were completed by laparoscopy, all 
others were converted to open surgery after randomisation. The LOLA group of the 
Ladies trial was terminated early for safety reasons after the third planned interim analysis 
after 75 patients were enrolled, the data were reported to the DSMB on Nov 14, 2012. As 
the DSMB requested additional data, the final data on which the decision was taken 
included 46 lavage and 40 sigmoidectomy patients from the LOLA group. During the first 
two analyses, the DSMB raised concerns about the safety of the patients in the lavage 
group because of the high short-term morbidity and reintervention rate, but the numbers 
were too small to form a conclusion. At the third analysis, the interim data for in-hospital 
major morbidity or mortality was 16 (35%) of 46 in the lavage group versus seven (18%) of 
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Patients randomised as Hinchey III 
(LOLA & DIVA)
N = 90
Exclusion:
Sigmoid carcinoma  n = 1
Laparoscopic Lavage
(LOLA)
N = 47
Sigmoid resection
(LOLA & DIVA)
N = 43
Patients with perforated diverticulitis
N = 563
Exclusions  Hinchey III
Age >85y n = 31
Previous surgery or radiation n = 9
>20mg daily steroids n = 32
Shock with inotropic support n = 23
Dementia n = 5
Other indication for sugery n = 36
Exclusions Hinchey IV
Unspecified n = 84
No informed consent obtained n = 157
Recieved assigned 
treatment
N = 45
Recieved assigned 
treatment
N = 41
Included in intention-to-treat analysis laparoscopic lavage
N = 46
Included in intention-to-treat analysis sigmoid resection
N = 42
Protocol violation:
>20mg steroids n = 1
Patients randomised as Hinchey IV 
(DIVA, inclusion ongoing)
N = 19
Hartmann’s prodedure
(DIVA)
N = 9
Primary anastomosis
(DIVA)
N = 10
Diagnostic laparoscopy
N = 186
Hinchey I-II n = 77
Cross-over to 
Hartmann’s 
N = 1
Cross-over to lavage
N = 1
Sepsis controlled
n = 35 (76%)
Sepsis not controlled
n = 11 (24%)
Late reintervention 
n = 11‡ 
    Diverticulitis n = 6
    Cancer n = 4
    Profylactic n = 1
Sepsis controlled 
 n = 9
Sh
or
t t
er
m
Lo
ng
 te
rm
Reintervention 
n = 9#
Death from multiple 
organ failure n = 2
Additional 
reinterventions n = 3*
Late reintervention n = 6† 
  Abdominal wall n = 1
  Stoma reversal n = 5
     Relaparotomy n = 1
No further surgery 
n = 24 (52%)
Late unrelated death 
n = 2
Stoma free & alive n = 36/46 (78%)$
   Never had a stoma n = 31/42 (74%)
   Stoma closed n= 5/11 (45%)
Alive at 12 months
n = 42 (91%)
Late unrelated death
 n = 3
Sepsis controlled
n = 38 (90%)
Sepsis not controlled
n = 4 (10%)
Late reintervention 
n = 2‡ 
Death shortly after 
discharge n = 1
Reintervention 
n = 3#
Death
n = 1
Sepsis controlled 
n = 3
No further surgery 
n = 13 (31%)
Stoma reversal related 
reintervention n = 3*
Stoma free & alive n = 30/42 (71%)‡
   Never had a stoma n = 7/36 (19%)
   Stoma closed n = 23/29 (79%)
Alive at 12 months
n = 36 (86%)
Stoma reversal
n = 1
Stoma reversal 
n = 23
Death shortly after 
discharge n = 1
Figure 1. Trial profile of included patients and additional treatment received. | Lavage group: # 
Laparoscopic Hartmann’s procedure (HP), laparoscopic primary anastomosis (PA) with ileostomy, 
4 open HP, 3 with multiple procedures. | *1 patient with four open lavages (OL) resulting in a 
laparostoma, 1 patient with redo laparoscopic lavage followed by open HP, 1 patient open HP 
followed by OL and open rectal stump reresection due to persistent leakage. | † 1 sigmoidectomy 
with primary anastomosis, abdominal wall and fistula correction following laparostoma, 1 
relaparotomy for haematoma after Hartmann’s reversal, 4 uncomplicated stoma reversals. | ‡ 4 
laparoscopic and 2 converted PA without ileostomy for persistent or recurrent diverticulitis or 
abscesses, 1 prophylactic single port PA without stoma. 2 open HP, 1 open PA for cancer, 1 liver 
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40 (complete data were not available for 2 patients) in the sigmoidectomy group (P=0.12), 
with 37 events in the lavage group and ten events in the sigmoidectomy group (P=0.0005). 
Surgical reinterventions accounted for most of these adverse events with 18 (lavage) 
versus two (sigmoidectomy) in-hospital reinterventions (P=0.0011) and 28 (lavage) versus 
11 (sigmoidectomy) overall surgical reinterventions (P=0.0219). Therefore, the DSMB 
advised to us to end the LOLA group of the trial as the safety of the participants in the 
lavage group was at risk. As the safety concerns were limited to the laparoscopic lavage 
group, the DIVA group was continued as planned after the ethical committee approved 
the amended protocol. Therefore, data about the comparison between sigmoidectomy 
with and without primary anastomosis will not be presented until the remaining DIVA 
group is closed. During the 12-month follow-up, no difference was reported in the 
incidence of the composite primary endpoint (30 patients in the lavage group vs 25 
patients in the sigmoidectomy group; OR 1.28, 95% CI 0.54–3.03, P=0.5804). This rate 
includes four (9%) and six (14%) patients who had died either postoperatively or during 
the follow-up in the lavage and sigmoidectomy group (OR 0.53, 95% CI 0.13–2.15, 
P=0.3772). Five patients died during their primary hospital stay or shortly thereafter, 
whereas the remaining five late deaths (two in the lavage group, three in the sigmoidectomy 
group) were unrelated to the study procedures (Appendix). The mean operating time was 
shorter for the lavage group with 60 min compared with 120 min in the sigmoidectomy 
group (mean difference [MD] –54.53, 95% BCa CI –68.04 to –40.26, P=0.0010). The 
length of postoperative hospital stay did not differ between the two groups, 8 days (IQR 
6–15) after lavage and 10 days (7–14) after sigmoidectomy (MD –0.62, 95% BCa CI –8.34 
to 6.38, P=0.8751). The combined major morbidity and mortality rate within 30 days after 
operation or in hospital was higher after laparoscopic lavage (18 [39%] patients in the 
laparoscopic lavage group compared with eight [19%] in the sigmoidectomy group [OR 
2.74, 95% CI 1.03–7.27, P=0.0427]), most of which could be explained with the higher 
rate of reinterventions in the lavage group (16 and three patients, OR 6.93, 95% CI 1.85–
metastasectomy plus diagnostic laparoscopy with peritoneal metastases followed by acute fascial 
dehiscence correction.| $ 36 of total 46 lavages were alive and stoma free at 12 months, 31 of 42 
patient alive never had a stoma, 5 of 11 patients alive with stoma were reversed. | Sigmoidectomy 
group: # 1 relaparotomy for acute fascial dehiscence, 1 suspected but unconfirmed anastomotic 
leak, 1 second look laparotomy in a patient with an open abdomen, who died shortly after 
discharge due to pneumosepsis. | * 1 revision of the obstructed anastomosis before the ileostomy 
reversal, 1 splenectomy and video assisted thoracoscopic surgery (VATS) for a splenic abscess and 
thoracic empyema | † 1 relaparoscopy for bleeding, 1 open lavage for haematoma 1 relaparotomy 
with end colostomy for anastomotic leakage. All following Hartmann’s reversal. | ‡ 30 of 42 total 
sigmoidectomies stoma free and alive at 12 months, 7 of 36 patients alive never had a stoma, 23 of 
29 patients alive with stoma were reversed. 
Figure 1. Continued
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26.00, P=0.0041). Short-term adverse events are summarised in Table 2 and the Appendix. 
Sepsis was controlled successfully in the short term, defined as not needing surgical 
reintervention and being alive, in 35 (76%) of the patients in the lavage group and 38 
(90%) of the patients in the sigmoidectomy group (Appendix). Persistent sepsis in the 
lavage group needed surgical reintervention in nine patients and was caused by faecal 
peritonitis or overt perforation in six patients. One patient was diagnosed with an 
underlying carcinoma during pathological assessment. Seven patients had a Hartmann’s 
procedure, one a primary anastomosis with ileostomy, and one patient had four 
relaparotomies after laparoscopic lavage, followed by delayed elective sigmoidectomy. 
Two other patients died from multiorgan failure. Three patients in the sigmoidectomy 
group needed reintervention because of an acute fascial dehiscence, an unconfirmed 
anastomotic leakage, and a negative second look laparotomy in a patient with an 
abdomen left open. One patient died because of massive arterial embolism and another 
two patients died shortly after extended hospital stay because of renal or respiratory 
failure. Routine pathological assessment revealed two patients with underlying carcinoma 
in the sigmoidectomy group, both treated with adjuvant chemotherapy. Stoma reversal 
surgery was done in five of 11 patients (one ileostomy, four of ten colostomies) in the 
lavage group and 24 of 35 in the sigmoidectomy group (12 of 14 ileostomies, 12 of 21 
colostomies). Morbidity occurred in one patient in the lavage group and six patients in 
the sigmoidectomy group after stoma reversal, including one patient (lavage) and three 
patients (sigmoidectomy) with a surgical reintervention, after Hartmann’s reversal. No 
reversal-related mortality occurred (Appendix). Laparoscopic lavage was successful in 24 
(52%) patients in the long term, defined as no acute or elective surgical reintervention or 
related mortality, and 31 (74%) of the 42 patients alive never had a stoma (Appendix). 
Seven patients had elective laparoscopic sigmoidectomy, of whom two were converted 
to laparotomy. Four had open surgery for colorectal cancer, of whom three were diagnosed 
during follow-up colonoscopy. The other patient presented with a colovesical fistula after 
8 months. Two of these four patients developed metastases. Two patients that had acute 
reoperation after laparoscopic lavage needed additional surgical reintervention, including 
one haematoma after Hartmann’s reversal. In the sigmoidectomy group, no further 
surgery was done in 13 (31%) patients, of whom 6 never had a stoma (Appendix). During 
follow-up, two patients needed surgical reintervention; one for revision of the obstructed 
anastomosis before the ileostomy could be reversed and the other patient needed 
splenectomy and video-assisted thoracoscopic surgery for a splenic abscess and thoracic 
empyema. Three more patients had surgical reintervention after Hartmann’s reversal, two 
postoperative haematomas, and one anastomotic leakage. 36 (78%) patients in the 
lavage group and 30 (71%) in the sigmoidectomy group were alive and stoma free after 
12 months (OR 1.53, 95% CI 0.55–4.30, P=0.4193). In each group, another six patients 
were alive but not stoma free at 12 months. Incisional hernia occurred in five patients 
each in both groups. Four of five hernias in the laparoscopic group occurred after 
conversion or relaparotomy, three had surgical repair. Of the five patients who had hernias 
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in the sigmoidectomy group, only one parastomal hernia was corrected during colostomy 
reversal. Long-term adverse events are summarised in Table 2 and the Appendix. The 
number of days alive and outside the hospital during the 12-month period did not differ 
between both groups (Appendix). The response rate of the quality of life questionnaires 
varied between 56 (64%) of 88 at 2 weeks and 52 (59%) of 88 at 6 months. 69 (78%) 
patients completed at least one of the questionnaires. No differences were identified in 
the main scores of the SF-36, GIQLI, and EQ5D questionnaires, and no subscale remained 
significant after the p values were corrected post hoc for multiple testing (Appendix). In a 
post-hoc subgroup analysis for patients aged younger than 60 years or 60 years and 
above, the primary endpoint did not differ between the two treatment groups. Post-hoc 
stratified analysis for patients with a low ASA grade (I or II) or high ASA grade (III or IV) did 
not show a significant between-group difference in the primary outcome (OR 1.36, 95% 
CI 0.51–3.62, P=0.5337; Appendix; article online).
Table 1. Baseline demographic and clinical characteristics in randomly assigned patients with 
perforated diverticulitis.
Laparoscopic lavage
N=46
Sigmoidectomy
N=42
Age, years 62.3 (12.7) 64.0 (12.3)
Gender
  Male
  Female
26 (56.5)
20 (43.5)
25 (59.5)
17 (40.5)
BMI, kg/m2 * 27.6 (6.2) 27.0 (4.4)
ASA  I
         II
         III
         IV
         missing
10 (21.7)
21 (45.7)
5 (10.9)
3 (6.5)
7 (15.2)
8 (19.0)
13 (31.0)
13 (31.0)
2 (4.8)
6 (14.3)
History of diverticulitis† 12 (31.6) 10 (26.3)
Previous laparotomy‡ 4 (8.9) 3 (7.3)
Disease severity pre-operative
APACHE II
POSSUM PS
POSSUM OS
7.3 (4.2)
20.8 (6.2)
17.1 (0.5)
9.0 (4.8)
22.8 (6.2)
20.0 (2.2)
Interval from ER to surgery 13 (8-32) 13 (6-42)
Gastrointestinal surgeon 37 (80.4) 36 (85.7)
Data are mean (SD) median (IQR) or number (%). BMI=Body-mass index. ASA=American Society 
of Anesthesiologists classification. APACHE II=Acute Physiology and Chronic Health Evaluation 
II. POSSUM PS= Physiology and Operative Severity Score for the enumeration of Mortality 
and Morbidity – Physiology Score. POSSUM OS= POSSUM Operative Score. ER=moment of 
presentation at the emergency department. Data provided for *n=40, n=39 †n=38, n=38 ‡n=45, 
n=41 patients in the laparoscopic lavage group and sigmoidectomy group respectively.
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DISCUSSION
In this study, which was terminated early, laparoscopic peritoneal lavage for purulent 
perforated diverticulitis did not result in a reduction in the composite endpoint of 
major morbidity and mortality compared with sigmoidectomy at 12 months. Although 
laparoscopic lavage did result in a higher acute reintervention rate, 76% of patients were 
discharged without further surgery. The higher morbidity rates did not result in excess 
mortality, suggesting that patients that fail lavage can be salvaged when reintervention is 
timely. The 24% failure to control sepsis with lavage could be attributed to misdiagnosis of 
faecal peritonitis in most cases. As the phlegmon is often located at the pelvic entrance, 
occluding the view on Douglas pouch, the limited exploration as described in our study 
protocol might have resulted in these misdiagnoses. A third of the pathological specimens 
from the sigmoidectomy group showed a perforation, similar to the 37% perforations 
identified in the pathological specimens of a previous study. These rates suggest 
a similar rate of sealed or missed perforations in the lavage group18. A CT scan with 
rectal contrast might be able to discriminate faecal from purulent peritonitis by showing 
Table 2. Serious adverse events as defined as major morbidity.
Laparoscopic lavage 
N=46
Sigmoidectomy 
N=42
P-Value
N patients N events N patients N events
Short term serious adverse events 18 (39%) 39 8 (19%) 14 0.0427
  Death 2 (4%) 2 1 (2%) 1 0.6237
  Surgical reintervention 9 (20%) 15 3 (7%) 3 0.1230
  Abscess with percutaneous drainage 9 (20%) 12 0 0 0.0027
  Fascial dehiscence 0 0 3 (7%) 3 0.1046
  Myocardial infarction 0 0 1 (2%) 1 0.4773
  Respiratory failure 6 (13%) 6 2 (5%) 2 0.1955
  Renal failure 2 (4%) 2 3 (7%) 2 0.9207
Long term serious adverse events 17 (37%) 30 17 (40%) 20 0.1156
  Death 2 (4%) 2 5 (12%) 5 0.1875
  Surgical reintervention 13 (28%) 16 5 (12%) 6 0.1156
  Abscess with percutaneous drainage 2 (4%) 4 2 (5%) 2 0.9207
  Fascial dehiscence 5 (11%) 5 5 (12%) 5 0.4359
  Sigmoid carcinoma 5 (11%) 5 2 (5%) 2 0.3047
Recurrent diverticulitis 9 (20%) 9 1 (2%) 1 0.0315
Composite primary outcome (major 
morbidity or mortality at 12 months) 30 (67%) - 25 (60%) - 0.5804
Data are number (%) unless otherwise stated. Short term is defined as within 30-days or in-hospital, 
long term is defined as after 30-days or discharge and within 12 months.
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contrast extravasation. However, the use of rectal contrast for acute abdominal CT scans 
is not routine practice and is barely discussed in guidelines19. The use of rectal contrast 
might also help to diagnose underlying colorectal carcinoma. Seven (8%) patients were 
diagnosed with a sigmoid carcinoma, which is not unusual compared with the 3% and 
7% reported in two previous trials on perforated diverticulitis20,21. These carcinomas have 
been responsible for a third of the elective sigmoidectomies in the lavage group. At the 
time we initiated the Ladies trial, the evidence for laparoscopic lavage consisted of limited 
and low quality evidence from case series. A success rate of 96% for laparoscopic lavage 
with low mortality (2%) and morbidity (10%) was reported in a systematic review including 
231 patients from 13 papers9. More recently published case series show higher failure 
rates of up to 34% and a morbidity rates up to 56% for laparoscopic lavage (panel and 
Appendix)15,22. The favourable results of the largest series by Myers and colleagues8 and 
several other series might have a selection bias because the complete population from 
which these patients were selected was not described and a large proportion of patients 
without perforation (Hinchey II) were included. The excellent results of the early case series 
are unlikely to be reproduced in large randomised controlled trials because selection 
bias is usually stronger in the series and the patient’s condition is a major predictor of 
postoperative outcomes17. Although the results of laparoscopic lavage were not as good 
as expected, the 30-day mortality rate of 2% in the sigmoidectomy group of this study 
was low compared with previous studies. However, these previously reported rates of 
10–22% include patients with faecal peritonitis, with a reported odds ratio for increased 
mortality of 3.9 in patients with faecal peritonitis17,23,24. While designing the study, we 
assumed that taking the short-term morbidity and mortality as the primary endpoint 
would underappreciate the benefits of lavage. We expected that in the sigmoidectomy 
group more late surgeries—eg, abdominal wall repairs, and morbidity associated with 
stoma closure—would occur. Stoma closure was part of the sigmoidectomy strategy and 
therefore not counted as an adverse event. Our power calculation was done on the basis 
of a 15% difference in the composite endpoint. Both the 10% and 25% for lavage and 
sigmoidectomy were conservative estimates, allowing for a clinically relevant difference 
and sufficient group size to avoid an underpowered study. Traditionally, surgical studies 
focused on morbidity and mortality and used these as primary outcomes. Similar outcomes 
are used in the other trials on perforated diverticulitis25-27. Other definitions of success can 
be used provided that no excess mortality exists in one of the study groups—eg, no further 
surgery, never having had a stoma, and enabling delayed laparoscopic surgery. Because 
of the design of the study, it had insufficient power to conclude on non-inferiority. A non-
inferiority trial with mortality as the primary endpoint would need a very large sample 
size, while patient accrual in emergency trials has been shown to be difficult28. Two earlier 
randomised trials of perforated diverticulitis were terminated at less than half of the 
calculated sample size because of a declining accrual rate20,21. Because of the parallel 
randomisation in the DIVA group, the ostomy reversal rate in the sigmoidectomy group 
Processed on: 22-2-2017
507513-L-bw-Mulder
94
Chapter 6
was affected by the allocation to Hartmann’s or primary anastomosis. However, this was 
not expected to affect the 12-month morbidity and mortality rate in our study because no 
differences were shown in recent randomised trials20,21. Although no differences between 
groups could be identified in the quality of life questionnaires, we did not collect data 
for patients’ satisfaction with the long-term result of the treatment. A higher satisfaction 
might be expected in those patients who never had a stoma and never needed additional 
surgery, even if an interventional drain had been necessary. Strengths of this study include 
conduct according to Good Clinical Practice principles and source verification of the 
data by an independent monitor. Running investigator driven trials according the Good 
Clinical Practice principles is uncommon in surgery, but was demanded by the Dutch 
Inspectorate of Health Care after irregularities reported in the conduct of the Dutch 
PROPATRIA study29. Another important strength of the study is that we were able to 
account for the eligible but not included patients. In this way, we have been able to assess 
and rule out a patient selection bias despite the low accrual rate of 34%. The participation 
of a large number of hospitals strengthens the external validity and applicability of the 
study results. At the same time, the low number of included patients per hospital can be 
seen as a weakness because of heterogeneity. We conclude that laparoscopic lavage is 
not superior to sigmoidectomy for the treatment of purulent perforated diverticulitis in 
terms of major morbidity and mortality at 12 months. Although the acute reintervention 
rate was higher after lavage, in more than three-quarters of these patients, the sepsis was 
controlled. No excess mortality was present in patients who failed lavage. Optimisation of 
preoperative imaging is warranted to identify those patients who are likely to fail lavage 
because of the presence of a persistent perforation or a perforated carcinoma. Pooling 
of the forthcoming data of the other perforated diverticulitis trials (DILALA, LapLAND, 
and SCANDIV)24–26 with our data might identify additional factors that contribute to an 
improved selection of patients that either need lavage or sigmoidectomy in the acute 
setting. 
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ABSTRACT
Background
The incidence of acute left-sided colonic diverticulitis (ACD) is increasing in the Western 
world. To improve the quality of patient care, a guideline for diagnosis and treatment of 
diverticulitis is needed. 
Methods
A multidisciplinary working group, representing experts of relevant specialties, was 
involved in the guideline development. A systematic literature search was conducted 
to collect scientific evidence on epidemiology, classification, diagnostics and treatment 
of diverticulitis. Literature was assessed using the classification system according to an 
evidence-based guideline development method, and levels of evidence of the conclusions 
were assigned to each topic. Final recommendations were given, taking into account the 
level of evidence of the conclusions and other relevant considerations such as patient 
preferences, costs and availability of facilities. 
Results
The natural history of diverticulitis is usually mild and treatment is mostly conservative. 
Although younger patients have a higher risk of recurrent disease, a higher risk of 
complications compared to older patients was not found. In general, the clinical diagnosis 
of ACD is not accurate enough and therefore imaging is indicated. The triad of pain 
in the lower left abdomen on physical examination, the absence of vomiting and a 
C-reactive protein >50 mg/l has a high predictive value to diagnose ACD. If this triad is 
present and there are no signs of complicated disease, patients may be withheld from 
further imaging. If imaging is indicated, conditional computed tomography, only after 
a negative or inconclusive ultrasound, gives the best results. There is no indication for 
routine endoscopic examination after an episode of diverticulitis. There is no evidence 
for the routine administration of antibiotics in patients with clinically mild uncomplicated 
diverticulitis. Treatment of pericolic or pelvic abscesses can initially be treated with 
antibiotic therapy or combined with percutaneous drainage. If this treatment fails, surgical 
drainage is required. Patients with a perforated ACD resulting in peritonitis should undergo 
an emergency operation. There is an ongoing debate about the optimal surgical strategy. 
Conclusion
Scientific evidence is scarce for some aspects of ACD treatment (e.g. natural history of 
ACD, ACD in special patient groups, prevention of ACD, treatment of uncomplicated 
ACD and medical treatment of recurrent ACD), leading to treatment being guided by 
the surgeon’s personal preference. Other aspects of the management of patients with 
ACD have been more thoroughly researched (e.g. imaging techniques, treatment of 
complicated ACD and elective surgery of ACD). This guideline of the diagnostics and 
treatment of ACD can be used as a reference for clinicians who treat patients with ACD. 
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INTRODUCTION
Left-sided diverticulosis of the colon is a common condition in Western society. The 
prevalence of diverticulosis coli depends on age and increases from about 5% around 40 
years of age to 65% at the age of 85 years or older1,2. It is estimated that approximately 
25% of the patients with diverticulosis will develop an episode of acute left-sided colonic 
diverticulitis (ACD)3. Patients with acute abdominal pain due to ACD impose an impressive 
burden to healthcare4 . In the past years, a dramatic rise in the number of hospitalizations 
for ACD has been noted in the Netherlands. In 2009, 18,355 patients were hospitalized 
with ACD as compared to 13,655 patients in 2006. Meanwhile, expenditures for these 
hospital admissions in the Netherlands exceed EUR 80 million per year5,6. This rise in 
hospital admissions is also notable in other countries. A recent study from the United 
States showed an increase in hospital admissions during the period 1998–2005 of 26%, 
with the greatest rise in patients between 18 and 44 years of age4. In the Netherlands, 
women make up 60% of hospital admissions for ACD6. This difference in incidence of 
ACD between men and women has been noticed in other countries as well. Patients 
younger than 50 years of age with ACD are predominantly men, whereas in the age 
group of 50–70 years there seems to be a preference for women7-11. Patients with mild 
(recurrent) diverticulitis are usually treated by a general practitioner or on an outpatient 
basis, which makes it difficult to accurately determine the true incidence and recurrence 
rates of diverticulitis. 
Although ACD is a very common disease, the clinical diagnosis remains a challenge for 
clinicians and health care researchers. Diagnostics and treatment of diverticulitis are 
mostly characterized by doctors’ personal preferences rather than standardized evidence-
based protocols. This is mainly due to the fact that there is a large amount of conflicting 
and low-quality evidence in publications regarding diverticulitis. To provide doctors and 
other health care providers support in clinical decision-making, practice guidelines can be 
developed. Guidelines are applicable nationwide, but if based on international literature 
can be applicable to developed countries. Therefore, a multidisciplinary working group 
developed national guidelines including the epidemiology, classification, diagnostics and 
treatment of ACD in all its aspects based on an evidence-based review of the international 
literature.
MeThODS
The guideline was written under the auspices of the Netherlands Society of Surgery, in 
collaboration with the Netherlands Societies of Internal Medicine, Gastroenterologists, 
Radiology, Health Technology Assessment and Dieticians. The working group consisted 
of four surgeons, a gastroenterologist, a radiologist, an internist specialized in infectious 
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diseases, a dietician and an epidemiologist and statistician. Participation of a patients’ 
representative in the working group was not possible because a patient association for 
patients with ACD does not exist in the Netherlands. The working group defined the 
following sections of relevance: terminology and classification, epidemiology, special 
patient groups with ACD, prevention of recurrent ACD, clinical diagnosis and radiological 
imaging, colonoscopy, treatment of uncomplicated and complicated ACD, and elective 
surgery and medical treatment in patients with ACD.
Search Strategy
Systematic searches of the Medline and Embase databases were performed using the 
keywords relevant to each section. Terms relevant to each section of the guideline were 
mapped to Medline Subjects Headings (MeSH) terms, as well as searched for as text 
items. Relevant keywords and search strategies can be found in Appendix 1. Articles 
describing randomized controlled trials and systematic reviews were searched for using 
the methodological filters of the Scottish Intercollegiate Guidelines Network (https:// 
www.sign.ac.uk/methodology/filters.html). Different date censoring and limitations were 
applied according to the relevance of each keyword. Only publications in English, French, 
German and Dutch were retrieved and read in full. The bibliographies of included articles 
were subsequently hand-searched for other relevant references, and experts in the field 
were asked if they found any relevant reports missing.
Critical Appraisal
Articles selected to support recommendations were assessed using the national 
classification system for evidence-based guideline development (http://www.cbo.nl), 
which is equivalent to the levels of evidence as published by the Centre for Evidence-Based 
Medicine of the University of Oxford (www.cebm.net; Table 1). Articles were classified 
according to the type of article and individually assessed for methodological quality using 
the GRADE method as proposed by the GRADE working group. That working group 
has developed a common, sensible and transparent approach to grading the quality of 
evidence and strength of recommendations (http://www.gradeworkinggroup.org).
The main literature on which the conclusion for each relevant topic is based is stated with 
the conclusion, accompanied by the level of evidence (Table 2). The final recommendations 
are based on the available evidence from the literature, also taking into account ‘soft’ 
factors such as patient preferences, costs and availability of facilities. Recommendations 
can be strong (‘we can be confident about the recommendation’, level 1) to weak (‘we 
cannot be confident’, level 4). A concept guideline was sent to all involved societies 
for comment and approval after which internal consensus was reached between the 
members of the working group. Amendments were made based upon these comments, 
leading to the final version of the guideline ‘Diagnostics and Treatment of Acute Colonic 
Diverticulitis’, as approved by all societies. 
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Table 1. Classification of evidence.
Level of 
evidence
Interventional 
research
Studies concerning 
diagnostic accuracy
Studies on complications 
or side-effects, etiology, 
prognosis 
A1 Systematic review/ meta-analysis of at least 2 independently performed level A2 
studies 
A2 Double blind 
controlled 
randomised 
comparative clinical 
trial of good study 
quality with an 
adequate number of 
study participants
Diagnostic test compared 
to reference test; criteria 
and outcomes defined in 
advance; assessment of 
test results by independent 
observers; independent 
interpretation of test 
results; adequate number 
of consecutive patients 
enrolled; all patients 
subjected to both tests
Prospective cohort with 
sufficient amount of study 
participants and follow-
up, adequately controlled 
for confounders; selection 
in follow-up has been 
successfully excluded
B Comparative studies, 
but without all the 
features mentioned 
for level A2 (including 
patient-control 
studies, cohort 
studies)
Diagnostic test compared to 
reference test, but without 
all the features mentioned 
in A2
Prospective cohort study, 
but without all the features 
mentioned for level A2 or 
retrospective cohort study or 
case-control study 
C Non-comparative studies
D Expert opinion
Table 2. Grading of the conclusions according to the level of evidence.
Level Conclusion based on
1 Systematic review (A1) or at least 2 independent studies with evidence level A2
(There is evidence that…)
2 One study with evidence level A2 or at least 2 independent studies with evidence level B
(It is likely that … )
3 One study with evidence level B or level C
(There are indications that…)
4 Expert opinion
(The working group recommends….)
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ReSULTS
Terminology and Classification
The term ‘diverticular disease’ used in Anglo-Saxon literature is made up of a spectrum 
of conditions all related to diverticulosis of the colon. Some use the term ‘diverticular 
disease’ for patients with symptoms associated with diverticulosis and distinguish 
diverticulitis as a different entity, whereas others include diverticulitis and diverticular 
bleeding in the term ‘diverticular disease’. The lack of uniformity in terminology results 
in difficulties interpreting and comparing findings between studies. It seems best to use 
the term ‘diverticulosis coli’ and to distinguish between uncomplicated (asymptomatic) 
and complicated (symptomatic) diverticulosis. Patients with uncomplicated diverticulosis 
have no symptoms, and therefore the term asymptomatic diverticulosis is also used. 
Complicated diverticulosis coli, or symptomatic diverticulosis coli, is the complete 
spectrum of symptoms that can arise in patients with diverticulosis coli. This includes 
patients with (chronic) persistent abdominal pain, acute colonic diverticulitis and 
diverticular bleeding. ACD refers to inflammation of diverticula. Uncomplicated ACD 
is referred to when inflammation of one or more diverticula leads to an inflammatory 
process without perforation or abscess formation. Complicated diverticulitis is associated 
with abscess formation, perforation or fistula formation. Recurrent episodes of ACD may 
result in stenosis and obstruction or fistula to nearby organs (mostly bladder) or the skin; 
these late complications are also referred to as complicated diverticulitis.
To classify acute diverticulitis, Hinchey et al.12 proposed a classification system, which is 
currently used in clinical practice in a modified version13 (Table 3). The Hinchey classification 
has traditionally been used to distinguish four stages of complicated diverticulitis. 
Wasvary et al.13 introduced stage 0, clinically mild diverticulitis, and differentiation in 
stage I between limited pericolic inflammation (stage Ia) and abscess formation smaller 
than 5 cm in the proximity of the primary inflammatory process (stage Ib). This broadened 
the original Hinchey classification by not only addressing perforated disease, but also by 
including mild clinical disease13,14. After the introduction of computed tomography (CT) 
for diagnosing acute diverticulitis, several radiologic classification systems were proposed 
additionally15,16. CT findings were correlated with the modified Hinchey scores to come to 
uniform reporting of CT findings (Table 3). 
Conclusion and Recommendations
Uniform terminology is needed in patients with diverticulosis coli. A distinction is made 
between uncomplicated (asymptomatic) diverticulosis and complicated (symptomatic) 
diverticulosis. The latter term is used for the complete spectrum of symptoms that can 
arise in patients with diverticulosis coli (level 4).
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epidemiology
Researching the natural history of ACD is hampered by a number of factors. There is 
no registry of patients regarding the natural course of the disease. Most patients with 
recurrent episodes of ACD have had elective surgery after two episodes of ACD, which 
makes it difficult to determine true recurrence rates in patients with ACD17. Recurrence 
rates of ACD, in which a recurrence is based on the clinical diagnosis without imaging, 
varies between 9 and 29% (level C9,18-23). The accuracy of the diagnosis in these studies 
is questionable because of the lack of a good reference test. There are two studies with 
adequate reference testing that give information on the natural disease history, and they 
report an estimated chance of recurrence of 9% (level C24) and 23% (level C25). The highest 
risk of recurrence seems to be in the first year (10%) and drops to approximately 3% in the 
years thereafter (level C21). The real risk of recurrence is underestimated in these studies; 
recurrence rates apply invariably to a selected group of patients, namely patients with 
symptoms severe enough for hospital admittance. The majority of recurrences tend to be 
mild recurrences that can be managed by conservative treatment (level C9,18,19,21-25). Based 
on recent studies, most perforations do not occur after recurrences, but after the first 
attack of ACD (level C26-33). Multiple recurrences were not associated with a higher chance 
of mortality, nor did they lead to a higher chance of complicated disease (level C26-33).
Conclusions and Recommendations
The natural history of diverticulitis is usually mild and most patients are treated successfully 
Table 3. CT findings according to Kaiser et al 200515.
Modified Hinchey classification Accompanying CT findings 
Stage 0 Clinically mild diverticulitis Diverticula with or without wall thickening of 
the colon
Stage Ia Confined pericolic inflammation and 
phlegmonous inflammation 
Colonic wall thickening with inflammatory 
reaction in pericolic fatty tissue
Stage Ib Abscess formation (<5cm) in the 
proximity of the primary inflammatory 
process
Alterations as stage Ia + pericolic or 
mesocolic abscess formation
Stage II Intra-abdominal abscess, pelvic 
or retroperitoneal abscess, 
abscess distant from the primary 
inflammatory process
Alteration as stage Ia + distant abscess 
formation (mostly pelvic or interloop 
abscesses)
Stage III Generalised purulent peritonitis Free air with local or generalised free fluid 
and possible thickening of the peritoneum
Stage IV Fecal peritonitis Similar findings to stage III
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by conservative means (level 3). Multiple recurrences do not lead to a higher risk of 
complicated diverticulitis (level 3). Patients should be informed of an approximately 25% 
risk of recurrence after an initial episode of ACD (level 3). 
Special Patient Groups
Young Patients
The definition of young age in patients with ACD is either below 40 or 50 years. Of all 
patients hospitalized for ACD, 18–34% are younger than 50 years34,35. Some authors have 
reported that young patients have an increased risk of complications and recommend 
early resection8,36-38. This assumption is based on outdated studies in which 48–88% 
of the patients who had surgery for suspected diverticulitis appeared to have another 
diagnosis at surgery. Recent studies, using CT to diagnose ACD, did not find a higher risk 
of complications in young patients (level C7,18-20,25,34,35,39,40 ). In young patients, the reported 
high risk of recurrent disease is caused by a higher accumulated risk due to higher life 
expectancy rather than absolute risk (level C18-20,40). There is no evidence that younger 
patients should be treated differently than older patients (level C20,25,34,35,39,40).
Immunocompromised Patients
In patients with a compromised immune system, an increased incidence of ACD has 
been reported compared to healthy individuals, especially in patients with kidney failure, 
organ transplant patients and patients using corticosteroids (level C41,42). These patients 
were significantly more often diagnosed with complicated diverticulitis (level C28,42-45). 
Screening and prophylactic sigmoid resection is not routine for patients waiting for organ 
transplantation (level C42,46). Patients with immune deficiency caused by HIV infection, 
diabetes, malignancy or chemotherapy do not have an increased risk of complicated 
diverticulitis (level C47,48). Some reports indicate an increased risk of ACD in obese 
patients, but evidence is inconsistent (level B49 and level C50,51). 
Conclusions and Recommendations
Young patients do not have a more aggressive course of ACD than older patients (level 
3). Young patients have a higher risk of recurrent disease, but the absolute risk difference 
is relatively small (level 3). Screening for diverticulosis in immunocompromised patients 
or patients awaiting organ transplantation in order to perform a prophylactic colonic 
resection is not effective (level 3).
Prevention of Diverticulitis
There are indications that people with a healthy lifestyle, characterized by physical 
exercise, a fiber-rich diet, limited intake of red meat, low alcohol consumption and 
nonsmoking, have a decreased risk of diverticulitis (level B52 and level C53). 
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Conclusions and Recommendations
Counseling patients on risk factors for developing diverticulosis should be included in 
treatment protocols (level 3). 
Clinical Diagnosis and Radiological Imaging
Clinical Diagnosis
The clinical diagnosis of ACD, based on reported complaints, physical examination and 
laboratory results, is correct in 43–68% of patients (level B54,55 and level C56,57). To improve 
diagnostic reliability, a clinical decision rule and a clinical scoring system for diagnosing 
ACD using logistic regression have been published54,55. Reliable independent individual 
risk factors for ACD in both studies were pain only in the left lower abdominal quadrant, 
the absence of vomiting and a C-reactive protein level >50 mg/l. If all three criteria were 
met, 97% of the patients had ACD (level B54,55).
Radiological Imaging
Radiological imaging techniques that are used for the diagnosis of ACD are soluble 
contrast enemas, ultrasound (US), CT and magnetic resonance imaging (MRI). Soluble 
contrast enemas are obsolete for diagnosing ACD due to low accuracy and the inability 
to determine the extent and complications of the disease (level A258 and level B59). 
The most used US technique to examine patients with suspected ACD is the graded 
compression procedure. With this technique, interposing fat and bowel can be displaced 
or compressed by means of gradual compression to show underlying structures60. US is 
a real-time dynamic examination with wide availability and easy accessibility. The use 
of CT in evaluation of patients with ACD has increased to a large extent. CT has the 
advantage of delineating the extent of the extraluminal disease process, has an unlimited 
view and may also direct therapeutic intervention in case of complicated disease, e.g. 
US-guided percutaneous drainage of intra-abdominal abscesses. CT criteria are also 
used as a prognostic tool to determine the risk of complications during conservative 
treatment16,61. The most used diagnostic criteria to diagnose ACD with US and CT are 
increased thickness of the colonic wall, pericolic fat stranding and presence of inflamed 
diverticula. To optimally depict diverticulitis, the use of intravenous, oral and/or rectal 
contrast agents are advised62. Studies report high diagnostic sensitivity and specificity 
for both US (92 and 90%, respectively) and CT after negative or inconclusive US (94 and 
99%, respectively; level A163,64). More recently, in a large prospective series of unselected 
patients with acute abdominal pain at the emergency department, for which imaging 
was indicated by the treating physician, a much lower sensitivity of 61% (52–70%) was 
found for US, whereas the sensitivity of CT for the diagnosis of ACD was 81% (74–88%). 
Sensitivity can be increased up to 94% by performing US first, and CT only in case of a 
negative or inconclusive US. This step-up approach lowered the exposure to ionizing 
radiation for the study population (level A265,66). Besides the known differences between 
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the techniques (availability, costs, reproducibility and interobserver differences), exposure 
to radiation during CT and contrast-induced nephropathy are a concern60. MRI has the 
advantage that no ionizing radiation and intravenous contrast medium are needed to 
reach a higher soft tissue contrast than CT. MRI is increasingly used in the acute setting for 
patients with acute abdominal pain, but accuracy data are still limited. Based on studies 
with small numbers of patients, sensitivity and specificity of MRI for diagnosing ACD vary 
between 86 and 100% and 88 and 100% (level B67,68 and level C69,70).
Conclusions and Recommendations
In general, the clinical diagnosis of ACD is not sufficiently accurate and therefore 
radiological imaging is indicated in these patients (level 2). Patients with mild symptoms 
and no signs of complicated ACD, and the combination of pain in the lower left abdomen 
on physical examination, the absence of vomiting and a C-reactive protein >50 mg/l may 
be withheld from initial imaging for diagnosing ACD (level 2). If imaging is indicated, a 
conditional CT after negative or inconclusive US is the most appropriate approach in 
diagnosing ACD (level 2).
Colonoscopy
Colonoscopy is not recommended in the acute phase to diagnose ACD (level B71 and level 
C72). Although proven feasible in one prospective study, it is rarely needed in the acute 
phase (level C). Possible difficulties of colonoscopy in the acute phase are incomplete 
examination due to pain, stenosis and incomplete bowel preparation. Discouragements 
to perform colonoscopy in the acute phase are based on the hypothesis that insufflation 
of air is associated with the risk of converting a sealed perforation to a free perforation73-75.
Colonoscopy is usually done 6 weeks after an episode of ACD, so as to exclude a colonic 
malignancy. The lifetime risk of developing colonic cancer is approximately 5%. After an 
episode of ACD, it is unlikely that patients have an increased risk of developing colonic 
cancer (level B76,77 and level C78). Although safe, routine performance of a colonoscopy 
in asymptomatic patients after an episode of ACD to exclude other diagnoses was not 
found to be helpful (level B71,79,80).
Conclusions and Recommendations
Colonoscopy in the acute phase of diverticulitis is not recommended for diagnostic 
purposes (level 3). There is no place for routine endoscopic examination after an episode 
of ACD (level 2).
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Treatment of Uncomplicated Diverticulitis
Most patients with uncomplicated diverticulitis (Hinchey 0 or Ia) can be treated conservatively 
with success rate of 93–100% (level C15,81-86). Conservative treatment includes antibiotics, 
starvation and bed rest in almost all studies. There is no evidence that bed rest, dietary 
restrictions or laxatives positively influence the treatment outcome of ACD. In patients 
who do not tolerate oral feeding, it is recommended to start parenteral feeding when oral 
feeding is not to be expected within 3 days (level D87). Almost all international guidelines 
advise the use of antibiotics for the treatment of diverticulitis17,88-91. However, there is no 
evidence that routine administration of antibiotics influences the course of uncomplicated 
diverticulitis (level A292 and level B79). Oral administration of antibiotics seems equally 
effective to intravenous administration (level B93). Intravenous administration over 4 days 
is equally effective as 7 days (level B84). A recent prospective randomized clinical trial did 
not find a reduction of abscess formation, perforation and recurrence rates with the use 
of antibiotics92. The use of antibiotics seems appropriate in patients presenting with signs 
of generalized infection (temperature >38.5° C), affected general condition or signs of 
bacteremia or septicemia and in immunocompromised patients.
Analgesia is part of the treatment of patients with ACD. There is no evidence that 
acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs) or morphinomimtics 
have a negative effect on the course of an episode of ACD. Multiple studies found that 
patients on home NSAID medication present more often with complicated diverticulitis, 
i.e. perforation (level C48,94-97). The (adverse) effect of NSAIDs started as an analgesic in 
patients with uncomplicated ACD has not been studied. Morphinomimetics can be safely 
administered to patients with acute abdominal pain without negatively affecting the 
diagnostic accuracy of clinical evaluation (level A298,99).
Conclusions and Recommendations
There is no evidence that bed rest, dietary restrictions or laxatives influence the 
treatment of ACD (no evidence). There is no evidence that antibiotics should be routinely 
administered to patients with uncomplicated diverticulitis (level 2). Antibiotic treatment is 
recommended when signs of generalized infection (temperature >38.5° C) and affected 
general condition or signs of bacteremia or septicemia are present (level 4). Antibiotic 
treatment is recommended in immunocompromised patients (level 4).
Treatment of Complicated Diverticulitis
Hinchey Ib and II
There are no high-quality reports on the management of patients with ACD and abscess 
formation (HincheyIb and II); therefore, no consensus has been reached about the most 
optimal treatment strategy. Since the introduction of broad-spectrum antibiotics and 
improvement in US- and CT-guided percutaneous drainage techniques, alternatives to 
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surgery have become available. Conservative treatment with antibiotics is successful in 
up to 73% (95% CI: 66.3–78.9) of patients presenting with an abscess of less than 4–5 cm 
in diameter (level C16,18,100-104). When conservative treatment fails, percutaneous drainage 
should be performed, which is successful in up to 81% (95% CI: 73.7–89.1) of patients 
(level C15,16,100-104). The risk of failure of conservative treatment is higher in patients with 
abscesses larger than 4–5 cm than in patients with smaller abscesses (level C15,16,100-104).
Hinchey III and IV
Peritonitis is the most life-threatening complication of ACD, with a mortality of 14%105,106. 
Perforation of the colon to the intra-abdominal cavity results in a purulent or fecal 
peritonitis. Perforation is a relatively rare complication with an incidence of 3.5 per 100,000 
individuals per year107. In a large population-based study from the United States, only 1.5% 
of patients with ACD were found to have a perforation, and 9.6% were found to have an 
abscess108. Peritonitis is a progressive disease leading to general signs of illness expressed 
in organ dysfunction or organ failure caused by bacteremia and septicemia. Prevention 
of these events by early intervention, i.e. aggressive resuscitation preventing inadequate 
tissue perfusion and oxygenation, the administration of broad spectrum antibiotics, 
and elimination of the source of infection, is the keystone of sepsis treatment109. Early 
treatment in patients with peritonitis significantly improves outcome109-111. No evidence-
based advice can be provided for the indications for surgery in patients with perforated 
diverticulitis, but the indication seems self-evident.
Operative Therapy
There are different surgical options for patients with Hinchey III and IV peritonitis: 
diverting colostomy, Hartmann’s procedure or primary resection with anastomosis, and 
laparoscopic lavage with drainage of the abdominal cavity. Hartmann’s procedure is the 
most performed, which is a two-stage procedure involving resection of the diseased 
colon, closure of the distal rectal stump and construction of an end colostomy. In the 
secondstage the colostomy is reversed; however, restoration of the bowel continuity is 
not performed in up to 55% of patients due to operative risks112. Alternatively, resection 
with primary anastomosis, with or without a protective ileostomy or colostomy, can be 
performed. A diverting ileostomy or colostomy combined with intraoperative irrigation 
of the afferent colon can be performed to reduce the rate of symptomatic complications 
in case of anastomotic leakage (level B113,114). Studies comparing mortality, morbidity, 
wound complications, operation time and antibiotic treatment of Hartmann’s procedure 
and primary anastomosis did not show any significant differences. However, most studies 
were prone to selection bias: patients were not randomized for Hartmann’s procedure or 
primary anastomosis and patient groups were not comparable on patient characteristics 
and disease severity. It is likely that the choice of operation is influenced by patient 
conditions and perioperative findings. Nevertheless, there are indications that Hartmann’s 
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procedure and primary anastomosis have comparable outcomes (level B113,115,116). 
However, in critically ill patients, hemodynamic instability is a relative contraindication for 
a primary anastomosis. Due to administration of inotropes to maintain sufficient blood 
pressure, splanchnic perfusion can be reduced, leading to increased risk of anastomotic 
leakage. This hypothesis has been confirmed (mainly in animal experiments) in studies 
on anastomotic healing in general surgery, although not after resection for diverticulitis. 
Fecal contamination of the abdominal cavity is not thought to be a contraindication 
for construction of a primary anastomosis117. Another treatment option in patients with 
purulent peritonitis is laparoscopic lavage and drainage of the abdominal cavity in which 
the colon is not resected. In nonrandomized series, hampered by patient selection, 
laparoscopic treatment accompanied by intravenous antibiotics seems to be an effective 
and safe treatment in Hinchey III patients (level C57,118). However, the results of the first 
randomized trial need to be reviewed for a definite conclusion119.
Conclusions and Recommendations
Smaller abscesses (<4–5 cm) can be treated with antibiotics alone, whereas larger 
abscesses can best be treated with percutaneous drainage combined with antibiotic 
treatment (level 3). Operative treatment is considered standard therapy for patients with 
Hinchey III and IV diverticulitis (no evidence). In hemodynamically stable patients with 
acute diverticulitis and an indication for operative treatment, primary anastomosis with 
or without a diverting ileostomy or colostomy is preferred over Hartmann’s procedure 
(level 2). In patients with Hinchey III diverticulitis, the safety and efficacy of treatment with 
laparoscopic peritoneal lavage is uncertain and will remain so until the results of the first 
randomized trial on the subject become available (level 3).
elective Surgery
The American Society of Colon and Rectal Surgeons (ASCRS) state in their most recent 
guideline that elective sigmoid resection after recovery from ACD should be made on 
a case-by-case basis90. This advice differs significantly from the previous advice, given 6 
years earlier, in which a plea for elective surgery after two episodes of diverticulitis was 
proposed120. Recent data on the natural history of diverticulitis has shown that recurrent 
episodes of diverticulitis mostly run a benign course and only 5.5% of the patients 
with recurrent hospitalizations for diverticulitis are subjected to emergency surgery20. 
Moreover, most patients who present with complicated diverticulitis do so at the time 
of their first attack (level C26,121,122). Recurrent diverticulitis even seems to reduce the risk 
of perforation, possibly due to adhesion formation caused by inflammation. Therefore, 
a policy of elective sigmoid resection after recovery from uncomplicated ACD does 
not decrease the likelihood of later emergency surgery, and the number of previous 
episodes itself is no longer an indication for elective sigmoid resection (level C18,26,33,121-123). 
Persistent colonic symptoms, particularly abdominal pain, have been reported in patients 
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after episodes of diverticulitis. It has been suggested that this pain represents increased 
visceral sensitivity124. These patients might benefit from early colonic resection.
 After elective sigmoid resection, there is a risk of anastomotic leakage, stoma formation, 
morbidity and mortality. Despite resection, even recurrent diverticulitis and continuing 
complaints have been described. Patients with immune deficiencies might benefit from 
early resection since they have a greater risk of perforations and a complicated course of 
recurrent episodes of diverticulitis (level C18,33,121,122).
Elective sigmoid resection for complicated diverticulosis can be performed either with 
an open or laparoscopic approach. Two randomized trials favored laparoscopic surgery 
over open surgery. In the ‘Sigma trial’, significantly more complications, higher pain 
scores and longer hospital stay were found among patients with open surgery. Operating 
time was significantly longer in the laparoscopic group, with a conversion rate of 19%. 
Quality of life was significantly better after 6 weeks, but did not differ after 6 months 
(level A2125). The study by Gervaz et al.126 also had equal long-term results, except for the 
cosmetic outcome, which was better in the laparoscopic group. No difference was found 
considering ventral hernia, patient satisfaction, quality of life or total costs (level A2). 
Laparoscopic surgery provides a faster functional recovery than open sigmoid resection 
and possibly less chance of complications, but the long-term advantages of laparoscopic 
sigmoid resection are not yet evident (level A2125,126 and level B127-131). Both the Sigma trial 
and the Gervaz study did not use the Enhanced Recovery after Surgery (ERAS) principles, 
which are now widely adopted in the perioperative care of patients with abdominal 
surgery. The ERAS program reduced the risk of complications and hospital stay of open 
surgery to a large extent130. In addition, laparoscopic surgery is often done by dedicated 
surgeons, while open surgery is usually performed by a much larger group of surgeons, 
possibly influencing the results.
To reduce the risk of recurrent diverticulitis, the sigmoid should be resected up to 
the proximal rectum (level C131,132). There is no evidence for the optimal proximal 
resection margin; however, a resection as limited as possible in soft compliant bowel is 
recommended90. 
Conclusions and Recommendations
Patient-related factors, not so much the number of previous episodes of diverticulitis, 
should play the most important role in selecting patients who might benefit from elective 
sigmoid resection (level 3). If appropriate laparoscopic expertise is present, laparoscopic 
surgery for recurrent episodes of diverticulitis might be favored over open sigmoid 
resection in terms of short-term outcome, but no long-term benefits have been reported 
(level 1). During elective sigmoid resection, the part of the colon resected proximally to 
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the inflammatory process should be as limited as possible with the proximal rectum as 
the distal margin (level 3).
Medical Treatment of Recurrent Diverticulitis
Traditionally, fiber-enriched diets in patients with diverticulitis have been considered 
to prevent recurrent episodes of ACD. However, randomized clinical trials on fiber-
enriched diets in patients with ACD have had inconsistent results133. A recently published 
systematic review of high-fiber dietary therapy could not include any studies concerning 
prevention of diverticulitis with a high-fiber diet134. Despite the lack of evidence, high 
daily fiber intake is recommended as treatment in various guidelines17,88,90,91. Since obesity 
and smoking are associated with an increased risk of complications of diverticulitis, 
weight reduction and cessation of smoking can have a favorable influence on prevention 
of recurrent diverticulitis (level B51,135). Although evidence on lifestyle advice to prevent 
recurrent episodes of ACD is missing, it is likely that the same measures to prevent ACD 
also apply to patients after an episode of ACD. Hence, a healthy lifestyle, characterized 
by physical exercise, a fiber-rich diet, little intake of red meat, low alcohol consumption 
and nonsmoking are advised in patients after an episode of ACD (level B52 and level C53).
Recently, new theories about similarities between ACD and inflammatory bowel disease 
have been proposed, leading to new treatment possibilities, such as probiotics, antibiotics 
and anti-inflammatory agents136. Regarding drug treatment, intermittent administration of 
a nonabsorbable antibiotic (rifaximin) after an episode of acute diverticulitis decreased the 
chance of readmission by 50% and of recurrent diverticulitis by 73% (level B137). Prevention 
of recurrent disease is more effective when 5-aminosalicylic acid (mesalazine) is combined 
with rifaximin, compared to rifaximin alone (level A2138 and level B139). Furthermore, a 
combination of probiotics and anti-inflammatory medication is preferred over treatment 
with probiotics alone (level A2140).
Residual complaints after an episode of diverticulitis occur often and medical treatment 
can reduce symptoms. In these patients a trial period of intermittent administration of 
a nonabsorbable antibiotic with mesalazine or probiotics should be considered. This 
is especially so since there is little risk from treatment by nonresorbable antibiotics 
or mesalazine combined with probiotics, while mortality and morbidity of operative 
treatment are substantial.
Conclusions and Recommendations
The working group advises to give lifestyle advice to patients following an attack of 
diverticulitis, focusing on increasing daily fiber intake, weight reduction, cessation of 
smoking and increasing physical activity (level 4). Nonabsorbable antibiotics seem 
to reduce the risk of recurrent episodes of diverticulitis (level 3). The combination of 
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5-aminosalicylic acid and rifaximin is more effective than rifaximin alone in the prevention 
of recurrent episodes of diverticulitis (level 2). The working group opinion is that in 
patients with recurrent diverticulitis or patients with residual complaints following an 
episode of diverticulitis, in which other pathologies have been excluded, a trial period of 
intermittent mesalazine, with or without a combination of an oral nonresorbable antibiotic 
or probiotic, should be considered (level 4).
CONCLUSION
This review of guidelines for diverticulitis summarizes the extensive literature available on 
epidemiology, prevention, diagnosing and treatment of patients with acute diverticulitis 
in all its aspects. The guideline was developed in order to standardize the treatment of 
patients with acute diverticulitis and to provide clinicians who deal with patients with 
diverticulitis on a daily basis, with an evidence-based medical approach in treating and 
counseling patients. Despite a large amount of literature, not all topics were equally 
well addressed. Nevertheless, this review is the best evidence-based approach currently 
available. The results of well-designed randomized studies will become available in 
the near future and give more insight into the optimal treatment of patients with acute 
diverticulitis of the colon.
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APPeNDIx 1
Search Strategies for the Relevant key Words
Last search update: February 2012
Subject: natural course of ACD
Date censoring: none
“Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All Fields] 
AND “Natural history” [MeSH] OR “Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” 
[MeSH] OR “diverticulitis” [All Fields] AND “Natural history” OR “Diverticulitis” [MeSH] 
OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All Fields] AND “uncomplicated”
Subject: natural course in young and immunocompromised patients
Date censoring: from 1960
Restrictions: none
“Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All 
Fields] AND “Young” OR “Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] 
OR “diverticulitis” [All Fields] AND “Recurrence” [MeSH] OR “Diverticulitis” [MeSH] OR 
“Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All Fields] AND “diabetes mellitus” 
[MeSH] OR “Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” 
[All Fields] AND “transplantation” [MeSH] OR “Diverticulitis” [MeSH] OR “Diverticulitis, 
Colonic” [MeSH] OR “diverticulitis” [All Fields] AND “immunosuppression” [MeSH] OR 
“Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All Fields] 
AND “AIDS or HIV” [MeSH] OR “Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” 
[MeSH] OR “diverticulitis” [All Fields] AND “neoplasms” [MeSH]
Subject: colonoscopy
Date censoring: from 1970
Restrictions: none
“Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All 
Fields] AND “colonoscopy” OR “Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” 
[MeSH] OR “diverticulitis” [All Fields] (“Diverticulitis” OR “Diverticular disease”) AND 
(“Colon carcinoma” OR “Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] 
OR “diverticulitis” [All Fields]) AND “colon cancer” OR “Diverticulitis” [MeSH] OR 
“Diverticulitis, Colonic”[MeSH] OR “diverticulitis” [All Fields] AND “IBD”
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Subject: clinical diagnosis
Date censoring: from 1980
Restrictions: none
“Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All Fields] 
AND “clinical parameters” OR “Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” 
[MeSH] OR “diverticulitis” [All Fields] AND “sensitivity” OR “Diverticulitis” [MeSH] OR 
“Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All Fields] AND “Diverticulitis” [MeSH] 
OR “Diverticulitis, Colonic”[MeSH] AND “diagnosis”
Subject: radiological imaging
Date censoring: from 1980
Restrictions: none
“Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All Fields] 
AND “contrast enema” OR “Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] 
OR “diverticulitis” [All Fields] AND “Ultrasonography” [MeSH] OR “ultrasonography” 
[subheading] OR “Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] OR 
“diverticulitis” [All Fields] AND “Tomography, Spiral Computed” [MeSH] OR “Tomography, 
XRay Computed” [MeSH] OR “Tomography Scanners, X-Ray Computed” [MeSH] OR 
“Computed Tomographic” [MeSH] OR “Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” 
[MeSH] OR “diverticulitis” [All Fields] AND “Magnetic Resonance Imaging” [MeSH] OR 
“Colonography”
Subject: uncomplicated diverticulitis
Date censoring: from 1975
Restrictions: none
“Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All Fields] 
AND “uncomplicated diverticulitis” OR “Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” 
[MeSH] OR “diverticulitis” [All Fields] AND “Anti-Bacterial Agents” [MeSH] OR “Anti-
Bacterial Agents” [Pharmacological Action] OR “Diverticulitis” [MeSH] OR “Diverticulitis, 
Colonic” [MeSH] OR “diverticulitis” ((“diverticulitis” [MeSH Terms] OR “diverticulitis” 
[All Fields]) AND (“intestines” [MeSH Terms] OR “intestines” [All Fields] OR “bowel” [All 
Fields]) AND (“rest” [MeSH Terms] OR “rest” [All Fields])) OR ((“diverticulitis” [MeSH] OR 
“diverticulitis” [All Fields]) AND (“bed rest” [MeSH] OR (“bed” [All Fields] AND “rest” [All 
Fields]) OR “bed rest” [All Fields] OR “bedrest” [All Fields])) OR “Diverticulitis” [MeSH] 
OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All Fields] AND ((“diverticulitis” 
[MeSH] OR “diverticulitis” [All Fields]) AND (“overweight” [MeSH] OR “overweight” [All 
Fields])) OR ((“diverticulitis” [MeSH] OR “diverticulitis” [All Fields]) AND “BMI” [All Fields]) 
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OR ((“diverticulitis” [MeSH] OR “diverticulitis” [All Fields]) AND “adipositas” [All Fields]) 
OR ((“diverticulum” [MeSH] OR “diverticulum” [All Fields] OR (“diverticular” [All Fields] 
AND “disease” [All Fields]) OR “diverticular disease” [All Fields]) AND “adipositas” [All 
Fields]) OR ((“diverticulum” [MeSH] OR “diverticulum” [All Fields] OR (“diverticular” [All 
Fields] AND “disease” [All Fields]) OR “diverticular disease” [All Fields]) AND “BMI” 
[All Fields]) OR ((“diverticulum” [MeSH] OR “diverticulum” [All Fields] OR (“diverticular” 
[All Fields] AND “disease” [All Fields]) OR “diverticular disease” [All Fields]) AND 
(“overweight” [MeSH] OR “overweight” [All Fields]))
“Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All Fields] 
AND [Diet Therapy] OR “Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] OR 
“diverticulitis” [All Fields] AND “Vegetables” OR “Diverticulitis” [MeSH] OR “Diverticulitis, 
Colonic” [MeSH] OR “diverticulitis” [All Fields] AND “Fruit” OR “Diverticulitis” [MeSH] 
OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All Fields] AND “Starvation” OR 
“Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All Fields] 
AND “Laxatives”
Subject: complicated diverticulitis
Date censoring: from 1990
Restrictions: Adults 19+, series >50 patients
“Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All Fields] 
AND “Abscess” [MeSH:NoExp] OR “Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” 
[MeSH] OR “diverticulitis” [All Fields] AND “Hinchey III” OR “Diverticulitis” [MeSH] OR 
“Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All Fields] AND “Hinchey IV” OR 
“Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All Fields] 
AND “Diverticulitis, Colonic/mortality” [MeSH] OR “Diverticulitis, Colonic” [MeSH] 
AND “Intestinal Perforation” [MeSH] OR “Diverticulitis” [MeSH] OR “Diverticulitis, 
Colonic” [MeSH] OR “diverticulitis” [All Fields] AND “laparoscopy” ( “diverticulitis”/exp 
OR “diverticulitis”:ab,ti OR “diverticular disease”:ab,ti) AND (“laparoscopy”/exp OR 
“laparoscopic surgery”/ exp OR “laparoscope”/exp OR “minimally invasive surgery”/ 
exp OR laparoscop * :ab,ti OR laparascop * :ab,ti OR (minimal * :ab,ti AND adj:ab,ti 
AND invasive:ab,ti)) AND (“acute disease”/exp OR “emergency”/exp OR acute:ab,ti OR 
emergenc * :ab,ti OR “colon perforation”/exp OR (perforat * :ab,ti AND [1970–2011]/py)) 
“Diverticulitis, Colonic” [MeSH] AND “Recurrence” [MeSH] AND “Therapeutics” [MeSH] 
database
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Subject: prevention of recurrence and antibiotics
Date censoring: from 1966
Restrictions: none
(“Diverticulitis” AND “Recurrence” AND “Therapy”) OR (“Diverticulum, Colon” [MeSH]) 
AND ((“Diet Therapy” [MeSH]) OR (“Dietary Fiber” [MeSH])) ((“diverticulitis” [MeSH 
Terms] OR “diverticulitis” [All Fields]) AND (“overweight” [MeSH Terms] OR “overweight” 
[All Fields])) OR ((“diverticulitis” [MeSH Terms] OR “diverticulitis” [All Fields]) AND 
“BMI” [All Fields]) OR ((“diverticulitis” [MeSH Terms] OR “diverticulitis” [All Fields]) 
AND “adipositas” [All Fields]) OR ((“diverticulum” [MeSH Terms] OR “diverticulum” 
[All Fields] OR (“diverticular” [All Fields] AND “disease” [All Fields]) OR “diverticular 
disease” [All Fields]) AND “adipositas” [All Fields]) OR ((“diverticulum” [MeSH Terms] 
OR “diverticulum” [All Fields] OR (“diverticular” [All Fields] AND “disease” [All Fields]) 
OR “diverticular disease” [All Fields]) AND “BMI” [All Fields]) OR ((“diverticulum” [MeSH 
Terms] OR “diverticulum” [All Fields] OR (“diverticular” [All Fields] AND “disease” [All 
Fields]) OR “diverticular disease” [All Fields]) AND (“overweight” [MeSH Terms] OR 
“overweight” [All Fields])) ((“diverticulitis” [MeSH Terms] OR “diverticulitis” [All Fields]) 
AND (“smoking” [MeSH Terms] OR “smoking” [All Fields])) (“diverticular disease” [MeSH 
Terms] OR “diverticular disease” [All Fields]) AND (“smoking” [MeSH Terms] OR “smoking” 
[All Fields]) ((“diverticulitis” [MeSH Terms] OR “diverticulitis” [All Fields]) AND (“exercise” 
[MeSH Terms] OR “exercise” [All Fields] OR (“physical” [All Fields] AND “exercise” 
[All Fields]) OR “physical exercise” [All Fields])) OR ((“diverticulum” [MeSH Terms] OR 
“diverticulum” [All Fields] OR (“diverticular” [All Fields] AND “disease” [All Fields]) OR 
“diverticular disease” [All Fields]) AND (“exercise” [MeSH Terms] OR “exercise” [All 
Fields] OR (“physical” [All Fields] AND “exercise” [All Fields]) OR “physical exercise” 
[All Fields])) OR ((“diverticulitis” [MeSH Terms] OR “diverticulitis” [All Fields]) AND 
(“physical therapy modalities” [MeSH Terms] OR (“physical” [All Fields] AND “therapy” 
[All Fields] AND “modalities” [All Fields]) OR “physical therapy modalities” [All Fields] 
OR “physiotherapy” [All Fields])) OR ((“diverticulum” [MeSH Terms] OR “diverticulum” 
[All Fields] OR (“diverticular” [All Fields] AND “disease” [All Fields]) OR “diverticular 
disease” [All Fields]) AND (“physical therapy modalities” [MeSH Terms] OR (“physical” 
[All Fields] AND “therapy” [All Fields] AND “modalities” [All Fields]) OR “physical therapy 
modalities” [All Fields] OR “physiotherapy” [All Fields]))
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Subject: Elective surgery
Date censoring: 1970
Restrictions: none
“Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All Fields] 
AND “Elective sigmoid resection” OR “Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” 
[MeSH] OR “diverticulitis” [All Fields] AND “Elective colectomy” OR “Diverticulitis” 
[MeSH] OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All Fields] OR “Surgery” 
AND “Diverticulitis” [MeSH] OR “Diverticulitis, Colonic” [MeSH] OR “diverticulitis” [All 
Fields] AND “laparoscopic colectomy” OR “Diverticulitis” [MeSH] OR “Diverticulitis, 
Colonic” [MeSH] OR “diverticulitis” [All Fields] AND “laparosc * ”.
Processed on: 22-2-2017
507513-L-bw-Mulder
122
Chapter 7
ReFeReNCeS
1. Painter NS, Burkitt DP. Diverticular disease of the colon, a 20th century problem. Clin 
Gastroenterol, 1975; 4: 3-21.
2. Parks TG. Natural history of diverticular disease of the colon. Clin Gastroenterol, 1975; 4: 53-
69.
3. Schoetz DJ, Jr. Diverticular disease of the colon: a century-old problem. Dis Colon Rectum, 
1999; 42: 703-709.
4. Etzioni DA, Mack TM, Beart RW, Jr., Kaiser AM. Diverticulitis in the United States: 1998-2005: 
changing patterns of disease and treatment. Ann Surg, 2009; 249: 210-217.
5. Draaisma WA, van de Wall BJ, Vermeulen J et al. [Treatment for diverticulitis not thoroughly 
researched]. Ned Tijdschr Geneeskd, 2009; 153: A648.
6. Prismant K. www.kiwaprismant.nl.
7. Ambrosetti P, Robert JH, Witzig JA et al. Acute left colonic diverticulitis in young patients. J 
Am Coll Surg, 1994; 179: 156-160.
8. Schauer PR, Ramos R, Ghiatas AA, Sirinek KR. Virulent diverticular disease in young obese 
men. Am J Surg, 1992; 164: 443-446; discussion 446-448.
9. Lahat A, Menachem Y, Avidan B et al. Diverticulitis in the young patient--is it different ? World 
J Gastroenterol, 2006; 12: 2932-2935.
10. Acosta JA, Grebenc ML, Doberneck RC et al. Colonic diverticular disease in patients 40 years 
old or younger. Am Surg, 1992; 58: 605-607.
11. Rodkey GV, Welch CE. Changing patterns in the surgical treatment of diverticular disease. Ann 
Surg, 1984; 200: 466-478.
12. Hinchey EJ, Schaal PG, Richards GK. Treatment of perforated diverticular disease of the colon. 
Adv Surg, 1978; 12: 85-109.
13. Wasvary H, Turfah F, Kadro O, Beauregard W. Same hospitalization resection for acute 
diverticulitis. Am Surg, 1999; 65: 632-635; discussion 636.
14. Klarenbeek BR, de Korte N, van der Peet DL, Cuesta MA. Review of current classifications for 
diverticular disease and a translation into clinical practice. Int J Colorectal Dis, 2012; 27: 207-
214.
15. Kaiser AM, Jiang JK, Lake JP et al. The management of complicated diverticulitis and the role 
of computed tomography. Am J Gastroenterol, 2005; 100: 910-917.
16. Ambrosetti P, Becker C, Terrier F. Colonic diverticulitis: impact of imaging on surgical 
management -- a prospective study of 542 patients. Eur Radiol, 2002; 12: 1145-1149.
17. Stollman NH, Raskin JB. Diagnosis and management of diverticular disease of the colon in 
adults. Ad Hoc Practice Parameters Committee of the American College of Gastroenterology. 
Am J Gastroenterol, 1999; 94: 3110-3121.
18. Broderick-Villa G, Burchette RJ, Collins JC et al. Hospitalization for acute diverticulitis does not 
mandate routine elective colectomy. Arch Surg, 2005; 140: 576-581; discussion 581-573.
19. Makela J, Vuolio S, Kiviniemi H, Laitinen S. Natural history of diverticular disease: when to 
operate? Dis Colon Rectum, 1998; 41: 1523-1528.
Processed on: 22-2-2017
507513-L-bw-Mulder
123
Guidelines of diagnostics and treatment of acute left-sided colonic diverticulitis
7
20. Anaya DA, Flum DR. Risk of emergency colectomy and colostomy in patients with diverticular 
disease. Arch Surg, 2005; 140: 681-685.
21. Haglund U, Hellberg R, Johnsen C, Hulten L. Complicated diverticular disease of the sigmoid 
colon. An analysis of short and long term outcome in 392 patients. Ann Chir Gynaecol, 1979; 
68: 41-46.
22. Larson DM, Masters SS, Spiro HM. Medical and surgical therapy in diverticular disease: a 
comparative study. Gastroenterology, 1976; 71: 734-737.
23. Parks TG. Natural history of diverticular disease of the colon. A review of 521 cases. Br Med J, 
1969; 4: 639-642.
24. Ambrosetti P, Grossholz M, Becker C et al. Computed tomography in acute left colonic 
diverticulitis. Br J Surg, 1997; 84: 532-534.
25. Biondo S, Pares D, Marti Rague J et al. Acute colonic diverticulitis in patients under 50 years of 
age. Br J Surg, 2002; 89: 1137-1141.
26. Chapman JR, Dozois EJ, Wolff BG et al. Diverticulitis: a progressive disease? Do multiple 
recurrences predict less favorable outcomes? Ann Surg, 2006; 243: 876-830; discussion 880-
873.
27. Nylamo E. Diverticulitis of the colon: role of surgery in preventing complications. Ann Chir 
Gynaecol, 1990; 79: 139-142.
28. Lorimer JW. Is prophylactic resection valid as an indication for elective surgery in diverticular 
disease? Can J Surg, 1997; 40: 445-448.
29. Somasekar K, Foster ME, Haray PN. The natural history diverticular disease: is there a role for 
elective colectomy? J R Coll Surg Edinb, 2002; 47: 481-482, 484.
30. Andeweg C, Peters J, Bleichrodt R, van Goor H. Incidence and risk factors of recurrence after 
surgery for pathology-proven diverticular disease. World J Surg, 2008; 32: 1501-1506.
31. Hart AR, Kennedy HJ, Stebbings WS, Day NE. How frequently do large bowel diverticula 
perforate? An incidence and cross-sectional study. Eur J Gastroenterol Hepatol, 2000; 12: 
661-665.
32. Pittet O, Kotzampassakis N, Schmidt S et al. Recurrent left colonic diverticulitis episodes: more 
severe than the initial diverticulitis? World J Surg, 2009; 33: 547-552.
33. Klarenbeek BR, Samuels M, van der Wal MA et al. Indications for elective sigmoid resection in 
diverticular disease. Ann Surg, 2010; 251: 670-674.
34. Schweitzer J, Casillas RA, Collins JC. Acute diverticulitis in the young adult is not “virulent.”. 
Am Surg, 2002; 68: 1044-1047.
35. Guzzo J, Hyman N. Diverticulitis in young patients: is resection after a single attack always 
warranted? Dis Colon Rectum, 2004; 47: 1187-1190; discussion 1190-1181.
36. Ouriel K, Schwartz SI. Diverticular disease in the young patient. Surg Gynecol Obstet, 1983; 
156: 1-5.
37. Freischlag J, Bennion RS, Thompson JE, Jr. Complications of diverticular disease of the colon 
in young people. Dis Colon Rectum, 1986; 29: 639-643.
38. Rothenberger DA, Wiltz O. Surgery for complicated diverticulitis. Surg Clin North Am, 1993; 
73: 975-992.
39. Nelson RS, Velasco A, Mukesh BN. Management of diverticulitis in younger patients. Dis 
Colon Rectum, 2006; 49: 1341-1345.
Processed on: 22-2-2017
507513-L-bw-Mulder
124
Chapter 7
40. Janes S, Meagher A, Faragher IG et al. The place of elective surgery following acute 
diverticulitis in young patients: when is surgery indicated? An analysis of the literature. Dis 
Colon Rectum, 2009; 52: 1008-1016.
41. Helderman JH, Goral S. Gastrointestinal complications of transplant immunosuppression. J 
Am Soc Nephrol, 2002; 13: 277-287.
42. Hwang SS, Cannom RR, Abbas MA, Etzioni D. Diverticulitis in transplant patients and patients 
on chronic corticosteroid therapy: a systematic review. Dis Colon Rectum, 2010; 53: 1699-
1707.
43. Dalla Valle R, Capocasale E, Mazzoni MP et al. Acute diverticulitis with colon perforation in 
renal transplantation. Transplant Proc, 2005; 37: 2507-2510.
44. Qasabian RA, Meagher AP, Lee R et al. Severe diverticulitis after heart, lung, and heart-lung 
transplantation. J Heart Lung Transplant, 2004; 23: 845-849.
45. Lederman ED, Conti DJ, Lempert N et al. Complicated diverticulitis following renal 
transplantation. Dis Colon Rectum, 1998; 41: 613-618.
46. McCune TR, Nylander WA, Van Buren DH et al. Colonic screening prior to renal 
transplantation and its impact on post-transplant colonic complications. Clin Transplant, 1992; 
6: 91-96.
47. Sachar DB, Ndsg. Diverticulitis in immunosuppressed patients. J Clin Gastroenterol, 2008; 42: 
1154-1155.
48. Lorimer JW, Doumit G. Comorbidity is a major determinant of severity in acute diverticulitis. 
Am J Surg, 2007; 193: 681-685.
49. Sorser SA, Hazan TB, Piper M, Maas LC. Obesity and complicated diverticular disease: is there 
an association? South Med J, 2009; 102: 350-353.
50. Zaidi E, Daly B. CT and clinical features of acute diverticulitis in an urban U.S. population: 
rising frequency in young, obese adults. AJR Am J Roentgenol, 2006; 187: 689-694.
51. Dobbins C, Defontgalland D, Duthie G, Wattchow DA. The relationship of obesity to the 
complications of diverticular disease. Colorectal Dis, 2006; 8: 37-40.
52. Aldoori W, Ryan-Harshman M. Preventing diverticular disease. Review of recent evidence on 
high-fibre diets. Can Fam Physician, 2002; 48: 1632-1637.
53. Aldoori WH, Giovannucci EL, Rimm EB et al. A prospective study of diet and the risk of 
symptomatic diverticular disease in men. Am J Clin Nutr, 1994; 60: 757-764.
54. Andeweg CS, Knobben L, Hendriks JC et al. How to diagnose acute left-sided colonic 
diverticulitis: proposal for a clinical scoring system. Ann Surg, 2011; 253: 940-946.
55. Lameris W, van Randen A, van Gulik TM et al. A clinical decision rule to establish the diagnosis 
of acute diverticulitis at the emergency department. Dis Colon Rectum, 2010; 53: 896-904.
56. Laurell H, Hansson LE, Gunnarsson U. Acute diverticulitis--clinical presentation and differential 
diagnostics. Colorectal Dis, 2007; 9: 496-501; discussion 501-492.
57. Toorenvliet BR, Bakker RF, Breslau PJ et al. Colonic diverticulitis: a prospective analysis of 
diagnostic accuracy and clinical decision-making. Colorectal Dis, 2010; 12: 179-186.
58. Cho KC, Morehouse HT, Alterman DD, Thornhill BA. Sigmoid diverticulitis: diagnostic role of 
CT--comparison with barium enema studies. Radiology, 1990; 176: 111-115.
Processed on: 22-2-2017
507513-L-bw-Mulder
125
Guidelines of diagnostics and treatment of acute left-sided colonic diverticulitis
7
59. Ambrosetti P, Jenny A, Becker C et al. Acute left colonic diverticulitis--compared performance 
of computed tomography and water-soluble contrast enema: prospective evaluation of 420 
patients. Dis Colon Rectum, 2000; 43: 1363-1367.
60. Stoker J, van Randen A, Lameris W, Boermeester MA. Imaging patients with acute abdominal 
pain. Radiology, 2009; 253: 31-46.
61. Ambrosetti P. Acute diverticulitis of the left colon: value of the initial CT and timing of elective 
colectomy. J Gastrointest Surg, 2008; 12: 1318-1320.
62. Balfe DM, Levine MS, Ralls PW et al. Evaluation of left lower quadrant pain. American College 
of Radiology. ACR Appropriateness Criteria. Radiology, 2000; 215 Suppl: 167-171.
63. Lameris W, van Randen A, Bipat S et al. Graded compression ultrasonography and computed 
tomography in acute colonic diverticulitis: meta-analysis of test accuracy. Eur Radiol, 2008; 18: 
2498-2511.
64. Liljegren G, Chabok A, Wickbom M et al. Acute colonic diverticulitis: a systematic review of 
diagnostic accuracy. Colorectal Dis, 2007; 9: 480-488.
65. Lameris W, van Randen A, van Es HW et al. Imaging strategies for detection of urgent 
conditions in patients with acute abdominal pain: diagnostic accuracy study. BMJ, 2009; 338: 
b2431.
66. van Randen A, Lameris W, van Es HW et al. A comparison of the accuracy of ultrasound and 
computed tomography in common diagnoses causing acute abdominal pain. Eur Radiol, 
2011; 21: 1535-1545.
67. Heverhagen JT, Sitter H, Zielke A, Klose KJ. Prospective evaluation of the value of magnetic 
resonance imaging in suspected acute sigmoid diverticulitis. Dis Colon Rectum, 2008; 51: 
1810-1815.
68. Halpenny DF, McNeil G, Snow A et al. Prospective evaluation of the value of magnetic 
resonance imaging in suspected acute sigmoid diverticulitis. Dis Colon Rectum, 2009; 52: 
1030-1031; author reply 1031.
69. Ajaj W, Ruehm SG, Lauenstein T et al. Dark-lumen magnetic resonance colonography in 
patients with suspected sigmoid diverticulitis: a feasibility study. Eur Radiol, 2005; 15: 2316-
2322.
70. Schreyer AG, Furst A, Agha A et al. Magnetic resonance imaging based colonography for 
diagnosis and assessment of diverticulosis and diverticulitis. Int J Colorectal Dis, 2004; 19: 
474-480.
71. Lahat A, Yanai H, Menachem Y et al. The feasibility and risk of early colonoscopy in acute 
diverticulitis: a prospective controlled study. Endoscopy, 2007; 39: 521-524.
72. Sakhnini E, Lahat A, Melzer E et al. Early colonoscopy in patients with acute diverticulitis: 
results of a prospective pilot study. Endoscopy, 2004; 36: 504-507.
73. Hale WB, Ndsg. Colonoscopy in the diagnosis and management of diverticular disease. J Clin 
Gastroenterol, 2008; 42: 1142-1144.
74. Crispin A, Birkner B, Munte A et al. Process quality and incidence of acute complications in a 
series of more than 230,000 outpatient colonoscopies. Endoscopy, 2009; 41: 1018-1025.
75. Brayko CM, Kozarek RA, Sanowski RA, Howells T. Diverticular rupture during colonoscopy. Fact 
or fancy? Dig Dis Sci, 1984; 29: 427-431.
Processed on: 22-2-2017
507513-L-bw-Mulder
126
Chapter 7
76. Krones CJ, Klinge U, Butz N et al. The rare epidemiologic coincidence of diverticular disease 
and advanced colonic neoplasia. Int J Colorectal Dis, 2006; 21: 18-24.
77. Stefansson T, Ekbom A, Sparen P, Pahlman L. Association between sigmoid diverticulitis 
and left-sided colon cancer: a nested, population-based, case control study. Scand J 
Gastroenterol, 2004; 39: 743-747.
78. Meurs-Szojda MM, Terhaar sive Droste JS, Kuik DJ et al. Diverticulosis and diverticulitis form 
no risk for polyps and colorectal neoplasia in 4,241 colonoscopies. Int J Colorectal Dis, 2008; 
23: 979-984.
79. Hjern F, Josephson T, Altman D et al. Conservative treatment of acute colonic diverticulitis: are 
antibiotics always mandatory? Scand J Gastroenterol, 2007; 42: 41-47.
80. Lahat A, Yanai H, Sakhnini E et al. Role of colonoscopy in patients with persistent acute 
diverticulitis. World J Gastroenterol, 2008; 14: 2763-2766.
81. Alonso S, Pera M, Pares D et al. Outpatient treatment of patients with uncomplicated acute 
diverticulitis. Colorectal Dis, 2010; 12: e278-282.
82. Al-Sahaf O, Al-Azawi D, Fauzi MZ et al. Early discharge policy of patients with acute colonic 
diverticulitis following initial CT scan. Int J Colorectal Dis, 2008; 23: 817-820.
83. Tursi A, Brandimarte G, Elisei W et al. Assessment and grading of mucosal inflammation in 
colonic diverticular disease. J Clin Gastroenterol, 2008; 42: 699-703.
84. Schug-Pass C, Geers P, Hugel O et al. Prospective randomized trial comparing short-term 
antibiotic therapy versus standard therapy for acute uncomplicated sigmoid diverticulitis. Int J 
Colorectal Dis, 2010; 25: 751-759.
85. Ribas Y, Bombardo J, Aguilar F et al. Prospective randomized clinical trial assessing the 
efficacy of a short course of intravenously administered amoxicillin plus clavulanic acid 
followed by oral antibiotic in patients with uncomplicated acute diverticulitis. Int J Colorectal 
Dis, 2010; 25: 1363-1370.
86. Eglinton T, Nguyen T, Raniga S et al. Patterns of recurrence in patients with acute diverticulitis. 
Br J Surg, 2010; 97: 952-957.
87. Basisset kwaliteits indicatoren publieke gezondheidszorg. http://www.igz.nl.
88. Kohler L, Sauerland S, Neugebauer E. Diagnosis and treatment of diverticular disease: 
results of a consensus development conference. The Scientific Committee of the European 
Association for Endoscopic Surgery. Surg Endosc, 1999; 13: 430-436.
89. Surgical treatment of diverticulitis. Patient Care Committee of the Society for Surgery of the 
Alimentary Tract (SSAT). J Gastrointest Surg, 1999; 3: 212-213.
90. Rafferty J, Shellito P, Hyman NH et al. Practice parameters for sigmoid diverticulitis. Dis Colon 
Rectum, 2006; 49: 939-944.
91. World Gastroenterology Organisation. http://www.worldgastroenterology.org/
diverticulardisease.html.
92. Chabok A, Pahlman L, Hjern F et al. Randomized clinical trial of antibiotics in acute 
uncomplicated diverticulitis. Br J Surg, 2012; 99: 532-539.
93. Ridgway PF, Latif A, Shabbir J et al. Randomized controlled trial of oral vs intravenous therapy 
for the clinically diagnosed acute uncomplicated diverticulitis. Colorectal Dis, 2009; 11: 941-
946.
Processed on: 22-2-2017
507513-L-bw-Mulder
127
Guidelines of diagnostics and treatment of acute left-sided colonic diverticulitis
7
94. Wilson RG, Smith AN, Macintyre IM. Complications of diverticular disease and non-steroidal 
anti-inflammatory drugs: a prospective study. Br J Surg, 1990; 77: 1103-1104.
95. Morris CR, Harvey IM, Stebbings WS et al. Anti-inflammatory drugs, analgesics and the risk of 
perforated colonic diverticular disease. Br J Surg, 2003; 90: 1267-1272.
96. Goh H, Bourne R. Non-steroidal anti-inflammatory drugs and perforated diverticular disease: a 
case-control study. Ann R Coll Surg Engl, 2002; 84: 93-96.
97. Corder A. Steroids, non-steroidal anti-inflammatory drugs, and serious septic complications of 
diverticular disease. Br Med J (Clin Res Ed), 1987; 295: 1238.
98. Ranji SR, Goldman LE, Simel DL, Shojania KG. Do opiates affect the clinical evaluation of 
patients with acute abdominal pain? JAMA, 2006; 296: 1764-1774.
99. Manterola C, Vial M, Moraga J, Astudillo P. Analgesia in patients with acute abdominal pain. 
Cochrane Database Syst Rev, 2011; CD005660.
100. Ambrosetti P, Chautems R, Soravia C et al. Long-term outcome of mesocolic and pelvic 
diverticular abscesses of the left colon: a prospective study of 73 cases. Dis Colon Rectum, 
2005; 48: 787-791.
101. Hamy A, Paineau J, Societe de chirurgie viscerale de lo. [Percutaneous drainage of 
perisigmoid abscesses of diverticular origin]. Ann Chir, 2001; 126: 133-137.
102. Brandt D, Gervaz P, Durmishi Y et al. Percutaneous CT scan-guided drainage vs. 
antibiotherapy alone for Hinchey II diverticulitis: a case-control study. Dis Colon Rectum, 2006; 
49: 1533-1538.
103. Siewert B, Tye G, Kruskal J et al. Impact of CT-guided drainage in the treatment of diverticular 
abscesses: size matters. AJR Am J Roentgenol, 2006; 186: 680-686.
104. Singh B, May K, Coltart I et al. The long-term results of percutaneous drainage of diverticular 
abscess. Ann R Coll Surg Engl, 2008; 90: 297-301.
105. Antolovic D, Reissfelder C, Koch M et al. Surgical treatment of sigmoid diverticulitis--analysis 
of predictive risk factors for postoperative infections, surgical complications, and mortality. Int 
J Colorectal Dis, 2009; 24: 577-584.
106. Vermeulen J, Akkersdijk GP, Gosselink MP et al. Outcome after emergency surgery for acute 
perforated diverticulitis in 200 cases. Dig Surg, 2007; 24: 361-366.
107. Morris CR, Harvey IM, Stebbings WS, Hart AR. Incidence of perforated diverticulitis and risk 
factors for death in a UK population. Br J Surg, 2008; 95: 876-881.
108. Ricciardi R, Baxter NN, Read TE et al. Is the decline in the surgical treatment for diverticulitis 
associated with an increase in complicated diverticulitis? Dis Colon Rectum, 2009; 52: 1558-
1563.
109. Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: international guidelines for 
management of severe sepsis and septic shock: 2012. Crit Care Med, 2013; 41: 580-637.
110. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe 
sepsis and septic shock. N Engl J Med, 2001; 345: 1368-1377.
111. Lin SM, Huang CD, Lin HC et al. A modified goal-directed protocol improves clinical outcomes 
in intensive care unit patients with septic shock: a randomized controlled trial. Shock, 2006; 
26: 551-557.
Processed on: 22-2-2017
507513-L-bw-Mulder
128
Chapter 7
112. Vermeulen J, Coene PP, Van Hout NM et al. Restoration of bowel continuity after surgery 
for acute perforated diverticulitis: should Hartmann’s procedure be considered a one-stage 
procedure? Colorectal Dis, 2009; 11: 619-624.
113. Salem L, Veenstra DL, Sullivan SD, Flum DR. The timing of elective colectomy in diverticulitis: a 
decision analysis. J Am Coll Surg, 2004; 199: 904-912.
114. Kam MH, Tang CL, Chan E et al. Systematic review of intraoperative colonic irrigation vs. 
manual decompression in obstructed left-sided colorectal emergencies. Int J Colorectal Dis, 
2009; 24: 1031-1037.
115. Abbas S. Resection and primary anastomosis in acute complicated diverticulitis, a systematic 
review of the literature. Int J Colorectal Dis, 2007; 22: 351-357.
116. Constantinides VA, Heriot A, Remzi F et al. Operative strategies for diverticular peritonitis: a 
decision analysis between primary resection and anastomosis versus Hartmann’s procedures. 
Ann Surg, 2007; 245: 94-103.
117. Vermeulen J, Lange JF. Treatment of perforated diverticulitis with generalized peritonitis: past, 
present, and future. World J Surg, 2010; 34: 587-593.
118. Alamili M, Gogenur I, Rosenberg J. Acute complicated diverticulitis managed by laparoscopic 
lavage. Dis Colon Rectum, 2009; 52: 1345-1349.
119. Swank HA, Vermeulen J, Lange JF et al. The ladies trial: laparoscopic peritoneal lavage 
or resection for purulent peritonitis and Hartmann’s procedure or resection with primary 
anastomosis for purulent or faecal peritonitis in perforated diverticulitis (NTR2037). BMC Surg, 
2010; 10: 29.
120. Wong WD, Wexner SD, Lowry A et al. Practice parameters for the treatment of sigmoid 
diverticulitis--supporting documentation. The Standards Task Force. The American Society of 
Colon and Rectal Surgeons. Dis Colon Rectum, 2000; 43: 290-297.
121. Janes S, Meagher A, Frizelle FA. Elective surgery after acute diverticulitis. Br J Surg, 2005; 92: 
133-142.
122. Collins D, Winter DC. Elective resection for diverticular disease: an evidence-based review. 
World J Surg, 2008; 32: 2429-2433.
123. Richards RJ, Hammitt JK. Timing of prophylactic surgery in prevention of diverticulitis 
recurrence: a cost-effectiveness analysis. Dig Dis Sci, 2002; 47: 1903-1908.
124. Simpson J, Neal KR, Scholefield JH, Spiller RC. Patterns of pain in diverticular disease and the 
influence of acute diverticulitis. Eur J Gastroenterol Hepatol, 2003; 15: 1005-1010.
125. Klarenbeek BR, Veenhof AA, Bergamaschi R et al. Laparoscopic sigmoid resection for 
diverticulitis decreases major morbidity rates: a randomized control trial: short-term results of 
the Sigma Trial. Ann Surg, 2009; 249: 39-44.
126. Gervaz P, Inan I, Perneger T et al. A prospective, randomized, single-blind comparison of 
laparoscopic versus open sigmoid colectomy for diverticulitis. Ann Surg, 2010; 252: 3-8.
127. Siddiqui MR, Sajid MS, Qureshi S et al. Elective laparoscopic sigmoid resection for diverticular 
disease has fewer complications than conventional surgery: a meta-analysis. Am J Surg, 2010; 
200: 144-161.
128. Purkayastha S, Constantinides VA, Tekkis PP et al. Laparoscopic vs. open surgery for 
diverticular disease: a meta-analysis of nonrandomized studies. Dis Colon Rectum, 2006; 49: 
446-463.
Processed on: 22-2-2017
507513-L-bw-Mulder
129
Guidelines of diagnostics and treatment of acute left-sided colonic diverticulitis
7
129. Siddiqui MR, Sajid MS, Khatri K et al. Elective open versus laparoscopic sigmoid colectomy for 
diverticular disease: a meta-analysis with the Sigma trial. World J Surg, 2010; 34: 2883-2901.
130. Nygren J, Soop M, Thorell A et al. An enhanced-recovery protocol improves outcome after 
colorectal resection already during the first year: a single-center experience in 168 consecutive 
patients. Dis Colon Rectum, 2009; 52: 978-985.
131. Thaler K, Weiss EG, Nogueras JJ et al. Recurrence rates at minimum 5-year follow-up: 
laparoscopic versus open sigmoid resection for uncomplicated diverticulitis. Surg Laparosc 
Endosc Percutan Tech, 2003; 13: 325-327.
132. Benn PL, Wolff BG, Ilstrup DM. Level of anastomosis and recurrent colonic diverticulitis. Am J 
Surg, 1986; 151: 269-271.
133. Brodribb AJ. Treatment of symptomatic diverticular disease with a high-fibre diet. Lancet, 
1977; 1: 664-666.
134. Unlu C, Daniels L, Vrouenraets BC, Boermeester MA. A systematic review of high-fibre dietary 
therapy in diverticular disease. Int J Colorectal Dis, 2012; 27: 419-427.
135. Turunen P, Wikstrom H, Carpelan-Holmstrom M et al. Smoking increases the incidence of 
complicated diverticular disease of the sigmoid colon. Scand J Surg, 2010; 99: 14-17.
136. Floch CL. Diagnosis and management of acute diverticulitis. J Clin Gastroenterol, 2006; 40 
Suppl 3: S136-144.
137. Porta E, Germano A, Ferrieri A, Koch M. The natural history of diverticular disease of the 
colon: a role for antibiotics in preventing complications? A retrospective study. Riv Eur Sci Med 
Farmacol, 1994; 16: 33-39.
138. Tursi A, Brandimarte G, Daffina R. Long-term treatment with mesalazine and rifaximin versus 
rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis, 
2002; 34: 510-515.
139. Tursi A. New physiopathological and therapeutic approaches to diverticular disease of the 
colon. Expert Opin Pharmacother, 2007; 8: 299-307.
140. Dughera L, Serra AM, Battaglia E et al. Acute recurrent diverticulitis is prevented by oral 
administration of a polybacterial lysate suspension. Minerva Gastroenterol Dietol, 2004; 50: 
149-153.
Processed on: 22-2-2017
507513-L-bw-Mulder2
Processed on: 22-2-2017
507513-L-bw-Mulder
Treatment of 
complications 
following  
intra-abdominal 
infection
PART Two
Processed on: 22-2-2017
507513-L-bw-Mulder
8ChAPTeR
Processed on: 22-2-2017
507513-L-bw-Mulder
Experimental 
study on 
synthetic and 
biologic mesh 
implantation in 
a contaminated 
environment
IM Mulder
EB Deerenberg
N Grotenhuis
M Ditzel
J Jeekel
JF Lange
British Journal of Surgery, 2012 Dec; 99(12): 1734-1741
Processed on: 22-2-2017
507513-L-bw-Mulder
134
Chapter 8
ABSTRACT
Background
Implantation of meshes in a contaminated environment can be complicated by mesh 
infection and adhesion formation.
Methods
The caecal ligation and puncture model was used to induce peritonitis in 144 rats. Seven 
commercially available meshes were implanted intraperitoneally: six non-absorbable 
meshes, of which three had an absorbable coating, and one biological mesh. Mesh 
infection, intra-abdominal abscess formation, adhesion formation, incorporation and 
shrinkage were evaluated after 28 and 90 days. Histological examination with haematoxylin 
and eosin and picrosirius red staining was performed.
Results
No mesh infections occurred in Sepramesh, Omyramesh and Strattice . One mesh infection 
occurred in Parietene and Parietene Composite. Significantly more mesh infections were 
found in C-Qur (15 of 16; P≤0.006) and Dualmesh (7 of 15; P≤0.035). Sepramesh showed 
a significant increase in adhesion coverage from 12.5% at 28 days to 60.0% at 90 days 
(P=0.010). At 90 days there was no significant difference between median adhesion 
coverage of Parietene Composite (35.0%), Omyramesh (42.5%), Sepramesh (60.0%) 
and Parietene (72.5%). After 90 days the adhesion coverage of Strattice was 5.0%, 
and incorporation (13.4%) was significantly poorer than for other non-infected meshes 
(P≤0.009). Dualmesh showed shrinkage of 63% after 90 days.
Conclusion
Parietene Composite and Omyramesh performed well in a contaminated environment. 
Strattice had little adhesion formation and no mesh infection, but poor incorporation. 
Some synthetic meshes can be as resistant to infection as biological meshes.
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SURGICAL ReLeVANCe
Surgeons are reluctant to use synthetic materials in contaminated environments owing to 
the risk of mesh infection. Mesh infection often necessitates removal of the mesh, leaving 
an abdominal wall deficit larger than the original hernia. Recently developed biological 
meshes are suggested to allow implantation in a contaminated environment.
This experiment shows promising results regarding infection rate, incorporation and 
adhesion formation of certain synthetic meshes in a contaminated environment. 
Biological meshes showed no mesh infection and little adhesion formation. However, 
incorporation of biological meshes was poor, making the biomechanical strength of the 
repair questionable. In contaminated abdominal wall surgery one-stage repair might be 
performed with implantation of certain types of synthetic mesh. 
INTRODUCTION
Mesh reinforcement during ventral hernia repair drastically reduces 10-year recurrence 
rates1,2. Non-absorbable synthetic materials are currently the most commonly used 
prosthesis for reinforcement of ventral hernias. Advantages of synthetic meshes are low 
recurrence rates, ease of use and relatively low costs. However, implantation of synthetic 
meshes can be complicated by mesh infection and adhesion formation. Mesh infection is 
a feared complication and reported in up to 16% of patients after abdominal wall repair3. 
The risk of mesh infection is increased in a contaminated environment, which makes the 
use of synthetic mesh debatable4. Mesh infection after implantation often necessitates its 
removal, which leaves the patient with a contaminated field and an abdominal wall deficit 
that is often larger than the original hernia. Macroporous meshes have been preferred 
because large pores permit infiltration of macrophages and allow rapid fibroplasia 
and angiogenesis, with reduced infiltration and growth of bacteria5,6. The drawback of 
macroporous meshes is the increased risk of visceral adhesions to the site of the repair, 
with associated small bowel obstruction, pain, infertility and enterocutaneous fistula 
formation5,7,8. These adhesions arise as a result of fibrin deposition in the abdominal cavity, 
with subsequent formation of adhesions. The presence of contamination increases fibrin 
deposition, leading to an increased amount and tenacity of adhesions intra-abdominally 
and to the mesh9. In a clean environment antiadhesive coatings have proved to reduce 
adhesion formation to macroporous meshes8,10,11. The aim of the study was to compare 
commercially available synthetic and biological meshes in terms of infection rate, 
adhesion formation, incorporation and shrinkage after implantation in a contaminated 
environment.
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MeThODS
One hundred and forty-four male Wistar rats weighing 250–350 g were obtained from 
a licensed breeder (Harlan Laboratories, Boxmeer, The Netherlands). They were bred 
under specific pathogen-free conditions, kept under standard laboratory conditions in 
individually ventilated cages, and fed freely with standard rat chow and water throughout 
the experiment. The protocol of the experiment was approved by the Ethical Committee 
on Animal Experimentation of Erasmus University Rotterdam.
Peritonitis model
Rats were anaesthetized by isoflurane/oxygen inhalation and received buprenorphine 
analgesia (0.05 mg/kg subcutaneously). The abdomen was shaved and the skin disinfected 
with 70% alcohol, after which the abdominal cavity was opened through a 3-cm midline 
incision. To induce peritonitis, a caecal ligation and puncture (CLP) model was used12. The 
caecum was carefully manipulated outside the abdominal cavity and ligated just distal 
to the ileocaecal valve with a monofilament nonabsorbable suture (4-0 Ethilon; Ethicon, 
Johnson & Johnson, Somerville, New Jersey, USA), maintaining the continuity of the 
bowel. The caecum was punctured distally to the ligation with an 18-G needle. The fascia 
and skin were closed with a running absorbable suture (5-0 Safil; B. Braun, Melsungen, 
Germany). After 24 h the abdomen was reopened, a culture swab was taken to confirm 
peritonitis, the necrotic caecum was resected and the abdominal cavity was rinsed with at 
least 20 ml phosphate-buffered saline at 37°C. A sterile mesh, measuring 2.5 × 3 cm, was 
implanted intraperitoneally with three transmuscular nonabsorbable sutures (5-0 Ethilon) 
on both sides of the incision in all mesh groups. No mesh was implanted in the control 
group. After administration of gentamicin (6 mg/kg intramuscularly) the abdominal wall 
and skin were closed separately with a running absorbable suture (5-0 Safil).
Implanted meshes
The rats were divided into eight groups, a control group that received no mesh and 
groups in which one of the following seven meshes was implanted intraperitoneally: non-
cross-linked collagen (Strattice; LifeCell, Branchburg, New Jersey, USA), polypropylene 
(Parietene; Sofradim, Trevoux, France; part of Covidien, North Haven, Connecticut, USA), 
collagen–polyethyleneglycol–glycerol-coated polypropylene (Parietene Composite; 
Sofradim), omega-3-fatty acid coated polypropylene (C-Qur; Atrium, Hudson, New 
York,USA), carboxymethylcellulose–sodium hyaluronate coated polypropylene 
(Sepramesh; Bard, New Providence, New Jersey, USA), expanded polytetrafluoroethylene 
(PTFE) (Dualmesh; Gore, Flagstaff, Arizona, USA) and condensed PTFE (Omyramesh; B. 
Braun).
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Measurements
Half of the surviving animals were killed after 28 days and half after 90 days. The abdomen 
was shaved, disinfected and opened through a U-shaped incision extending laterally and 
caudally to the mesh. Directly after opening the abdomen, a swab of the abdominal 
cavity was taken for culture. Mesh infection was defined as the presence of abscesses of 
the mesh, and parts of the mesh were cultured for microbiological evaluation. Adhesions 
were scored using a grid placed over the mesh, dividing it into 30 equal squares. The 
tenacity of the adhesions was graded using the Zühlke score, a four-degree classification 
of adhesions based on histological and morphological criteria13. Pictures of the abdominal 
wall with mesh and any adhesions were taken with a 5.0-megapixel digital camera. The 
abdominal cavity was inspected for abscesses; when present, these were scored and 
cultured at four sites: the liver, abdominal wall, bowel and omentum14. Mesh incorporation 
was defined as the percentage of the mesh edge incorporated into the abdominal wall, 
taking into account any shrinkage. Shrinkage was defined as the relative loss of surface 
compared with the original size of the mesh, measured with a caliper. The animals were 
killed by cardiac cut. All measurements were carried out by two independent observers 
and disagreements reconciled by discussion.
histological evaluation
At least two representative samples of macroscopically non infected meshes with adjacent 
abdominal wall were excised by full-thickness (mesh and abdominal wall muscle) biopsy 
punches of 5 mm diameter. The samples were embedded in Tissue-Tek (Sakura, Alphen, 
Rijn, The Netherlands) and immediately frozen in liquid nitrogen. Frozen sections of 6 μm 
were made using a cryostat (Leica; Davis Instruments, Vernon Hills, Illinois, USA). Sections 
were stained with either haematoxylin and eosin or picrosirius red (Direct Red 80; Fluka 
Chemie, Zwijndrecht, The Netherlands)15. Samples were assigned a random number 
before evaluation and scored by two observers blinded to the specific type of mesh. 
Fibrosis, lymphocyte infiltration and angiogenesis were scored macroscopically at 200× 
magnification using a light microscope (Olympus, Center Valley, Pennsylvania, USA). The 
following grading scale was used: 0, none present; 1, little; 2, moderate; and 3, extensive. 
The picrosirius red-stained sections were analysed for collagen and scored by means of 
the same scale for the presence of collagen around the mesh and abdominal wall.
Statistical analysis
Results are presented as median (interquartile range). Mesh infection, tenacity and 
percentage of adhesions, histological score, abscess formation, survival and weight were 
compared using Kruskal–Wallis, Mann–Whitney U, χ2 and Fisher’s exact tests as the data 
did not show a normal distribution. If the overall test showed differences, pairwise tests 
were done to determine the groups causing the overall significance. Exact methods for 
significance were used when computational limits allowed these. All reported P values are 
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two-sided and P<0.050 was considered statistically significant. In view of the numbers, it 
was not possible to adjust the P values using Bonferroni’s correction. Statistical analysis 
was performed using PSAW statistical software package version 17 (IBM, Armonk, New 
York, USA).
ReSULTS
During the first 2 days of the experiment 22 (15.3%) of the 144 rats died. Necropsy was 
performed and septicaemia was found to be the cause of death in all rats (Table 1). 
On day 13 one rat in the C-Qur group died from intestinal obstruction due to severe 
adherence of the bowel to the infected mesh. Abdominal cultures on day 1 confirmed 
bacterial contamination in all animals with Gram-positive (Enterococcus, Staphylococcus, 
Streptococcus) and Gram-negative (Escherichia coli and Proteus) microorganisms. All 
animals exhibited symptoms of sepsis including apathetic behaviour, ocular exudates, 
piloerection, diarrhoea and weight loss. The maximum percentage weight loss varied 
between 11.1 and 14.2%, and was more pronounced in the C-Qur group (P≤0.048 
compared with other groups).
Table 1. Postoperative mortality and number of animals at 28 and 90 days after surgery.
No. analysed
Group Mesh material
No. of  
animals
Postoperative 
death
28 
days
90 
days
Control No mesh 18 2 8 8
Strattice Non-cross-linked collagen 18 4 7 7
Parietene Polypropylene 18 2 8 8
Parietene  
Composite 
Collagen-polyethyleneglycol-
glycerol-coated polypropylene
18 4 7 7
Sepramesh 
Carboxymethylcellulose-dodium 
hyaluronate-coated polypropylene
18 2 8 8
C-Qur 
Omega-3-fatty acid-coated 
polypropylene
18 2  8* 8
Dualmesh Expanded polytetrafluoroethylene 18 3 7 8
Omyramesh Condensed polytetrafluoroethylene 18 3 7 8
Total 144 22 60 62
*One rat in the C-Qur group died after 13 days. The results of this rat were analysed together with 
the rats killed after 28 days in the C-Qur group. 
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Mesh infection
At the time of death macroscopic infection of the mesh was present in 24 (22.6%) of 
106 animals. The infection rate among C-Qur meshes was high (15 of 16 rats) compared 
with all other meshes (P≤0.006) (Figure 1). Dualmesh also showed a high infection rate 
(7 of 15 rats), significantly higher than all other groups apart from C-Qur (P≤0.035). All 
infected meshes became large fibrotic pseudotumours. No additional mesh infection was 
discovered by microbiological culture of the meshes.
Abscesses
Intra-abdominal abscesses were found in 37 rats (62%) after 28 days and 27 (44%) after 
90 days (P=0.049).The majority of abscesses were located at the caecum or abdominal 
wall. There was no significant difference between groups in intra-abdominal abscesses 
(P=0.482).
Adhesions
After 28 and 90 days the surfaces of all infected meshes were completely covered with 
adhesions. Owing to the high infection rate in C-Qur and Dualmesh the median adhesion 
coverage was 90–100% (Figure 2). After 28 days significantly less adhesion to the mesh 
surface was found for Strattice (median 10.0% (5.0–10.0)) and Sepramesh (12.5% (6.3–
22.5)) compared with all other meshes (P≤0.004 and P≤0.017 respectively). Median 
adhesion coverage was 45.0% for Parietene Composite, 52.5% for Parietene and 55.0% 
for Omyramesh. Sepramesh showed an increase in adhesion formation from a median of 
12.5% at 28 days to 60.0% at 90 days (P=0.010). After 90 days Strattice (5.0 %(5.0–10.0)) 
Figure 1. Comparison of mesh infection rates (combined 28 and 90 days). Values are percentage of 
macroscopically infected meshes among surviving animals.
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had significantly less adhesion coverage than the other meshes (P≤0.003). At 90 days 
there was no significant difference between median adhesion coverage of Parietene 
Composite (35.0%), Omyramesh (42.5%), Sepramesh (60.0%) and Parietene (72.5%).
Incorporation
After 28 and 90 days C-Qur showed no or very little incorporation into the abdominal wall 
owing to the high rate of mesh infection (Figure 3). Strattice showed a poor incorporation 
of 22.7% at 28 days, which was lower than for Omyramesh (47.1%; P=0.004), Parietene 
Composite (42.5%; P=0.004) and Sepramesh (35.6%; P=0.004). The incorporation of 
Strattice was not improved after 90 days (median 13.4%). This was significantly worse 
than the incorporation of Parietene Composite (54.5%; P=0.003), Omyramesh (50.4%; 
P<0.001), Parietene (48.4%; P=0.009) and Sepramesh (40.9%; P=0.002). At 90 days, 
Dualmesh (29.4%) was incorporated more poorly than Parietene (P=0.020), Parietene 
Composite (P=0.009) and Omyramesh (P=0.002).
Shrinkage
The shrinkage of C-Qur could not be determined owing to the formation of large fibrotic 
pseudotumours in all but one of the meshes. The non-infected Dualmesh showed the 
Figure 2. Comparison of percentage of mesh adhesions at 28 and 90 days follow-up. Values are 
median (interquartile range). *28 days Strattice vs Parietene P<0.001, vs Parietene Composite 
P=0.004, vs C-Qur P<0.001, vs Dualmesh P=0.001, vs Omyramesh P=0.003. **90 days Strattice 
vs all other meshes P≤0.003. #28 days Sepramesh vs Parietene P=0.001, vs Parietene Composite 
P=0.009, vs C-Qur P<0.001, vs Dualmesh P<0.001, vs Omyramesh P=0.017. ##Sepramesh 28 vs 
90 days P=0.010. §28 days C-Qur vs Parietene P=0.006, vs Omyramesh P=0.005. §§90 days C-Qur 
vs Parietene P<0.001, vs Parietene Composite P=0.001, vs Sepramesh P<0.001, vs Omyramesh 
P=0.001. † 28 days Dualmesh vs Parietene P=0.004, vs Omyramesh P=0.008 (Mann-Whitney U 
test).
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highest percentage loss of mesh surface, of 63% after 90 days (P≤0.012 compared with 
other meshes). All other meshes had a median loss of mesh surface of between 0 and 10% 
after 28 days. Strattice showed a progressive median loss of surface from 0% at 28 days to 
23% at 90 days (P=0.003). After 90 days the purely synthetic Dualmesh, Omyramesh and 
Parietene showed shrinkage of between 0 and 15%. Parietene Composite and Sepramesh 
did not shrink after 90 days (P≤0.026 and P≤0.014 respectively compared with all other 
meshes).
histology
Fibrosis was observed in all mesh-surrounding tissues. This was especially pronounced 
for the four polypropylene based meshes and Omyramesh (Figure S1, supporting 
information). Dualmesh showed a clear encapsulation of the mesh, almost without cellular 
infiltration into it. A large number of vessels could be seen in the tissue surrounding 
Parietene Composite and Omyramesh. Because of wide intra-animal variation, no 
statistically difference was found for fibrosis, influx of lymphocytes, angiogenesis and 
collagen deposition (data not shown).
Figure 3. Comparison of percentage of mesh edge incorporation at 28 and 90 days follow-up. 
Values are median (interquartile range). *28 days Strattice vs Parietene Composite P=0.004, vs 
Sepramesh P=0.004, vs C-Qur P=0.010, vs Omyramesh P=0.004. **90 days Strattice vs Parietene 
P=0.009, vs Parietene Composite P=0.003, vs Sepramesh P=0.002, vs C-Qur P<0.001, vs 
Omyramesh P<0.001. #28 days C-Qur vs Parietene P=0.002, vs Parietene Composite P=0.001, vs 
Sepramesh P=0.002, vs Omyramesh P=0.001. ## 90 days C-Qur vs all other meshes P≤0.007. §28 
days Dualmesh vs Parietene Composite P=0.023, vs Omyramesh P=0.023. §§90 days Dualmesh vs 
Parietene P=0.020, vs Parietene Composite P=0.009, vs C-Qur P=0.007, vs Omyramesh P=0.002. 
(Mann-Whitney U test).
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DISCUSSION
In this experimental contaminated environment, the collagen-coated polypropylene 
mesh Parietene Composite and the condensed PTFE Omyramesh had a low risk of 
infection, moderate adhesion formation and good incorporation. The biological Strattice 
mesh did not become infected and showed remarkably little adhesion formation, but 
poor incorporation. If a mesh is used in a contaminated environment, consensus exists 
that a biological collagen mesh or a synthetic macroporous, monofilament mesh may be 
advantageous5,16-18. Biological collagen meshes have been developed specifically for a 
contaminated environment and Strattice did not show any mesh infection in this experiment. 
Biological meshes, particularly Strattice, have shown improved clearance of bacteria, 
which decreases the possibility of infection and formation of adhesions19. A prospective 
multicentre study of contaminated ventral hernia repair with Strattice reported a similar 
low infection rate with little need to remove the mesh20. The macroporous Parietene, 
Parietene Composite, Sepramesh and Omyramesh had a low risk of infection. Large 
pores allow admission of macrophages, fibroplasia and angiogenesis, which improves the 
ability to clear infection5,6. In this study, however, the macroporous C-Qur mesh showed 
a high infection rate. This polypropylene mesh is coated with anti-inflammatory omega-3 
fatty acids. In an experimental clean environment macrophages were scarcely present 
in the mesh after implantation11,21. It might be hypothesized that the anti-inflammatory 
properties of the omega-3 fatty acid coating have prevented macrophage penetration, 
although no clinical or experimental literature on the characteristics of omega-3 fatty 
acids in the presence of bacteria has yet been published. Dualmesh showed a high 
infection rate, probably because of its partially microporous structure (smaller than 
10 μm). The increased risk of infection after surgery with Dualmesh, and the need to 
remove the prosthesis in case of infection, is notorious in the clinical situation22-24. Mesh 
infection is caused by infiltration and proliferation of bacteria within the pores and 
interstices of synthetic materials. Small pores prevent infiltration of immune cells and 
make microporous meshes more susceptible to infection5,25.Additionally, the hydrophobic 
visceral surface of Dualmesh decreases adhesion of tissue cells, allowing bacteria a free 
passage to the implant surface16. Intra-abdominal adhesion and abscess formation are 
important causes of morbidity and mortality following contaminated abdominal surgery. 
During peritonitis fibrin is deposited in the abdominal cavity, inducing adhesion formation 
and providing possible niduses for abscess formation9. Biological Strattice mesh showed 
low adhesion formation after 90 days, confirming previous experimental results26-28. 
Sepramesh showed a significant increase in adhesion formation between 28 and 90 days, 
implying that the cellulose–hyaluronate coating is absorbed before a neoperitoneal layer 
is formed. These results confirm that adhesion formation in the presence of mesh is not 
complete after 7 days8,11. The surface of Parietene Composite and Omyramesh were least 
covered with adhesions after 90 days. Low adhesion formation on the collagen-coated 
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Parietene Composite has been described in a clean environment8,11. The present results 
suggest that the collagen coating remains present until a neoperitoneum has formed, 
even in a contaminated environment. The low adhesion formation on Omyramesh 
confirms experimental findings with this relatively new mesh in a clean environment29,30. 
The low adhesion formation might be explained by its smooth, monolayer, non-fibrous, 
macroporous structure. The plain polypropylene Parietene mesh was largely covered 
with adhesions. Clinically, uncoated polypropylene meshes are known to induce 
severe adhesion formation with attachment of intestine to the mesh when implanted 
intraperitoneally7,31. In 21% of patients with an intraperitoneal uncoated polypropylene 
mesh, adhesions made bowel resection necessary during re-exploration in one study7. 
The non-infected, partially microporous, expanded PTFE Dualmesh had an alarmingly 
high shrinkage rate (median 63% after 90 days). Such shrinkage has frequently been 
reported experimentally, but this does not seem to be correlated with a higher recurrence 
rate clinically8,23,32. A fibrous capsule surrounding the mesh was observed, almost without 
cellular infiltration into the mesh. Contraction of this capsule was probably the cause 
of shrinkage, which might have been more pronounced in the small meshes used in 
the present experiment compared with the much larger meshes used clinically. Of the 
macroporous meshes, the plain polypropylene Parietene showed the most shrinkage 
(15% after 90 days), confirming experimental results32,33. The biological Strattice mesh had 
a 23% loss of surface after 90 days, probably caused by collagenase activity. Premature 
weakening of the biomechanical properties of the scaffold combined with insufficient 
incorporation can possibly result in loss of the prosthesis and hernia recurrence34. Until 
evidence of biomechanical strength after hernia repair with biological meshes has been 
provided, synthetic meshes are preferred for primary repair.
Translation of experimental results to the clinical situation should be done with caution. 
However, the CLP model is suitable for studying the behaviour of synthetic and biological 
meshes experimentally in a contaminated environment. In this model, as in clinical 
infections, peritonitis arises from a complex interaction of the immune system with 
inflammatory, haemodynamic and biochemical alterations similar to human sepsis, with a 
consistent increase in cytokine levels35-38. Another advantage of this experimental model is 
the use of rats of the same age and sex, and specified pathogen-free bacterial status. This 
minimizes biological and microbiological variability, and makes it suitable for comparing 
characteristics of different meshes in a similar contaminated environment38. A limitation of 
the model is the size of the mesh and mesh pores in relation to the abdominal wall, which 
is different between rats and humans. This might lead to an overestimation of shrinkage. 
The meshes in this experiment were fixated with six sutures. In humans the number 
of fixation points in relation to the mesh size would be much higher. This might have 
influenced incorporation, as described in previous experimental mesh studies8,11. Finally, 
the concentration of the antiadhesive coatings and its systemic effects during breakdown 
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in this model might be different from the human situation. The experimental results of 
synthetic mesh implantation in a contaminated environment make strict contraindication 
in humans questionable. Although there are no meshes without disadvantages, certain 
permanent synthetic meshes might be somewhat infection-resistant and therefore useful 
for permanent hernia repair in a contaminated environment. 
SUPPLeMeNT
Figure S1 Histological samples after 90 days. a,c,e,g,i haematoxylin and eosin staining and b,d,f,h,j 
picrosirius red staining of histological samples after 90 days (original magnification ×40). a,b 
Polypropylene (Parietene; Sofradim, Trevoux, France; part of Covidien, North Haven, Connecticut, 
USA); c,d collagen–polyethyleneglycol–glycerol-coated polypropylene (Parietene Composite; 
Sofradim); e,f carboxymethylcellulose–sodium hyaluronate-coated polypropylene (Sepramesh; 
Bard, New Providence, New Jersey, USA); g,h expanded polytetrafluoroethylene (Dualmesh; Gore, 
Flagstaff, Arizona, USA); i,j condensed polytetrafluoroethylene (Omyramesh; B. Braun, Melsungen, 
Germany); and k,l non-cross-linked collagen mesh (Strattice; LifeCell, Branchburg, New Jersey, 
USA). The purple and pink cells in the haematoxylin and eosin-stained sections are fibroblasts and 
lymphocytes. The synthetic fibres of the Parietene (a,b), Parietene Composite (c,d), Sepramesh 
(e,f) and Omyramesh (i,j) are surrounded with fibrotic tissue with newly formed collagen. Around 
Dualmesh (g,h) a cellular layer is observed, forming a capsule; cellular infiltration into the mesh is 
minimal. In the picrosirius red-stained section of the Strattice mesh (l) it is impossible to differentiate 
between the collagen of the mesh and newly formed collagen (C/F). M, abdominal wall muscle; F, 
mesh fibres, C, newly formed collagen layer 
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ABSTRACT
Background
This experimental study investigates infectious complications and functional outcome of 
biological meshes in a contaminated environment.
Methods
In 90 rats peritonitis was induced, and after 24 hours, a biological mesh was implanted 
intraperitoneally including 2 non-crosslinked mesh groups (Strattice and Surgisis ) and 2 
crosslinked mesh groups (CollaMendFM and Permacol ). Sacrifice was after 90 and 180 
days.
Results
More mesh infections occurred in crosslinked meshes compared with non-crosslinked 
meshes (70% vs 4%; P<0.001). Mesh infection was the highest in crosslinked CollaMendFM 
(81.2%) and lowest in non-crosslinked Strattice groups (0%). Incorporation into the 
abdominal wall was poor in all meshes (0% to 39%). After 180 days no residue of non-
crosslinked Surgisis mesh was found. After 180 days, shrinkage was 0.8% in crosslinked 
Permacol and 20% in Strattice groups. Strattice showed the least adhesion formation 
(median 5%).
Conclusions
Infection rate of biological meshes in a contaminated field was the highest in crosslinked 
meshes. All biological meshes showed poor incorporation, which makes long-term 
abdominal wall repair questionable.
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INTRODUCTION
Many factors are of influence on the functional outcome of abdominal wall repair, such 
as patient characteristics, site of implantation, the presence of contamination, and the 
chosen mesh material. Especially in the presence of bacterial contamination, repair of 
abdominal wall defects is a continuing challenge for surgeons. Contamination can be 
caused by intra-abdominal and surgical site infection, incarcerated and strangulated 
hernia, concomitant bowel surgery, the presence of a colostomy, acute evisceration, and 
open abdomen. Introduction of synthetic meshes in abdominal wall repair significantly 
decreased recurrence rates1,2. However, implantation of a synthetic prosthesis into a 
contaminated environment generates an increased risk for infection3,4. Mesh infection 
often necessitates removal of the mesh, leaving an abdominal wall deficit, sometimes 
larger than the original hernia, and closure can only be accomplished with contact of 
the mesh with the intra-abdominal content. Recommendations on mesh selection have 
been developed by the Ventral Hernia Work Group in 20085. In case of ventral hernia 
repair with mesh implantation in patients with grade-3 and -4 risk of surgical site infection, 
biological mesh is recommended. 
Biological meshes are extracellular scaffolds, processed from animal (bovine or porcine) 
small intestine submucosa, pericardium, or dermis. The donor tissue is said to be cleared 
of cells and immunogenic particles, after which a scaffold of extracellular matrix (ECM) 
remains. After implantation, the scaffold is gradually vascularized and remodelled into 
the host tissue while degradation of theECM takes place6,7. To increase biomechanical 
strength, chemical crosslinking of the biological mesh can be conducted. Crosslinking 
stabilizes the 3- dimensional structure of the ECM. This improves withstanding of 
enzymatic degradation of the ECM, which can be accelerated because of inflammation 
or infection at the implantation site8-10. Initial animal and clinical data seemed promising; 
however, compelling evidence is lacking as these data mainly report on clean cases and 
short follow-up with only a small portion in contaminated cases11. Furthermore, recent 
clinical reports have been published on infectious complications of both non-crosslinked 
and crosslinked meshes12-17.
The objective of this experimental study was to investigate the infectious complications 
and functional outcome of crosslinked and non-crosslinked biological meshes in a 
contaminated environment in a model of abdominal wall repair in the rat.
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MeThODS
Animals
Experimental protocols were approved by the Ethical Committee on Animal 
Experimentation of the Erasmus University Rotterdam. Ninety male rats of the outbred 
Wistar strain were obtained from a licensed breeder (Harlan, the Netherlands) and 
accustomed to laboratory conditions 2 weeks before the start of the experiment. The 
animals were bred under specific pathogen-free conditions, were kept under standard 
laboratory conditions in individually ventilated cages in pairs, and had free access to 
standard rat chow and water throughout the experiment.
Peritonitis model
Rats were anaesthetized with isoflurane and O2 inhalation (Pharmachemie, Haarlem, 
the Netherlands) and received buprenorfin analgesia 0.05 mg/kg subcutaneously 
(Reckitt Benckiser Healthcare (UK) Limited, Kingston upon Thames, United Kingdom). 
Procedures were performed under aseptic conditions. The abdomen was shaved and 
the skin disinfected with 70% alcohol, after which the abdominal cavity was opened 
through a 3-cm midline incision through the skin and linea alba. To induce peritonitis, 
the cecal ligation puncture model was performed in all rats18,19. The cecum was carefully 
manipulated outside the abdominal cavity and ligated just distal to the ileocecal valve 
with a monofilament nonabsorbable nylon suture (Ethilon 4-0; Ethicon, Somerville, NJ), 
maintaining the continuity of the bowel. Distally, the cecum was punctured once with an 
18-ga needle. The fascia and the skin were closed with running absorbable polyglycolic 
acid sutures (Safil 5-0; B Braun, Melsungen, Germany). After 24 hours of recovery, the 
animals were re-anesthetized, the abdomen was reopened, a culture swab taken to 
confirm peritonitis, the necrotic cecum resected, and the abdominal cavity was rinsed 
with at least 20 mL phosphate-buffered saline at 37°C. A sterile mesh, measuring 2.5 x 3 
cm, was implanted intraperitoneally with 6 transmuscular nonabsorbable sutures (Ethilon 
5-0) in all mesh groups. In the control group no mesh was implanted. After administration 
of gentamicin 6 mg/kg intramuscularly (Centrafarm, Etten Leur, the Netherlands), the 
abdominal wall and skin were separately closed with a running absorbable suture (Safil 
5-0). Buprenorfin analgesia 0.05 mg/kg was administrated twice daily on the days animals 
were operated and the first day after mesh implantation.
Implanted meshes
The control group received no mesh, and in the mesh groups, 1 of 4 biological meshes 
was implanted within the peritoneal cavity. Four commercially available biological 
meshes were implanted; non-crosslinked porcine dermis Strattice (LifeCell, Branchburg, 
NJ), non-crosslinked porcine submucosa Surgisis (Cook, Bloomington, IN), crosslinked 
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porcine dermis CollaMendFM (C.R. Bard [Davol, Inc],Warwick, RI) and crosslinked porcine 
dermis Permacol (Covidien, Norwalk, CT). Prostheses were prepared according to the 
manufacturer’s instructions before implantation.
Measurements
Animals were divided in groups according to implanted mesh and intended time of 
sacrifice, 90 or 180 days after implantation of the mesh. During the experiment, animals 
were weighed daily and scored for their wellness using an objective 12-point scoring 
system during the first 14 days of the experiment, thereafter once a week20. In case of 
severe infectious complication, weight loss of 20% or more, or a wellness score of less than 
5 out of 12 points, animals were euthanized before the intended end of the experiment 
and analyzed together with the surviving animals of the group. On all euthanized and 
deceased animals necropsy was performed. 
During sacrifice, the animals were anaesthetized with isoflurane and O2 inhalation; the 
abdomen was shaved, disinfected, and opened through a U-shaped incision extending 
laterally and caudally to the mesh. Macroscopically, mesh infection was defined as the 
presence of abscesses of the mesh. Parts of the mesh were cultured for microbiological 
evaluation. In all mesh groups, mesh surface and coverage of the mesh surface with 
adhesions were scored using a grid placed over the mesh, dividing it into 30 equal 
squares and facilitating accurate estimation of adhesion formation. Tenacity of adhesions 
was scored using the Zühlke score, a 4-degree classification of adhesions based on 
histologic and morphologic criteria21. Pictures of the abdominal wall with the mesh and 
the present adhesions were taken (5.0 megapixels digital camera, Sony Cybershot, Tokyo, 
Japan). The abdominal cavity was inspected for abscesses, and when present, scored and 
cultured at 4 sites of the peritoneum (liver, abdominal wall, bowel, and omentum) using an 
objective abscess size scoring system22. Mesh incorporation was defined as percentage 
of the mesh edge incorporated into the abdominal wall, taking into account any surface 
reduction (Figure 1). If only the sutures secured the mesh to the abdominal wall and 
no ingrowth of the mesh was seen, ingrowth was scored as 0%. Surface reduction was 
defined as the relative loss of surface compared with the original size of the implanted 
mesh measured with a calliper. All measurements were performed by 2 independent 
observers and disagreements reconciled after discussion. The animals were euthanized 
by cardiac cut at the end of the experiment during anesthesia.
Statistical analysis
Mesh infection, tenacity, and percentage of adhesions, abscess formation, survival, 
and weight were compared using nonparametric tests as the data did not show normal 
distribution (Kruskal-Wallis, Mann-Whitney, chi-square, and the Fisher exact tests). 
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Therefore, all results are presented using the median and the interquartile range (IQR). In 
case the overall test showed differences, the pairwise tests were done to determine the 
groups causing the overall significance. 
Exact methods for significance were used when computational limits allowed these. All 
reported P values are 2-sided and considered significant if less than 0.05. In view of the 
small sizes of the groups, it was not possible to adjust the P values using the Bonferroni 
correction. Statistical analysis was performed using PSAW statistical software package, 
version 17 (IBM SPSS statistics).
ReSULTS
During the 2 days after implantation of the mesh, 18 of the 90 rats (20%) were prematurely 
taken out of the experiment because of a low wellness score. Postoperative mortality 
was not statistically different between the groups. In all rats necropsy was performed 
and septicemia was found to be the cause of death. Abdominal cultures at day 1 
confirmed bacterial contamination in all animals with gram-positive (Enterococcus, 
Staphylococcus, Streptococcus) and gram-negative microorganisms (Escherichia coli and 
Proteus). All animals demonstrated signs of sepsis including apathetic behaviour, ocular 
exudates, piloerection, diarrhea, and weight loss. Mortality in the groups is depicted 
in Table 1. Maximum percentage weight loss was significantly higher in CollaMendFM 
after postoperative day 5 compared with the other groups (median: CollaMendFM, 12%; 
Strattice, 11%; Surgisis, 9%; Permacol, 9%; P<0.020).
Figure 1. Example of incorporation of the edge of biological mesh in the abdominal wall.
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Mesh infection and abdominal abscesses
Seven animals (44%) with a CollaMendFM mesh and 1 animal (7%) with a Permacol mesh 
were euthanized before the intended time point because of clinically evident mesh 
infection with transcutaneous migration of the prosthesis. At sacrifice, macroscopic 
infection of the mesh was present in 22 of 57 animals (39%). In Figure 2, the percentage of 
mesh infections per mesh group is shown. The mesh infection rate was significantly higher 
for crosslinked meshes compared with non-crosslinked meshes (70% vs 4%; P<0.001). In 
16 animals, the mesh was encapsulated by a large abscess, and in 6 animals, abscesses in 
parts of the mesh were found (Figure 3). No additional mesh infections were discovered 
by microbiological culture of the meshes performed during sacrifice. 
Intra-abdominal or abdominal wall abscesses were found in 42% of all surviving animals 
at sacrifice. Most abscesses were located at the ligation of the cecal stump. There was 
no significant difference in amount and size of intra-abdominally (non-mesh related) 
observed abscesses (P=0.321) between the meshes. Although when differentiated 
between crosslinked and non-crosslinked meshes, more abscesses were observed in the 
animals with crosslinked meshes implanted (P=0.011).
Surface reduction 
The 22 animals with infected meshes were excluded from this analysis because surface 
of the mesh could not be accurately measured. The CollaMendFM groups were excluded 
from analysis because, after excluding the animals with infected meshes, an insufficient 
number of animals were left to perform statistical testing. Loss of surface of Surgisis was 
significantly higher at both time points compared with Strattice and Permacol (P<0.036). 
Both at 90 and 180 days, only in 2 animals a very thin residue of the Surgisis mesh could 
be found macroscopically. Loss of surface after 90 days was significantly higher in the 
Strattice compared with the Permacol group (median [IQR], 23% [10-46] vs 3% [0-7]; 
Table 1. Postoperative mortality and animals analyzed at both time points per group. 
Group Material Animals
Postoperative 
mortality
90 days 180 days
Control No mesh 18 2 8 8
Strattice Non-crosslinked dermis 18 4 7 7
Surgisis Non-crosslinked submucosa 18 5 6 7
Permacol Crosslinked dermis 18 5 7* 6
CollamendFM Crosslinked dermis 18 2 9* 7*
Total 90 18 37 35
*One rat in the Permacol group and 7 rats in the CollamendFM were euthanized before the 
intended end point. The results of these rats were analyzed together with the rats sacrificed at the 
intended end point. 
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P=0.033). In the Strattice group, loss of surface after 180 days was median 20% (IQR, 
10-41) and median 1% (IQR, 0-3) for the Permacol group (P=0.075). After grouping the 
scaffolds by crosslinking, surface reduction of the mesh was lower in the crosslinked group 
(median [IQR], 2% [0-4]) compared with the noncrosslinked group (23% [10-46]; P<0.001).
 
Figure 2. Comparison of combined percentage (90 and 180 days) of mesh infection. Values are 
percentage of macroscopically infected meshes of surviving animals. 
* Non-crosslinked meshes § Crosslinked meshes
Figure 3. Macroscopic evaluation of mesh infection. Meshoma of a Permacol mesh (A, B) and 
formation of mesh abscess in a Permacol mesh (C).
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Incorporation 
Overall incorporation of the biological meshes into the abdominal wall at 90 and 180 
days was poor (range, 0%-39%). At 90 days, incorporation of all meshes was median 4% 
(IQR, 0-21) and at 180 days median 0% (IQR, 0-11). Due to the high infection rate, the 
CollaMendFM mesh showed incorporation of median 0% at 90 and 180 days (IQR, 0-24; 
IQR, 0-17, respectively). Most Surgisis meshes could not be identified at 90 and 180 days, 
leading to an overall incorporation of 0% (IQR, 0-0). Strattice showed incorporation of 
median 14% (IQR, 10-21) at 90 days, decreasing to median 10% (IQR, 6-12) at 180 days 
(P=0.128). Permacol was incorporated median 21% (IQR, 3-39) at 90 days, decreasing 
to 6% (IQR, 0-31) at 180 days (P=0.320). At both time points, incorporation was not 
different between Strattice and Permacol (P=0.513 and P=0.506). There was no difference 
in incorporation between crosslinked and non-crosslinked meshes (P=0.537).
Adhesions
In the control group, 6 of 15 rats (40%) showed visceral adhesions to the midline scar with 
a maximum Zühlke score of 2. Adhesion coverage per mesh group is depicted in Figure 
4. At 90 and 180 days, median 100% of the original implantation site of the Surgisis 
was covered with adhesions (90 days IQR, 76%-100%; 180 days IQR, 100%-100%). 
CollaMendFM was covered with median 100% adhesions at 90 and 180 days (90 days 
IQR, 95%-100%; 180 days IQR, 100%-100%). Strattice had little adhesion formation to 
the mesh at 90 and 180 days (both time points median 5%; IQR, 5%-10%), which was 
significantly lower than the other meshes (P<0.038). At 90 days, median 68% (IQR, 48%-
93%) of mesh surface of Permacol was covered by adhesions and at 180 days, median 42% 
(IQR 13%-100%). Alteration in adhesion coverage between 90 and 180 days in all mesh 
groups was not significantly different (P>0.356). Tenacity of adhesions was higher after 
90 days for CollaMendFM (median Zühlke score, 4; IQR, 3-4) compared with Permacol 
(median Zühlke score, 3; 3-3) and Strattice groups (median Zühlke score, 3; IQR, 3-3, 
respectively; P=0.012 and P=0.031). After 180 days, the tenacity of adhesions decreased 
and was lowest for Strattice (median Zühlke score, 2; IQR, 2-3), which was significantly 
lower than that for Permacol (median Zühlke score, 3; IQR, 3-3), CollaMendFM (median 
Zühlke score, 3; IQR, 3-4) and Surgisis (median Zühlke score, 3; IQR, 3-3, respectively; 
P=0.013, P=0.007, and P=0.008, respectively). 
After grouping the scaffolds by crosslinking, the percentage of the mesh covered with 
adhesions and the tenacity of the adhesions to the mesh were found to be higher in the 
crosslinked group (P=0.01 and P=0.024, respectively).
Comments
Crosslinked biological meshes were found to have a significantly higher percentage of 
mesh infection (70% vs 4%; P<0.001) and intra-abdominal abscesses (P=0.011) than non-
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crosslinked biological meshes. Infectious complications required euthanasia before the 
intended time point in almost half of animals in the crosslinked CollaMendFM group, as 
described in previous animal experiments23-27.These results are in accordance with clinical 
reports of infectious complications of biological meshes instigating the debate on the 
indications for their clinical use12-15,17,28,29. The development of infection in crosslinked 
meshes seems comparable to mesh infection in microporous synthetic meshes by 
preclusion of immune cells30. Crosslinking appears to decrease the pore size of biological 
meshes to a pore size small enough to provide a suitable housing for bacteria while 
preventing access of macrophages, fibroblasts, blood vessels, and collagen fibers into 
the pores31,32. This may lead to encapsulation rather than remodelling of the mesh33,34.
However, not all crosslinked meshes have similar densities of crosslinking because of 
differences in processing. Another interference of mesh integration could be the 
sterilization technique. CollaMendFM and Surgisis inhibiting tissue integration and 
reducing tensile strengths35,36.
However, the influence of sterilization techniques on these parameters is still largely 
untested. This could be of importance considering the differences found in performance 
between the crosslinked meshes. In previous studies, the possible effect of crosslinking 
on the occurrence of infectious complications was not addressed. This experiment is the 
first step in acquiring more knowledge on the effect of crosslinking on the occurrence 
of infectious complications after implantation of biological meshes in a contaminated 
environment. 
Figure 4. Comparison of percentage of each mesh covered with adhesions after 90 and 180 days 
follow-up. Values are median (interquartile range). Strattice has significant lower adhesion formation 
than Surgisis, Permacol and CollaMendFM at 90 and 180 days, * P<0.05.
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In abdominal wall repair with a biological mesh, resistance to degradation is critical to 
prevent recurrence of hernia. During the remodelling process, after implantation a delicate 
balance exists between ECM degradation and deposition of host collagen. The donor 
material of the ECM seems to influence the rapidity of degradation of the mesh. High 
levels of hydroxyproline in collagenase assay suggest low resistance of the submucosa-
based mesh to enzymatic degradation37. This was illustrated in the present and previous 
experiments by the complete disappearance of the small intestine submucosa–based 
Surgisis, which makes long-term hernia repair questionable34,38. Meshes derived from 
dermis were observed to have little surface reduction in the present experiment, with a 
20% reduction in noncrosslinked Strattice and 1% in crosslinked Permacol after 6 months. 
Chemical crosslinking is performed to make biological meshes more resistant to matrix 
metalloproteases and native and bacterial collagenase. Our experiment also showed 
decreased surface reduction in the crosslinked group; however, when only dermal 
meshes were investigated, there was no difference in surface reduction between non-
crosslinked and crosslinked meshes. In the present experiment, under contaminated 
conditions, crosslinked meshes showed poor incorporation in the abdominal wall. The 
best incorporation was 21% by Permacol after 90 days, which was decreased to only 6% 
at 180 days. This disappointing incorporation of crosslinked meshes can be explained 
by delayed collagen degradation, leading to decreased angiogenesis and inflammation 
due to foreign body reaction resulting in poor tissue integration and adhesion 
formation14,24,26,27. This foreign body reaction can be provoked by exposure of antigenic 
epitopes known to hinder successful xenotransplantation. For example, galactose-alpha-
1,3-galactose (alpha-gal) is proven to be present in the ECM of non-crosslinked Surgisis 
39. Crosslinking can initially mask these antigenic epitopes, but with mesh degradation, 
epitopes become exposed40,41. Exposure of epitopes leads to production of antibodies 
in humans and primates activating humoral immune and complement response39,42. 
Adhesion formation seems to be related to foreign body reaction to the mesh and sutures 
and the presence of mesh infection in the present experiment. The amount of adhesions 
found in this experiment is consistent with earlier experimental reports19,26,27. One clinical 
study evaluated adhesions by laparoscopic re-exploration after ventral hernia repair and 
found similar surface area and tenacity of adhesions in the biological meshes compared 
with synthetic meshes43. 
To create a contaminated environment, we used the cecal ligation puncture model, which 
was originally designed as a sepsis model. In this model, as in clinical infections, peritonitis 
arises from a complex interaction of the immune system with inflammatory, hemodynamic, 
and biochemical alterations with a consistent increase of cytokine levels44-47. Additionally, 
in this model genetically identical rats were used of the same age and sex and specified 
pathogen-free bacterial status. This minimalizes biological and microbiological variability 
and makes the model suitable for comparing the behaviour of various meshes in a 
contaminated environment but does not reflect daily practice46. 
Processed on: 22-2-2017
507513-L-bw-Mulder
160
Chapter 9
A limitation of the model in this experiment is that only a single dose of aminoglycoside 
is administrated, where this does not reflect the treatment of humans with abdominal 
sepsis. Administration of antibiotics in rats with fecal peritonitis does reduce bacteremia, 
bacteria concentration, and mortality rates48. But previous experiments proposed a 
drawback regarding the use of antibiotics because of the possible marked bacterial cell 
death causing the release of toxic components against the immunologic system and 
the triggering of uncontrolled activation of this system49-51. Previous animal experiments 
found that when antibiotics were added to the surgical treatment, the inflammatory 
response is minimized, but there is no difference in survival or amount of intra-abdominal 
abscesses52,53. Therefore, surgical control of the source of infection remains the most 
important treatment in abdominal sepsis. However, the adjunct of systemic antibiotics 
to surgical treatment is firmly established in the postoperative period in humans because 
it reduces the systemic effects of peritonitis and could influence late complications like 
abscess or fistula formation54. 
Therefore, translation of experimental results to the clinic situation should be done with 
caution.
In the clinical setting, biological meshes are often implanted in the intraperitoneal or 
sublay position. A limitation of the present animal study is that thickness and size of the 
mesh in relation to the abdominal wall is dissimilar between rats and humans. Furthermore, 
the chosen intraperitoneal placement of the mesh could have influenced incorporation of 
the mesh in the abdominal wall because the mesothelial layer of the peritoneum is less 
vascularized than the retromuscular space55. On the other hand, closure of the peritoneal 
layer is often deficient when attempting sublay positioning of the mesh in humans, making 
the used model clinically relevant.
CONCLUSIONS
In conclusion, this experiment demonstrates a high infection rate and increased adhesion 
formation of crosslinked biological meshes (Permacol and CollaMendFM). Resistance 
to infection of non-crosslinked Strattice could allow implantation in the contaminated 
environment. However, the poor incorporation of all biological meshes and complete 
degradation of Surgisis makes long-term biomechanical strength of hernia repair 
questionable. Implantation of biological prostheses could be a valid choice in staged 
contaminated abdominal wall repair. Prevention of mesh infection associated with high 
costs for intensive care treatment, reoperation, and prolonged hospital stay might justify 
the high costs of a biological mesh.
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ABSTRACT 
Background
This study investigates long-term incorporation, adhesion formation, mesh infection and 
shrinkage after implantation of biological meshes in non-contaminated environment.
Methods
In 64 rats a mesh-model was used to implant various meshes intraperitoneally: 2 
non-crosslinked mesh groups (Strattice and Surgisis) and 2 crosslinked mesh groups 
(CollaMendFM and Permacol). Sacrifice was after 90 and 180 days. 
Results
High numbers of infectious complications were observed (12.5% transcutaneous 
prosthesis migration and 23.4% macroscopic mesh infection). Incorporation of meshes 
was poor (0% to 36.8%) on postoperative day (POD) 180. Mesh shrinkage was highest 
in Surgisis (POD 90 57%, P<0.01). On POD 180, shrinkage did not differ between the 
meshes. Surgisis had the highest adhesion score on POD 90 (90%, P<0.023). Adhesions 
covering the mesh was least in Strattice (5%, P<0.029).
Conclusions
Experimental intraperitoneal implantation of biological meshes is accompanied by various 
infectious complications with little incorporation and will most likely not adequately 
prevent the formation of recurrent incisional hernia.
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INTRODUCTION
The number of patients undergoing elective abdominal wall hernia repair with mesh in 
the United States was approximately 48,000 in 20101. The subsequent economic burden 
is justified by the increased quality of life and core physiology after hernia repair2,3. Many 
different mesh types have been introduced on the market with different indications. 
Synthetic meshes are suggested to be contraindicated in clean-contaminated and 
contaminated fields following reports on increased susceptibility to infection, fistula 
formation and adhesion formation. Biological meshes were introduced aiming to reduce 
infectious complications by complete integration in the host tissue and ingrowth of 
mononucleair cells. Early short term results after implantation of biological meshes were 
promising, although mainly investigated in a clean environment. Thereafter reviews 
concluded that biological meshes should be incorporated in the surgeons armentarium 
which resulted in widespread implantation of these grafts4-7. 
The Ventral Hernia Working Group of the European Hernia Society recommended use of 
biological mesh in case of a potentially contaminated or infected wound due to the risk of 
infectious complications. Consensus on the use of biological meshes has not been reached 
and surgeons over the world struggle with these recommendations in daily practice8-10. 
In clinical studies with Strattice and Surgisis meshes recurrence of hernia was high which 
could be due to use of non-crosslinked meshes11,12. In a previous animal model infection 
rate was increased in crosslinked meshes and incorporation of all biological meshes was 
poor in a contaminated environment13. Sustainable hernia repair and low rates of mesh 
infection when using biological meshes is essential to compete with synthetic meshes in 
a clean environment.
Long-term follow-up on biological meshes in clinical and animal studies is still scarce. 
This study aimed to compare two commercially available crosslinked with two non-cross-
linked biological meshes in intra-peritoneal position in a rat model. The meshes were 
tested on infectious complications, adhesion formation, shrinkage and incorporation after 
a period of 90 and 180 days. 
MATeRIALS AND MeThODS
Animals
Sixty-four male rats of the outbred Wistar strain weighing 288-422 grams were obtained 
from a licensed breeder (Harlan, the Netherlands) and bred under specific pathogen-free 
conditions. The animals were accustomed to laboratory conditions one week before the 
start of the experiment. They were kept under standard laboratory conditions in individually 
ventilated cages and fed with standard rat chow and water ad libitum throughout the 
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experiment. Experimental protocols were approved by the Ethical Committee on Animal 
Experimentation of the Erasmus University Rotterdam.
Implanted meshes
Animals were divided into 8 groups and 4 different commercially available biological 
meshes were implanted; non crosslinked porcine dermis Strattice (Lifecell, Branchburg, 
NJ), non crosslinked porcine submucosa Surgisis (Cook, Bloomington, IN), crosslinked 
porcine dermis Permacol (Covidien, Norwalk, CT) and crosslinked porcine dermis 
CollamendFM (C.R. Bard/Davol, Inc, Warwick, RI). Prostheses were prepared according to 
the manufacturer’s instructions before implantation.
Mesh model
Rats were anaesthetized with isoflurane/O2 inhalation (Pharmachemie, Haarlem, the 
Netherlands) and received buprenorfin analgesia 0.05 mg/kg subcutaneously (Reckitt 
Benckiser healthcare limited, Kingston upon tames, United Kingdom). Procedures were 
performed under aseptic conditions. The abdomen was shaved and the skin disinfected 
with 70% alcohol, after which the abdominal cavity was opened through a 3 cm midline 
incision through the skin and linea alba. A sterile mesh, measuring 2.5x3cm, was implanted 
intraperitoneally with three transmuscular non-absorbable sutures (Ethilon 5-0) on both 
sides of the incision in all mesh groups. Thereafter the abdominal wall and skin were 
separately closed with a running absorbable suture (Safil 5-0).
Measurements
In case of severe infectious complications animals were euthanized before the intended 
endpoint. These animals were analysed together with the surviving animals sacrificed at 
the intended endpoint. Half of the surviving animals were sacrificed after 90 days and half 
after 180 days. During sacrifice the abdomen was shaved, disinfected and opened through 
a U-shaped incision extending lateral and caudal to the mesh. Mesh incorporation was 
defined as percentage of the mesh edge incorporated into the abdominal wall, taking 
into account any shrinkage (example on page 154 of this thesis). In all mesh groups mesh 
surface and coverage of the mesh surface with adhesions was scored using a grid placed 
over the mesh, dividing it into 30 equal squares and facilitating accurate estimation of 
adhesion formation. Tenacity of adhesions was scored using the Zühlke-score, a 4-degree 
classification of adhesions based on histological and morphological criteria14. Pictures of 
abdominal wall with mesh and the present adhesions were taken (5.0 megapixels digital 
camera; Sony Cybershot). Macroscopically mesh infection was defined as the presence of 
abscesses of the mesh. Shrinkage was defined as the relative loss of surface compared with 
the original size of the implanted mesh measured with a calliper. All measurements were 
performed by 2 independent observers and disagreements reconciled after discussion. 
The animals were euthanized by cardiac cut. 
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Statistical analysis
Incorporation, mesh infection, tenacity and percentage of adhesions, abscess formation, 
survival, weight and shrinkage were compared using non-parametric tests (Kruskal Wallis, 
Mann Witney, Chi-square, Fisher’s exact and Spearman’s rho) since the data did not 
show a normal distribution. Therefore all results are presented using the median and the 
interquartile range (IQR). In case the overall test showed differences, the pairwise tests 
were done to determine the groups causing the overall significance. Exact methods for 
significance were used when computational limits allowed these. All reported p-values 
are two-sided and considered significant if less than 0.05. In view of the small sizes of the 
groups, it was not possible to adjust the p-values using Bonferroni’s correction. Statistical 
analysis was performed using PSAW statistical software package, version 17 (IBM SPSS 
statistics).
ReSULTS
Mesh infection
During the experiment 8 animals were euthanized due to clinically evident mesh infection 
with transcutaneous migration of the prosthesis between day 49 and 87. In all euthanized 
rats, 7 animals of the CollamendFM group and 1 of the Surgisis group, necropsy was 
performed and large mesh abscesses were found intra abdominally. In total 15 of 64 rats 
(23.4%) were found to have macroscopic infection of the mesh at time of sacrifice. In Figure 
1 the amount of mesh infections per mesh-group is shown. Strattice had a significantly 
lower number of mesh infections compared to CollamendFM at 90 days (P<0.001). At 180 
days CollamendFM showed a significantly higher rate of mesh infection compared to all 
other meshes (P<0.004). Maximum percentage of weight loss was significantly higher in 
CollamendFM compared to all other groups (median 6, compared to Strattice 2; Surgisis 
3; Permacol 3.5, P=0.001).
Mesh incorporation
Animals with mesh infection were not included in this analysis because no incorporation 
of the mesh was found in these animals. Incorporation of the meshes was not significantly 
different between the groups at 90 days (median 13.2%, IQR 0-24.2%). Data per mesh is 
shown in Figure 2. No Surgisis meshes could be identified at 180 days and incorporation 
was scored as 0%. Therefore at 180 days the incorporation of Surgisis (0%, 0-0) was 
significantly lower than Strattice (13.7%, 10.3-22.4; P<0.001) and Permacol (20.7%, 5.7-
24.5; P<0.001). For each mesh no difference in incorporation of the mesh was observed 
between 90 and 180 days. 
Processed on: 22-2-2017
507513-L-bw-Mulder
172
Chapter 10
Adhesions
At 90 days Surgisis had the highest percentage of mesh adhesions to the mesh implantation 
site (90%, 32.5-100) which was significantly more than all other meshes (P<0.023). Data 
per mesh is shown in Figure 3. Strattice showed a significantly smaller percentage of mesh 
surface covered with adhesions (5.0%, 5.0-5.0; median Zühlke 2) compared to all other 
meshes (P<0.029). When only considering non-infected meshes there was no longer a 
difference in adhesion coverage between Strattice and CollamendFM . 
At 180 days CollamendFM had the highest rate of adhesions coverage (median 100, IQR 
100-100; median Zuhlke 3) of the mesh due to the high amount of infected meshes. This 
was significantly more than all other meshes (P<0.029). Adhesions were found at median 
40% (IQR 11.2-63.7) of the size of the original implantation site of the Surgisis. Of the non-
infected meshes Strattice had the least adhesions (5%, 5.0-5.0) which was significantly less 
than Surgisis (P<0.001) and Permacol (P<0.001).
Shrinkage
Surface of the mesh could not be accurately measured in infected meshes therefore these 
were excluded from the analysis. Shrinkage of the mesh was highest in Surgisis at 90 
days were a residue of median 43% of the original size was found (shrinkage 57%, IQR 
37.0-69.5). Data per mesh is shown in Figure 4. This shrinkage of Surgisis was significantly 
higher than Strattice (33.0%, 22.5-36.5; P=0.02), Permacol (3.0%, 0.0-7.0; P=0.003) and 
CollamendFM (0.0%, 0.0-2.2; P=0.016).
Figure 1. Comparison of combined percentage (90 and 180 days) of mesh infection. Values are 
percentage of macroscopically infected meshes of surviving animals. 
* Non-crosslinked meshes § Crosslinked meshes.
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Figure 2. Percentage of the mesh edge incorporated into the abdominal wall, only non-
infected meshes included. Values are median (interquartile range). At 180 days: 
*no Surgisis mesh could be identified and P<0.001 compared to Strattice and Permacol 
(n=7). 
Figure 3. Comparison of percentage of each mesh covered with adhesions at the 90 and 
180 days follow-up assessment. Values are median (interquartile range). *n=7. At 90 days: ± 
P<0.023 compared to all other meshes; ° P<0.029 compared to all other meshes. 
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Correlation between adhesion formation and incorporation
At 90 days CollamendFM showed a significant correlation between adhesion coverage 
of the mesh and incorporation of the mesh edge (ρ=-0.973; P=0.01). At 180 days there 
was no correlation. When the animals in group 90 days and 180 days were combined 
CollamendFM showed a correlation coefficient of ρ=-0.612; P=0.05. This correlation 
coefficient indicates that in CollamendFM meshes increase of adhesion formation was 
correlated with a decrease of incorporation.
DISCUSSION 
Based on the results of our long-term animal study we advocate more reluctance on 
implantation of biological meshes for abdominal wall repair. When biological meshes 
are implanted in an intraperitoneal position, incorporation in the abdominal wall is 
poor and adhesion formation and infection susceptibility remain a problem. The best 
results in our study were found with implantation of non-crosslinked Strattice. Adhesion 
coverage was low as 5%, but incorporation after 180 days was only 13.7%. Crosslinked 
Permacol had the better long-term incorporation (20.7%) but adhesion coverage of 
15%. Worst results were found with crosslinked CollaMend and non-crosslinked Surgisis. 
Figure 4. Percentage of shrinkage of the mesh surface, only non-infected meshes included. Values 
are median (interquartile range). At 90 days: *P<0.016 compared to all other meshes. At 180 days 
there was no difference between the mesh groups.
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After implantation of CollaMend infection of the mesh occurred in over 60% leading 
to a very low incorporation and increased adhesion formation. Non-crosslinked Surgisis 
dissolved completely within 180 days but induced substantial adhesion formation. These 
characteristics of biological meshes at long-term follow-up make the strength of the 
abdominal wall repair questionable. Moreover the adverse effects are comparable to 
intraperitoneally used (coated) synthetic meshes. 
It is a recurrent phenomenon in research where initial studies on new technology 
describe positive results (whether or not industry driven) and subsequently critical reviews 
are published only after years of trial and error. The first studies on biological meshes 
were mainly case series with large variation in sample size, mesh material, implantation 
technique, follow-up and study endpoints7,15. Although the majority of cases were 
implanted in a non-contaminated environment they have also led to recommendations 
for the use in contaminated surgical fields. In recent years authors have started to publish 
their doubts on biological meshes15,16.
The aim of biological mesh implantation is to create a functional abdominal wall by 
deposition of native collagen during mesh degradation (‘remodelling’). In our current study 
incorporation of the mesh was highest in Permacol however with only 20.7% incorporation 
(20.7%, 5.7-24.5), followed by Strattice (13.7%, 10.3-22.4). The steps in this dynamic 
process include inflammatory response, cellular penetration and neovascularisation of the 
mesh, fibroblast infiltration and collagen deposition17. It appears that all meshes induce 
varying levels of foreign body reaction and fibrosis. Multiple characteristics of the mesh 
influence this response: mesh material, weight, pore size, crosslinking and sterilisation 
technique. More data is becoming available on histopathologic responses to specific 
synthetic and biological meshes in animal models16,18,19. Novitsky et al observed that 
crosslinked meshes caused extensive foreign body reaction with fibrous encapsulation 
and no evidence of integration or remodelling of the mesh16. Dissimilarities have been 
found between crosslinked and non-crosslinked meshes suggesting that improved 
integration into host tissue in non-crosslinked matrix is due to a moderate mononucleair 
cell reaction20. Possible cause of this foreign body reaction is due to presence of nucleair 
material in the mesh or exposure of antigentic epitopes following implantation21-25. It 
is suggested that some crosslinking processes damage the extracellular matrix and 
negatively influence the host response leading to encapsulation, decreased fibroblast 
penetration in the matrix and little collagen synthesis20,23,26-28. Similar results have been 
found in patients who underwent removal of porcine biologic mesh where no to little 
evidence of neovascularisation or neocellularisation was detected in crosslinked meshes17. 
Non-crosslinked Strattice mesh showed highest degree of new collagen deposition and 
organization in the study by Novitsky et al. which is comparable to the results in our 
current study28. 
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 Clinical studies like the multicentre RICH study showed similar results with a recurrence 
hernia rate of 19% after 1 year and 28% after 2 years11. Likewise, Rosen et al recorded a 
recurrence rate of 31.3% with a follow-up of 21.7 months after implantation of biological 
mesh29. These results can hardly be called sustainable hernia repairs and are not that 
dissimilar to synthetic meshes6,30. Increasingly synthetic meshes are being implanted 
in clean-contaminated and contaminated surgical field with quite favorable results31-34. 
Recent studies in grade II contaminated wounds showed lower recurrence rate after 
implantation of synthetic meshes compared to biological meshes with similar adverse 
event35.
Possible factors affecting the collagenesis and consequential recurrence rate of hernias 
are high rates of postoperative infectious adverse-events. Ambivalent results have been 
published previously: Basta et al reported a 51.4% incidence of wound complications 
leading to recurrence hernia rate of 18.9% with postoperative wound infection being 
the only predictor of recurrence with an odds ratio of 22.136. Increased infection rate 
of biological meshes could be due to bacterial niches in biomesh pores and bacterial 
formation of biofilms37. 
Perhaps the advantage of biological meshes over synthetic material is the possibility of 
performing aggressive salvage procedures with removing parts of an infected mesh in 
situ to avert removal of all material with subsequently recurrence of hernia. 
An important factor when choosing a mesh are the associated costs. Biological meshes 
are substantially more expensive than synthetic meshes4,6. However costs can be reduced 
when delayed primary closure with implantation of a biological mesh is possible during 
one hospital admission. In this way the number of admissions and in-hospital days can 
be reduced compared to staged repair38. Additional benefit is earlier restoration of 
abdominal wall function which may lead to accelerated return to work. 
A limitation of our study might be the implantation of the mesh in an intraperitoneal 
position. After intraperitoneal placement of the mesh there is no close vascular supply to 
facilitate neovascularisation and fibroblasts have difficulty reaching the mesh39. However 
in previous animal studies intraperitoneal or extraperitoneal implantation of the mesh did 
not affect host tissue incorporation or mesh degradation19. Contact of the mesh with the 
intraperitoneal compartment can often not be avoided due to the large dimensions of the 
hernia defect11,36. In the retrospective analysis of the RICH study there was no difference 
in hernia recurrence rate when the retro-rectus plane was compared to intraperitoneal 
placement. In 2 trials sublay procedures are found to result in less wound complications 
and seromas compared to onlay procedures40,41. It is suggested that further randomized 
trials on the optimal placement is needed to guide decision-making17,38. 
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Another limitation is that this research was performed in animals without any predisposing 
collagen disease or hernia defect. 
CONCLUSIONS
We advocate more caution with implantation of biological meshes for abdominal wall 
repair. There seems to be no evidence for previously purported hypothesis that biological 
material enables ingrowth of cells and vessels resulting in a sustainable hernia repair. 
Implantation of biological mesh does not seem to reduce infection rate which is a 
significant factor for the recurrence of incisional hernia. Biological meshes might not have 
the required characteristics for implantation in clean environment with high infection rate 
and low incorporation of the mesh in the current experiment. 
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ABSTRACT
Background
Adhesion formation after surgery for peritonitis-related conditions, with such associated 
complications as intestinal obstruction, pain, and infertility, remains an important problem. 
Applying a liquid barrier intra-peritoneally might reduce initial adhesion formation.
Methods
A combination of the cecal ligation and puncture model of peritonitis with the side-wall 
defect (SWD) model of adhesion formation was performed. Forty rats were assigned 
randomly to receive no barrier or 1mL or 2mL of the cross-linked polyvinyl alcohol 
and carboxymethylcellulose (PVA/CMC) hydrogel A-Part Gel (B. Braun Aesculap AG, 
Tuttlingen, Germany). After 14 days, the animals were sacrificed, and adhesion formation 
and abscess formation were scored.
Results
Thirty animals survived, distributed equally among the groups. There were significantly 
fewer adhesions to the SWD in the PVA/CMC groups (median 0) than in the control group 
(median 26%–50%) (P<0.05). The median tenacity of the adhesions was significantly 
higher in the control group (Zühlke score 2) than in the PVA/CMC groups (Zühlke score 
0) (P<0.05). The amount and size of intra-abdominal abscesses were not significantly 
different in the three groups.
Conclusion
In this experiment, PVA/CMC hydrogel reduced the amount of adhesions to the SWD and 
between viscera significantly with equal risk of abscess formation.
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INTRODUCTION
The formation of intra-abdominal adhesions remains a common serious problem in surgical 
practice. Formation of adhesions is observed after both open and laparoscopic surgery, 
with a reported incidence as high as 97%1,2. Complications of intra-abdominal adhesions 
include intestinal obstruction, chronic pain, infertility, and troublesome reinterventions. Of 
all patients undergoing open abdominal surgery, 35% will be readmitted for complications 
related to adhesions3. The cumulative risk of adhesive small-bowel obstruction after 
colectomy is 11%–25% after one year and 30% after 10 years4,5. During reintervention, 
some extent of adhesiolysis is unavoidable, leading to inadvertent enterotomy in 19% of 
patients owing to the severity of the adhesions or to iatrogenic bowel injury6.
Adhesion formation is initiated by the inflammatory response following visceral damage 
as a result of intra-abdominal surgery and infection7. The underlying mechanism is local 
tissue ischemia and mesothelial injury. The mesothelial and submesothelial cells express 
proteases and protease inhibitors, disrupting the balance between coagulation and 
fibrinolysis and creating fibrous bands that form adhesions7,8. Furthermore, inflammation 
intensifies this reaction by attracting and activating fibroblasts and disrupting 
fibrinolysis9,10. Adhesion formation is controlled by macrophages and T lymphocytes and 
takes place mainly during the first two weeks of healing, before the defect has been 
covered with mesothelium11-13. Adhesion formation can be prevented by a physical barrier 
that separates the injured tissue from adjacent organs and the peritoneum during the 
crucial healing period2,14-16.
Abdominal surgery for intra-abdominal infection with peritonitis is associated with high 
morbidity and mortality rates and complicated frequently by abscess formation. In 
peritonitis, severe inflammation of the peritoneum occurs, increasing adhesion formation. 
Prevention of adhesion formation after peritonitis seems the ultimate challenge for 
proving the effectiveness of an anti-adhesion barrier. It also is crucial that the barrier does 
not promote infection or abscess formation17,18.
Cross-linked biocompatible polyvinyl alcohol (PVA) hydrogels reduce adhesion formation 
after non-infectious abdominal surgery16,19-21. The aim of our experiment was to investigate 
the effects of PVA hydrogel on adhesion and abscess formation in an experimental 
bacterial peritonitis and adhesion model in rodents.
MATeRIALS AND MeThODS
To study the effects of PVA hydrogel on adhesion and abscess formation, a combination 
of the cecal ligation and puncture (CLP) peritonitis model and the cecal abrasion 
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sidewall defect (SWD) adhesion model was used. We believe that our combination 
model resembles adhesion formation in a clinical situation after abdominal surgery in 
the presence of peritonitis. The protocol of the experiment was approved by the Animal 
Experiments Committee of the Erasmus University, Rotterdam.
Study design
In 40 male Wistar rats, the CLP model was created by ligation and puncture of the cecum. 
The following day, the necrotic cecum was resected and the SWD model created. The 
hydrogel studied in this experiment was A-Part Gel (B. Braun Aesculap AG, Tuttlingen, 
Germany), which is a crosslinked PVA and carboxymethylcellulose (CMC) formulation. 
After completion of the SWD model, the rats were assigned randomly to one of three 
experimental groups: A (control), B (1mL of A-Part Gel), or C (2mL of A-Part Gel). The 
viscous PVA/CMC gel was administered with a special nozzle to the sites of peritoneal 
damage; that is, the SWD and around the cecal stump. The abdominal wall and skin were 
closed separately with continuous, absorbable suture. After 14 days, the animals were 
sacrificed humanely and scored on adhesion and abscess formation.
Animals
Inbred male rats of the Wistar strain weighing 294–355 g were obtained from a licensed 
breeder (Harlan, The Netherlands) and accustomed to laboratory conditions two weeks 
before the start of the experiment. They were bred under specified pathogen-free 
conditions, kept under standard laboratory conditions in individually ventilated cages 
(temperature 20–24°C; relative humidity 50%–60%; 12 h light/dark cycles), and fed 
standard rat chow and water ad libitum during the entire experimental period.
Procedure
Day 0: CLP model. The surgery was performed under aseptic conditions. At the start of 
the experiment, the animals were anesthetized using isoflurane/O2 by inhalation, and 
buprenorphine analgesia (0.05mg/kg) was administered subcutaneously. The abdomen 
was shaved and cleaned with isopropyl alcohol 70%, after which a 3-cm midline incision 
was made. The cecum was manipulated carefully to the outside of the abdominal cavity 
and ligated just distal to the ileocecal valve with a monofilament non-absorbable suture 
(4-0 Ethilon, Ethicon, Inc., Somerville, NJ), maintaining the continuity of the bowel. 
Distally, the cecum was punctured once with an 18-gauge needle. Some fecal material 
was expressed through the puncture hole and cultured. The cecum was replaced intra-
peritoneally, and the abdominal wall and skin were closed separately with running 
polyglycolic acid sutures (5-0 Safil, B. Braun Melsungen AG, Melsungen, Germany). For 
resuscitation, 5mL isotonic sodium chloride solution was administered, and animals were 
placed under a heating lamp during the immediate post-operative period.
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Day 1: CLP and SWD model. The animals were anesthetized using isoflurane/O2 
inhalation, and buprenorphine analgesia (0.05 mg/kg) was administered subcutaneously. 
The abdomen was re-opened through the midline incision, and a culture swab of the 
abdominal cavity was obtained to confirm fecal peritonitis. The necrotic cecum was 
resected and the abdominal cavity rinsed with at least 20mL of phosphate buffered saline 
warmed to 37°C. The remaining cecum was abraded lightly with dry sterile gauze until 
punctate bleeding was observed. From the left anterior abdominal wall, a tissue strip 
of 0.5 x 2.0 cm, including peritoneum and muscle, was excised. Before closure of the 
abdomen, animals were assigned randomly to one of the three experimental groups. 
All animals received gentamicin (6mg/kg intramuscular), buprenorphine (0.05mg/kg 
subcutaneously), and isotonic sodium chloride solution (5mL subcutaneously).
Day 1: Application of PVA/CMC hydrogel. Animals in Group A served as the control group 
and received no additional treatment. Group B received 1mL of PVA/CMC hydrogel, 
and Group C received 2mL of hydrogel. The hydrogel was applied to the SWD and the 
abraded cecum. Finally, the abdominal wall and skin were closed separately with running 
polyglycolic acid sutures (5-0 Safil).
Day 14: Sacrifice. The animals were anesthetized using isoflurane/O2 by inhalation and 
shaved. After disinfection, the ventral abdominal wall was opened through a U-shaped 
incision, and a swab of the abdominal cavity was taken. The amount and tenacity of 
the adhesions was scored, and pictures were taken (5.0-megapixel digital camera; Sony 
Cybershot , Tokyo, Japan). The abdominal cavity was inspected for abscesses, which were 
scored and cultured when found. The animal was then euthanized by cardiac cut.
Measurements
Wellness and survival. During the experiment, animals were weighed daily and scored for 
their wellness using an objective 12-point scoring system22. Animals with a weight loss of 
20% or more or a wellness score of < 5 were euthanized. A necropsy was performed on 
all euthanized and deceased animals.
Adhesions. Two independent observers assessed adhesion coverage of the surface of the 
abdominal wall defect in a blinded manner using a scoring system, dividing the defect 
into four squares of 0.5 · 0.5 cm (0%, 1%–25%, 26%–50%, 51%–75%, or 76%–100%) and 
categorized the tenacity of the adhesions using the objective Zühlke score, which is based 
on histologic and morphologic criteria (Table 1)23. In case of inter-observer disagreement, 
the mean Zühlke score was calculated. The amount of adhesions (between viscera or 
between viscera and the abdominal wall, including the midline scar) was scored and the 
severity of the adhesions was graded by the Zühlke score. 
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Abscesses. Two independent observers assessed the amount and size of abscesses at four 
sites in the peritoneum: liver, abdominal wall, bowel, and omentum using an objective 
size scoring system (Table 2)24.
Cultures. The fecal sample, intra-abdominal swab, and abscess cultures were evaluated 
for the strains and amount of bacteria present.
Statistical analysis
Adhesion formation and tenacity, abscess formation, survival, animal weight, and wellness 
score were compared using non-parametric tests (Kruskal–Wallis, Mann–WhitneyU) 
because the data did not show a normal distribution. Therefore, all results are presented 
Table 1. Zühlke Scoring System for adhesions. 
zühlke Score Definition
0 No adhesions
1 Minimal, filmy adhesions requiring little blunt dissection
2 Moderate adhesions requiring blunt and partly sharp dissection; beginning of 
vascularisation
3 Strong adhesions; lysis possible by sharp dissection only; clear vascularisation
4 Very strong adhesions; sharp dissection only; organs attached (damage of 
organs difficult to prevent)
Translated and reprinted from: Zühlke HV, Lorenz EM, Straub EM, Savvas V: [Pathofysiology and 
classification of adhesions] (GER). Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir 1990:1009-
1016.
Table 2. Abscess Scoring System.
 Score Definition
0 No abscess present at the site
0.5 One small abscess present at the site
1 Several small abscesses present at the site
2 Medium abscess present at the site
3 Large or several medium abscesses present at the site
4 One very large or several large abscesses present at the site
Translated and reprinted from: Rodgers KE, Schwartz HE, Roda N et al. Effect of oxiplex® films 
(PEO/CMC) on adhesion formation and reformation in rabbit models and on peritoneal infection in 
a rat model. Fertil Steril 2000;73(4):831-838.
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using the median and the interquartile range. All reported p values are two-sided and 
considered significant if P<0.05. Statistical analysis was performed using the PSAW 
statistical software package (IBM SPSS Statistics, Chicago, IL).
ReSULTS
No animals needed to be euthanized because of a weight loss of 20% or more or a wellness 
score < 5. A total of 30 animals survived; 10/14 (72%) in both experimental groups (B and 
C) and 10/12 (83%) in the control group (A)(P=0.81). No differences in weight change or 
wellness score were observed among the three groups. Ten animals died within 24 h after 
the second operation. All were found to have died of sepsis secondary to fecal peritonitis. 
Adhesions
Adhesions to the surface of the SWD were significantly different among the groups 
(P=0.009) (Table 3). There were significantly more adhesions (median 26%–50%) to 
the SWD in the control group than in the PVA/CMC groups (median 0)(P=0.02), but no 
difference in adhesions between the two PVA/CMC groups (P=1.00). The tenacity of the 
adhesions also was significantly different among the groups (P=0.004) (Table 4). There was 
a significant difference in adhesion tenacity between the PVA/CMC groups (both having 
a median Zühlke score of 0) and the control group (median Zühlke score 2)(P=0.01 and 
P=0.02), but no difference between the PVA/CMC groups (P=0.74). Visceral adhesions 
between intestinal loops or between intestinal loops and the abdominal wall (including 
the midline scar) appeared in 70% of the control group, 50% of the PVA/CMC 1-mL 
group, and 40% of the PVA/CMC 2-mL group (P=0.31). The tenacity was the greatest in 
the control group (median Zühlke score 3.5) compared with the PVA/CMC 1mL (median 
Zühlke score 0.5) and PVA/CMC 2mL (median Zühlke score 0), but this difference was not 
statistically significant. In all surviving animals, adhesions to the cecal stump occurred with 
comparable tenacity in all groups (median Zühlke score 3–3.5)(P=0.32).
Abscesses
The amount and size of intra-abdominal abscesses were not significantly different among 
the three groups (P=0.48 and P=0.10). In the control group, four abscesses were found 
in three animals, with an abscess score ranging from 1 to 4. In the PVA/CMC 1-mL group, 
seven abscesses were found in six animals, with a score between 0.5 and 2. In the PVA/
CMC 2-mL group, five abscesses were found in five animals, with a score of 0.5 and 1.
Cultures
The feces of the rats contained no bacteria other than what was expected in view of 
their specified pathogen-free status. The culture taken on Day1 proved fecal peritonitis 
in all 40 rats. During sacrifice, no bacteria were found intra-abdominally. All abscesses 
contained one or more fecal bacteria.
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DISCUSSION
The formation of adhesions begins with injury to two opposing layers of the peritoneum, 
with exudate contributing to the deposit of fibrin. The PVA/CMC hydrogel separates the 
damaged peritoneal surfaces during the crucial remesothelialisation phase in the first 
two postoperative weeks and reduces initial adhesion formation11-13. This hydrogel is 
completely biodegradable, and no residues are found after two weeks25.
A serious concern about barriers is their influence on infection. It was especially 
interesting that in our experiment, the risk of abscess formation was equal in all groups, 
with or without PVA/CMC gel. We believe that our experimental model combining 
peritonitis and adhesions resembles adhesion formation after clinical abdominal surgery 
in the presence of peritonitis. The CLP model produces generalized peritonitis with an 
immunologic response secondary to the spill of the animal’s own stool into the peritoneal 
cavity through the devascularized and punctured cecum. This model closely mimics the 
clinical situation of peritonitis induced by bowel perforation, and subsequent surgical 
source control followed by post-operative adhesion and abscess formation26. In peritonitis 
models, abscess formation increases until two weeks postoperatively and then decreases 
in the following weeks27,28. The CLP model combines an acceptable mortality rate of 15%–
30% with a high incidence of abscess formation29-31. The SWD model promotes adhesion 
formation and mimics peritoneal trauma caused by laparotomy. It is a dependable, 
Table 4. Zühlke score of adhesions on side wall defect by treatment group.
zühlke Score Control A-Part 1 ml A-Part 2 ml
0 3 9 8
1 2 0 1
2 0 1 0
3 1 0 1
4 4 0 0
Table 3. Adhesion coverage of side wall defect by treatment group.
Adhesion coverage (%) Control A-Part 1 ml A-Part 2 ml
0 3 9 8
1-25 2 0 1
26-50 1 0 1
51-75 0 0 0
76-100 4 1 0
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predictable, and readily quantifiable model that allows objective measurement of the 
extent of adhesion coverage32,33.
Adhesions are formed predominantly during the first two weeks of healing, before 
the defect is covered by mesothelium11-13. The amount of adhesions does not increase 
after 14 days, and the situation at that time therefore is representative of the long-term 
effects. On the other hand, the tenacity of the adhesions is influenced by the chronic 
inflammatory response and therefore probably will change over time. The combination 
of the two models promotes a severe inflammatory response with subsequent adhesion 
formation. An inflammatory reaction occurs, causing an influx of inflammatory cells and 
activating mesothelial cells, leading to fibrinous exudate. The exudate becomes denser 
as a result of persisting fibroblasts, and adhesions are formed7.
In this experiment, the SWD and other visceral adhesions (except to the cecum) were 
significantly fewer in the groups in which the PVA/CMC hydrogel was used as a barrier. 
The PVA/CMC probably remained in place on the SWD because of the flat surface of 
the abdominal wall and the prostrate position of the rodents. There was no reduction 
of adhesion formation to the cecal stump. This might be the result of the PVA/CMC 
hydrogel not remaining at the site because of the roundness and gravity making the 
gel shift from the cecum, losing its barrier function. Also, the non-absorbable suture 
and possible microscopic fecal leakage from the cecal stump might have given rise to 
adhesion formation.
In this experiment, the PVA/CMC hydrogel was safe and efficient in reducing adhesion 
formation in a peritonitis model. Because both concentrations (1mL and 2 mL) of the 
hydrogel provided the same reduction of adhesion formation and no difference in abscess 
formation, we conclude that 1mL of A-Part is an adequate dosage to reduce adhesion 
formation in a Wistar rat weighing 300–350 mg. The promising efficacy demonstrated 
by the A-Part hydrogel in this experiment stimulated us to investigate this product 
further, focusing on its safety when applied around an intestinal anastomosis and in the 
presence of synthetic material such as intra-abdominally placed meshes33. The promising 
experimental results also led to initiation of a clinical trial of the safety and efficacy of the 
hydrogel34.
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DIVeRTICULITIS
The incidence of acute diverticulitis is rising which is accompanied with many challenges 
in its diagnosis and treatment. In this thesis we investigated several components of the 
treatment of patients with diverticular disease to improve patient care in an evidence 
based manner. 
A number of issues in the treatment of diverticular disease remain unresolved. Future 
research should focus on the etiopathogenesis, prevention and minimally invasive 
treatment of diverticulitis. 
Consensus on the etiopathogenesis of diverticulitis is shifting away from traditional 
dogmas of fecalith obstruction of a diverticulum. It is now hypothesised that in patients 
with diverticular disease the changes in colonic flora promote disease and inflammation. 
The intestine has been shown to harbour a complex bacterial community. This commensal 
gut flora (intestinal microbiota) protects against epithelial cell injury, regulates fat storage 
and influences the function of the gut immune system1-4. Disease specific variations in 
the composition of the colonic microbiota have been identified in inflammatory bowel 
disease and metabolic syndrome5-9. Characterization of the colonic microbiota in patients 
with diverticular disease might clarify its possible role in the pathogenesis of this disease 
and inflammatory episodes. Additionally, microbiome analysis might offer a new way of 
diagnosing diverticulitis. 
This hypothesis on etiopathogenesis also offers new opportunities to treat diverticulosis 
with mesalazine, probiotics or intraluminal antibiotics to prevent progression of disease 
to diverticulitis or recurrence of inflammatory episodes. However current evidence from 
previous research is not strong enough to recommend medical treatment to prevent 
relapse10-12. 
Identifying patients with diverticulitis correctly can be difficult because of the great variation 
in the intensity of symptoms at presentation. A clinical decision model might increase 
the accuracy of clinical diagnosis and could assist the clinician in omitting unnecessary 
additional imaging13-15. The three strongest clinical features are direct tenderness in the 
left lower quadrant, the absence of vomiting and a C-reactive protein >50mg/L. In a 
quarter of patients the diagnosis can be made clinically based on these three features13. 
Such a model can withhold one out of five patients from additional imaging to diagnose 
diverticular disease14. In patients without these features, imaging is required to reach 
adequate diagnostic accuracy. 
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Ultrasound and Computed Tomography (CT) scanning are daily practice in patients 
suspected for diverticulitis to assess alternative diagnosis or confirm the diagnosis and 
differentiate between complicated and non-complicated diverticular disease. 
Ultrasound has an important role in diagnosing diverticulitis due to its wide-spread 
availability, low cost and possibility to be repeated as often as needed. It is the first choice 
diagnostic in many patients, in particular patients with renal insufficiency, pregnancy 
and contrast allergy. The limitations of ultrasound include operator dependency, poor 
assessment in obese patients and reduced outcome with patients with abdominal 
tenderness because compression of the transducer probe is too painful. CT scanning 
has higher accuracy in detection of free air and deeply located or small fluid collections 
and can help differentiate diverticulitis from colon carcinoma. An important difference 
between these two imaging modalities is that ultrasound does not require ionizing 
radiation or the application of oral, rectal or intravenous contrast. Considering that patients 
with diverticulitis are prone to recurrence they may need multiple CT examinations with 
increased risk of radiation exposure.
Considering all of the arguments a step-up approach is advised starting with ultrasound 
and only performing CT scanning when the ultrasound is inconclusive, negative for 
diverticulitis or suspected for complicated disease. 
Currently the most used classification system for diverticular disease is the modified 
Hinchey classification, which is based on intra-operative findings. This classification is no 
longer suitable for clinical practice because only a minority of patients with diverticular 
disease will be treated operatively. 
A new classification system for diverticulitis should focus on different types of presentation 
and radiological findings. Perhaps diagnostic laparoscopy should be more liberally 
implemented in the diagnostic step-up approach to differentiate between purulent and 
faecal peritonitis. Such a new grading system can help to tailor treatment in patients with 
diverticular disease.
Parallel to the reduced invasive diagnostic evaluation of diverticular disease treatment 
has become less aggressive too. Decades ago peritonitis required explorative laparotomy 
regardless of cause and severity of the disease. With recent improvement of medical, 
radiological and surgical treatment the management can be more tailor made and many 
patients can be treated conservatively.
It is now recommended to omit antibiotics in CT proven diverticulitis with small abscess 
formation (<5cm)16,17. Furthermore patients are encouraged to continue oral intake 
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when tolerated and ambulatory treatment of these patients seems safe and effective. 
Avoidance of overtreatment has many benefits: cost reduction, diminished development 
of antimicrobial resistance and increased quality of life for the patient.
Another dogma has been challenged recently: pneumoperitoneum associated with 
acute diverticulitis is no longer an indication for emergency surgery in hemodynamically 
stable patients18-20. In carefully selected patients a non-operative treatment (including 
antibiotics, supportive care and radiological drainage of fluid collections) can be applied 
without increased complication rate. In these studies distant free air on CT-scan was 
not associated with poor outcome, and therefore is not per se an indication for surgery. 
However the evidence on non-surgical management of perforated diverticulitis is scarce 
and further research is required to demonstrate its safety. Perhaps a next trial should not 
focus on comparing operative techniques in purulent diverticulitis, but rather computed 
tomography, antibiotics, and watchful waiting compared with surgical intervention.
Of all patients with an episode of acute diverticulitis 25% present with complicated 
disease such as abscess formation, fistula, obstruction or perforated disease. In these 
patients Hartmann’s procedure and primary anastomosis with defunctioning stoma are 
historically the most accepted treatments. Both treatments can safely and effectively 
be performed laparoscopically21,22. Primary anastomosis seems to be preferred over 
Hartmann’s procedure because the last is associated with increased morbidity during 
the second stage (anastomotic leaks), longer hospital stay and longer follow-up with 
stoma23,24. However no definite conclusions on the preferred treatment can be drawn 
because previous randomised trials comparing these procedures are characterised by 
difficult accrual and preliminary termination of the trials23-25.
With increasing laparoscopic experience a new treatment method has been proposed for 
patients with perforated purulent diverticulitis: laparoscopic lavage and drainage. Four 
randomised trial were conducted to investigate the safety and efficacy of laparoscopic 
lavage26-29. Three trials have been published until now with similar results30-33.
The LOLA part of the Dutch LADIES trial was prematurely terminated after accrual of 
90 patients due to increased re-intervention rate in patients treated with laparoscopic 
lavage30. The high re-intervention rate could be because radiological drainage of intra-
abdominal abscesses was defined as re-intervention in this trial but not in the other trials. 
Persistent sepsis in the lavage group demanding surgical intervention was present in nine 
patients and was caused by faecal peritonitis and overt perforation in six patients. This 
demonstrates that laparoscopic lavage can only safely be performed in patients with true 
purulent peritonitis in the absence of visible perforation. After 12 months there was no 
difference in mortality (lavage 9% versus sigmoidectomy 14%) and morbidity. The number 
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of patients that were alive and stoma free was higher in those treated by laparoscopic 
lavage (78% ) compared to those in the sigmoidectomy group (71%). The majority of 
patients in the lavage group never had a stoma. Stoma reversal was not without risks and 
morbidity occurred in four out of 24 patients. 
The study was marked by a slow inclusion and a high number of patients not enrolled in 
the study although they met the inclusion criteria. 
Similar results were found in the SCANDIV trial comparing lavage with primary resection 
in 172 patients with Hinchey I to IV diverticulitis31. Patients with peroperative diagnosis 
of Hinchey IV were treated with sigmoidectomy. After 90 days there was no difference 
between the treatment groups in severe morbidity rate (31% lavage versus 22% 
sigmoidectomy) and mortality rates (13% versus 8%). Re-intervention was performed in 
more patients following laparoscopic lavage than after primary resection (20% versus 6%). 
Furthermore abscess formation and secondary peritonitis occurred more frequently in the 
laparoscopic lavage group.
There are a number of pitfalls in the trial design of the SCANDIV trial. One pitfall is the 
fact that the technique of primary resection, Hartmann’s procedure or primary resection 
and anastomosis, was determined by the surgeons preference. Furthermore results of the 
two surgical techniques were not reported separately therefore no conclusions can be 
made with regard to the preferred technique. Additionally due to randomization prior to 
diagnostic lavage in this trial a variety of possible biases can be identified. Firstly, due to 
the high number of alternative diagnosis made during surgical treatment a large amount 
of patients were excluded. The authors resolved this by increasing sample size during 
the trial with accompanying possible bias. Secondly, patients with Hinchey grade I and II 
were included in the trial although laparoscopic lavage has not been designed for these 
patients. Data on treatment of Hinchey III diverticulitis was taken together with Hinchey I 
and II and therefore cannot be discriminated. Finally the patients not included in the trial 
were found to have a higher ASA score and therefore results might not be applicable to 
very ill patients with acute complicated diverticulitis. 
The Scandinavian DILALA trial included 83 patients and randomised between laparoscopic 
lavage and Hartmann’s procedure32,33. Results showed no difference in mortality which 
was 8% in the group treated with laparoscopic lavage and 11% in the patients in the 
Hartmann’s procedure group after 90 days. After 3 months morbidity and re-operation 
rates were comparable. After a follow-up of 12 months laparoscopic lavage resulted in 
less reoperations, reduced length of hospital stay (median six versus nine days) and lower 
incidence of a stoma (7% versus 28%).
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However on the eligible but not included patients (52 patients) baseline characteristics 
are missing therefore selection bias and homogeneity of the groups cannot be assessed. 
Comparison of the outcome of the different studies is therefore difficult.
Results of the LAPLAND trial are still awaited. This trial will also randomise patients before 
diagnostic laparoscopy which might result in the inclusion of patients with other diagnosis.
Despite the three finished trial studying laparoscopic lavage as treatment of perforated 
diverticulitis the available evidence is still not very robust. However this alternative 
operative strategy seems to control abdominal sepsis with decreased stoma rates and 
mortality rates comparable to sigmoidectomy. 
Important drawback of laparoscopic lavage is the risk that possible undiagnosed colorectal 
cancer remains in situ. In the three published trials incidence of carcinoma varied between 
five and eight percent. Delayed diagnosis of colon carcinoma could lead to increased risk 
of metastasis and decreased survival. 
Long term results and pooling of original data of the trials will help us to determine 
if laparoscopic lavage is a safe and effective treatment for perforated diverticulitis. In 
addition the dilemma might be solved whether it can be used as a definitive treatment or 
should be considered a bridge to elective resection of the diseased bowel.
For years it was recommended to perform elective sigmoid resection after two episodes 
of acute diverticulitis and even after one episode in younger patients. However recurrent 
diverticulitis rarely progresses to complicated disease and the risk of free perforation 
decreases with the number of diverticulitis episodes. In papers on laparoscopic lavage 
only two percent of patients who did not undergo elective colectomy had recurrence of 
diverticulitis18,34. Elective colonic resection after two episodes of diverticulitis is therefore 
no longer the standard35. However elective colectomy might be justified in patients 
with persisting abdominal complaints following an episode of diverticulitis or high-risk 
patients for perforated disease, such as patients who use immunosuppression therapy, 
with chronic renal failure or collagen-vascular diseases. 
TReATMeNT OF COMPLICATIONS FOLLOWING INTRA-
ABDOMINAL INFeCTION
Incisional hernia is one of the most frequent postoperative complications following 
abdominal surgery36-38. The incidence is influenced by incision site, closure technique 
of the abdominal wall, and patient characteristics, such as obesity and collagen disease. 
Symptoms of incisional hernia vary from low body image, pain, strangulation and 
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incarceration of intra-abdominal organs to mortality39-41. Incisional hernia repair is one 
of the most performed surgeries for postoperative complications, with associated high 
costs. 
In this thesis we investigated various meshes in a rat model to find the most appropriate 
mesh to implant intraperitoneally in non-contaminated and contaminated environment. 
Many studies on mesh augmentation of the abdominal wall are annually published. Models 
to investigate hernia repair are mostly performed in animals of the same age and sex, and 
specified pathogen-free bacterial status. This minimizes biological and microbiological 
variability, making it suitable for comparing characteristics of different meshes in a similar 
contaminated environment42. To mimic contamination of the peritoneal cavity in humans 
and study the behaviour of meshes experimentally the caecal ligation puncture (CLP) 
model can be used. In this model, as in clinical infections, peritonitis arises from a complex 
interaction of the immune system with inflammatory, haemodynamic and biochemical 
alterations similar to human sepsis, with a consistent increase in cytokine levels42-45.
If a mesh is used in a contaminated environment, consensus exists that a biological 
collagen mesh or a synthetic macroporous, monofilament mesh may be advantageous46. 
The results of the animal experiments in Chapters 8, 9 and 10 of this thesis question 
this consensus47,48. In these experiments incorporation of biological meshes was poor 
after 180 days. Premature weakening of the biomechanical properties of the scaffold 
combined with insufficient incorporation can possibly result in loss of the prosthesis and 
hernia recurrence49. However, implantation of biological prostheses could be a valid 
choice as a temporary measure in staged repair of the abdominal wall.
An advantage of biological meshes over synthetic material might be the possibility 
of performing aggressive salvage procedures with removing only parts of an infected 
mesh. As a result removal of all material will subsequently cause recurrence of hernia. 
Until evidence is provided that biological meshes retain biomechanical strength with 
acceptable infectious complications synthetic meshes remain the preferred mesh material 
for (non-contaminated) primary hernia repair.
High costs of a biological mesh might be justified when it prevents mesh infection 
which is associated with high expenses for intensive care treatment, reoperation, and 
prolonged hospital stay. However in our experiments with crosslinked biological meshes 
infectious complications were unacceptably high in contaminated and non-contaminated 
environment. 
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Strict contraindication of synthetic mesh implantation in contaminated environment 
becomes questionable. In accordance with our results in Chapter 8 some synthetic meshes 
have quite favorable results after implantation in clean-contaminated and contaminated 
surgical fields47,50-53. A recent study in grade II contaminated wounds showed a lower 
hernia recurrence rate after implantation of synthetic meshes compared to biological 
meshes54. Although there are no meshes without disadvantages certain permanent 
synthetic meshes might be somewhat more infection-resistant and therefore useful for 
permanent hernia repair in a contaminated environment.
It is a recurrent phenomenon in research that initial reports (whether or not industry 
driven) on new technologies describe positive results and subsequently critical reviews are 
published only after years of trial and error. The perfect mesh is still to be developed. We 
propose independent laboratories, directed by scientific societies such as the European 
Hernia Society, in which new mesh-material is tested in standard conditions with respect 
to flexibility, pore size, adhesion formation, incorporation and infectious complications. 
Only after obtaining a quality mark by one of these independent laboratories producers 
should be permitted to implant the new product in patients. 
Additionally all patients with an abdominal wall repair should be registered in a prospective 
database, such as EuraHS and HerniaMed. In these registries data is collected on patient 
characteristics, comorbidities, surgical techniques, mesh characteristics, short- and long-
term postoperative complications, recurrence rates and patients quality of life. This data 
might help surgeons to choose the right mesh material and surgical techniques to perform 
sustainable hernia repair with little complications. Another advantage of prospective 
databases is that surgeons can learn from colleagues who report low recurrence rates and 
little complications. By comparing surgical techniques and postoperative care excellence 
can be striven for. 
Additionally, quality of care and cost reduction of complex abdominal wall hernia repair 
can be increased by centralization of care to experienced centres with high volume care. 
Intraperitoneal adhesion formation is another common postoperative complication 
following abdominal surgery. These adhesions cause a continuing risk for bowel 
obstruction, chronic pain, infertility and inadvertent bowel injuries at future operations. 
Awareness of adhesion formation is low and the related morbidity underestimated by 
general surgeons and gynaecologists55,56. To increase awareness and change clinical 
practice, the work of the Dutch Adhesion Group will have to be continued. 
Surgical treatment of adhesions induce formation of new adhesions, so prevention is 
the key to this clinical problem57,58. Prevention can be accomplished by systemic acting 
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pharmacological agents or intraperitoneally applied barriers. Ideally these agents should 
influence the balance between fibrinogenesis and fibrinolysis without increasing serious 
adverse events such as gastro-intestinal anastomotic leakage. 
Systemically administered agents have been tried extensively but were abandoned due 
to disappointing results in clinical trials59. Promising results have been found in preclinical 
studies with the use of Cromolyn (publication number EP2638904A1, application number 
EP20120159348). This drug has been used for decades in the prevention of asthmatic 
attacks. The suppression of the immune system is thought to limit intraperitoneal adhesion 
formation. A clinical trial is essential to confirm the preclinical results and monitor for 
possible complications. 
Intraperitoneally applied barriers have demonstrated that their use reduce adhesion 
formation59,60. However, clinicians are still reluctant to use these agents because they 
fear serious adverse effects and question cost-effectiveness. The results of the study 
presented in Chapter 11 on cross-linked polyvinyl alcohol and carboxymethylcellulose 
are promising on the prevention of adhesions in contaminated environment61. However 
more research should be performed to investigate potential infectious complications and 
negative effects on anastomotic healing. 
CONCLUSIONS
New approaches of the surgical treatment of intra-abdominal infection have been 
addressed in this thesis. New evidence has been delivered with respect to the treatment 
of diverticulitis, complications following mesh repair of the abdominal wall and prevention 
of adhesion formation. To improve knowledge on treatment of intra-abdominal infection 
and its complications we strongly need collaboration of experimental laboratories, 
standardization of techniques and prospective databases.
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Chapter 13
This thesis focussed on intra-abdominal infection, its treatment and complications 
following treatment of intra-abdominal infections.
In Chapter 2 the accuracy of preoperative staging of perforated diverticulitis with 
computed tomography (CT) scanning was assessed in a retrospective study. The CT 
findings were compared with the clinical findings during surgery and classified according 
to the Hinchey classification. This study showed that the positive predictive value of 
preoperative CT scanning for different stages of diverticulitis ranged from 45 to 89%. 
Accuracy was between 71 and 92%. There was a clear understaging of disease in patients 
with Hinchey 3 diverticulitis, 42% of patients were falsely classified as Hinchey 1 or 2. The 
presence of a large amount of free intra-abdominal air and fluid was strongly associated 
with Hinchey 3 and 4. 
Therefore, we concluded that current CT scanning does not seem to suffice to accurately 
predict the severity of perforated diverticulitis according to Hinchey’s classification. A new 
scoring system is needed to guide treatment in patients with diverticulitis. 
In Chapter 3 an overview of treatment options for perforated diverticulitis was given. 
Historically the most performed surgical treatment is sigmoidectomy with subsequent 
colostomy, also referred to as Hartmann’s procedure. However, this treatment strategy 
leads to high rates of permanent colostomies. Improvements in intensive care medicine 
and surgical technique has led to an increased number of patients treated with primary 
anastomosis instead of colostomy. Due to fear of anastomotic leakage this treatment is 
reserved mostly for young and healthy patients without faecal peritonitis. In this group 
of patients with purulent peritonitis, laparoscopic lavage of the abdomen with drainage 
could be an alternative treatment strategy.
In Chapter 4 a retrospective study on the early experience with laparoscopic lavage in 
patients with purulent peritonitis was presented. Laparoscopic treatment was successfully 
performed in the majority of patients, conversion to laparotomy was performed in 3%. 
Laparoscopic lavage was associated with 32% morbidity, and a fast recovery if sepsis 
was successfully controlled which occurred in 81.5% of patients. Patients in whom lavage 
was unsuccessful tended to have more co-morbidities, a higher preoperative C-reactive 
protein concentration and a higher Mannheim Peritonitis Index. After successful 
laparoscopic lavage treatment 10% of patients required subsequent sigmoid resection 
for recurrent diverticulitis during follow-up. Treatment strategy for perforated diverticulitis 
with laparoscopic lavage was feasible in the majority of patients, but identification of an 
overt sigmoid perforation and patient selection are of critical importance for successful 
treatment. 
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In Chapter 5 the protocol of a large randomized multicenter trial on the treatment 
of perforated diverticulitis was presented, the LADIES trial. This trial investigated the 
morbidity and mortality in patients with purulent and faecal generalised peritonitis 
following the three operative strategies; laparoscopic lavage and drainage, sigmoidectomy 
with primary anastomosis and Hartmann’s procedure. 
It was a five armed trial: patients with purulent peritonitis were randomised 2:1:1 
to laparoscopic lavage, Hartmann’s procedure or sigmoid resection with primary 
anastomosis. The aim of the LOLA trial was to show that laparoscopic lavage would lead 
to a 15% reduction in major morbidity and mortality compared to sigmoid resection. 
Patients with faecal peritonitis were to be randomised 1:1 into Hartmann’s procedure 
or sigmoid resection with primary anastomosis. All patients who underwent sigmoid 
resection (both purulent and faecal peritonitis) were to be analysed in the DIVA trial. This 
analysis aimed to prove that Hartmann’s procedure and sigmoid resection with primary 
anastomosis would lead to an equal 12 months mortality rate, yet sigmoid resection with 
primary anastomosis would lead to a 30% higher stoma-free survival.
In Chapter 6 we discussed the results of the LOLA arm of the LADIES trial. The main 
conclusion was that laparoscopic peritoneal lavage for purulent perforated diverticulitis 
does not reduce major morbidity and mortality compared to sigmoidectomy at 12 months 
follow-up. An increased acute reintervention rate was found in patients after laparoscopic 
lavage (39%) compared to sigmoidectomy (19%). However 76% of patients did not 
need further surgery during primary hospital stay. There was no difference between the 
treatment groups in stoma free rates in surviving patients after 12 months (78% lavage 
group, 71% sigmoidectomy groups), but in the lavage group 74% never had a stoma.
In Chapter 7 an overview of the available evidence combined with expert opinion was 
presented in a guideline for diagnosis and treatment of diverticulitis. The guideline was 
written under the auspices of the Netherlands Society of Surgery. The working group 
consisted of four surgeons, a gastroenterologist, a radiologist, an internist, a dietician and 
an epidemiologist and statistician. The evidence on treatment on some parts of diverticular 
disease is still scarce, leading to treatment strategies mainly being guided by the doctors 
personal preference. Although younger patients have a higher risk of recurrent disease 
there is not an increased risk of complications compared to older patients. 
The triad of pain in the lower left abdomen on physical examination, the absence of 
vomiting and a C-reactive protein >50 mg/l has a high predictive value to diagnose acute 
colonic diverticulitis. If this triad is present and there are no signs of complicated disease, 
patients may be withheld from further imaging. If imaging is indicated, ultrasound is 
the first modality of choice. Only after a negative or inconclusive ultrasound CT scan is 
advised. 
Processed on: 22-2-2017
507513-L-bw-Mulder
212
Chapter 13
The optimal treatment strategy depends on the degree of peritonitis. In general, patients 
with Hinchey 1 and 2 diverticulitis can be treated conservatively with fluids, analgesics, and 
antibiotics, with or without percutaneous drainage of abscesses. There is no indication for 
routine endoscopic examination after an episode of uncomplicated diverticulitis. 
There is no evidence for the routine administration of antibiotics in patients with clinically 
mild uncomplicated diverticulitis. Pericolic or pelvic abscesses can initially be treated with 
antibiotic therapy or combined with percutaneous drainage. If conservative treatment 
fails, emergency surgical intervention is indicated, in which resection with primary 
anastomosis is preferred above Hartmann’s procedure. The performance of a diverting 
loop-ileostomy to protect the anastomosis should be considered, especially in patients 
with a number of comorbidity factors.
In the last decades non-resectional treatment with laparoscopic lavage has increased 
in popularity for treating Hinchey 3 diverticulitis. Initial results showed morbidity and 
mortality rates <5%. The results of randomised controlled trials comparing laparoscopic 
lavage with resectional strategies were not included in this guideline because the trials 
were still recruiting patients. 
In Chapter 8 a rat model in a contaminated environment was presented. In 144 rats we 
compared seven intraperitoneally placed meshes on infectious complications, adhesion 
formation, incorporation and shrinkage after a follow-up of 28 or 90 days. Significantly 
more mesh infections were found after implantation of C-Qur (94%) and Dualmesh (47%). 
Sepramesh showed a significant increase in adhesion coverage from 12.5% at 28 days 
to 60% at 90 days. At 90 days there was no difference in adhesion formation between 
the synthetic meshes (35-73%). After 90 days the adhesion coverage of the biological 
Strattice mesh was 5%, and incorporation (13%) was significantly poorer than for other 
meshes. Dualmesh showed shrinkage of 63% after 90 days. 
This experimental results of synthetic mesh implantation in a contaminated environment 
make strict contraindication in humans questionable. Although there are no meshes 
without disadvantages, certain synthetic meshes might be somewhat more infection-
resistant and therefore useful for permanent hernia repair in a contaminated environment.
In Chapter 9 infectious complications and functional outcome of four biological meshes 
were investigated in 90 rats. Meshes were implanted in a contaminated environment 
and outcomes were measured after 90 or 180 days. More mesh infections occurred in 
crosslinked meshes compared with non-crosslinked meshes (70% vs 4%). Incorporation 
into the abdominal wall was poor in all meshes ranging from 0% to 39%. After 180 days 
no residue of non-crosslinked Surgisis mesh was found. After 180 days, shrinkage was 
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0.8% in crosslinked Permacol and 20% in non-crosslinked Strattice. Strattice showed the 
least adhesion formation (5%). 
In conclusion, this experiment demonstrates a high infection rate and increased adhesion 
formation of crosslinked biological meshes. Resistance to infection of non-crosslinked 
Strattice could allow implantation in the contaminated environment. However, the poor 
incorporation of all biological meshes and complete degradation of Surgisis makes long-
term biomechanical strength of hernia repair questionable. Implantation of biological 
prostheses could be a valid choice in staged contaminated abdominal wall repair. The 
high costs of a biological mesh can be justified by prevention of mesh infection which 
is associated with high costs for intensive care treatment, reoperation, and prolonged 
hospital stay.
In Chapter 10 four biological meshes implanted in a non-contaminated environment 
were compared after 90 or 180 days. In 64 rats infectious complications, incorporation, 
shrinkage and adhesion formation were investigated. High numbers of infectious 
complications were observed: 13% transcutaneous prosthesis migration and 23% 
macroscopic mesh infection. Incorporation of meshes was poor (0% to 37%) after 180 
days. Shrinkage did not differ between the meshes after 180 days. After 90 days Surgisis 
had the highest adhesion score (90%). Adhesions covering the mesh was least in Strattice 
(5%). 
We advocate more caution with implantation of biological meshes for abdominal wall 
repair. There seems to be no evidence for previously purported hypothesis that biological 
material enables ingrowth of cells and vessels resulting in a sustainable hernia repair. 
Implantation of biological mesh does not seem to reduce infection rate which is a 
significant riskfactor for the recurrence of incisional hernia. Biological meshes might not 
have the required characteristics for implantation in clean environment with high infection 
rate and low incorporation of the mesh in the current experiment. 
In Chapter 11 the influence of a new adhesion barrier on adhesion formation was 
investigated in a peritonitis rat model in 40 rats. Application of the anti-adhesive barrier, 
polyvinyl alcohol and carboxymethylcellulose hydrogel, resulted in fewer adhesions than 
in the control group. Additionally the tenacity of the adhesions was lower when the barrier 
was applied. There was no difference in amount and size of intra-abdominal abscesses 
between the study groups. 
Polyvinyl alcohol and carboxymethylcellulose hydrogel demonstrated promising efficacy 
in this experiment. Therefore further investigation of this product is needed focusing on 
its safety when applied around an intestinal anastomosis and in the presence of synthetic 
material such as intra-abdominally placed meshes. 
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Chapter 14
Dit proefschrift richt zich op de behandeling van intra-abdominale infecties en complicaties 
volgend op de behandeling van intra-abdominale infecties. 
In hoofdstuk 2 onderzochten wij de waarde van preoperatieve stadiering van 
geperforeerde diverticultis door middel van Computertomographie (CT) scan in een 
retrospectieve studie. De CT bevindingen werden vergeleken met de peroperatieve 
bevindingen en geclassificeerd volgens de Hinchey classificatie. De studie laat zien dat 
de positief voorspellende waarde van de preoperatieve CT scan varieerde tussen de 
45 en 89% voor verschillende stadia van diverticulitis. De diagnostische accuraatheid 
varieerde tussen de 71 en 92%. Er was een duidelijke onderstadiëring bij patiënten met 
Hinchey 3 diverticulitis, 42% van de patiënten werden onjuist geclassificeerd als Hinchey 
1 of 2. De aanwezigheid van een grote hoeveelheid vrij lucht en vocht intra-abdominaal 
was sterk geassocieerd met Hinchey 3 en 4. 
Daarom concluderen wij dat de huidige CT scans niet voldoen om de ernst van 
geperforeerde diverticulitis volgens de Hinchey classificatie te voorspellen. Een nieuw 
gradatie systeem is nodig om richting te geven aan de behandeling van patiënten met 
diverticulitis.
In hoofdstuk 3 werd een overzicht gegeven van behandelopties voor geperforeerde 
diverticulitis. Historisch gezien is de meest uitgevoerde chirurgische behandeling de 
sigmoidresectie met aanleg eindstandig colostoma, ook wel de Hartmann procedure 
genoemd. Echter, deze behandeling leidt tot hoge percentages permanente stoma´s. 
Verbetering in de intensive care behandeling en chirurgische technieken hebben geleid 
tot een toenemend aantal patiënten die behandeld worden met primaire anastomose 
in plaats van een colostoma. Door angst voor lekkage van de anastomose wordt deze 
behandeling voornamelijk uitgevoerd bij jonge en gezonde patiënten zonder fecale 
peritonitis. In deze groep patiënten met purulente perionitis zou laparoscopische lavage 
van het abdomen met drainage een alternatieve behandelstrategie kunnen zijn. 
In hoofdstuk 4 worden de resultaten van een retrospectieve studie over de eerste resultaten 
met laparoscopische lavage bij patiënten met purulente diverticulitis gepresenteerd. 
Laparoscopische behandeling werd succesvol uitgevoerd in de meerderheid van de 
patiënten, conversie naar laparotomie was in 3% noodzakelijk. Laparoscopische lavage 
was geassocieerd met een morbiditeit van 32%, en een snel herstel als de sepsis succesvol 
werd gecontroleerd wat het geval was bij 81,5% van de patiënten. Patiënten bij wie lavage 
niet succesvol was hadden meer comorbiditeiten, aan hogere preoperatieve C-reactief 
proteine concentratie en een hogere Mannheim Peritonitis Index. Na succesvolle 
laparoscopische lavage ondergingen 10% van de patiënten een sigmoid resectie 
vanwege recidief diverticulitis tijdens de follow-up periode. Operatieve behandeling voor 
geperforeerde diverticulitis door middel van laparoscopische lavage was mogelijk in de 
Processed on: 22-2-2017
507513-L-bw-Mulder
217
Samenvatting
14
meerderheid van de patiënten, maar identificatie van duidelijke sigmoid perforatie en 
patiënt selectie zijn van cruciaal belang voor een succesvolle behandeling. 
In hoofdstuk 5 werd het protocol gepresenteerd van een grote gerandomiseerde 
multicenter trial naar de behandeling van geperforeerde diverticulitis, de LADIES 
trial. Deze trial onderzocht de morbiditeit en mortaliteit in patiënten met purulente 
en fecale gegeneraliseerde peritonitis na behandeling door 3 operatieve strategiën: 
laparoscopische lavage en drainage, sigmoidresectie met primaire anastomose en de 
Hartmann procedure.
Het was een 5-armige trial: patiënten met purulente peritonitis werden 2:1:1 
gerandomiseerd voor laparoscopische lavage, Hartmann procedure of sigmoidresectie 
met primaire anastomose. Het doel van de LOLA trial was aantonen dat laparoscopische 
lavage zou leiden tot een reductie van 15% in ernstige morbiditeit en mortaliteit vergeleken 
met sigmoid resectie. Patiënten met fecale peritonitis werden 1:1 gerandomiseerd 
tusssen Hartmann procedure en sigmoid resectie met primaire anastomose. Alle 
patiënten die een sigmoid resectie ondergingen (zowel purulente als fecale peritonitis) 
werden geanalyseerd in de DIVA trial. Deze analyse had als doel bewijzen dat Hartmann 
procedure en sigmoidresectie met anastomose zouden leiden tot een gelijke mortaliteit na 
12 maanden, maar een 30% hogere stoma vrije overleving voor de patiënten behandeld 
met een sigmoid resectie met primaire anastomose. 
In hoofdstuk 6 bediscussierden we de resultaten van de LOLA arm van de LADIES trial. 
De belangrijkste conclusie was dat laparoscopische lavage voor purulente diverticulitis de 
ernstige morbiditeit en mortaliteit niet verminderde in vergelijking met sigmoidresectie 
na 12 maanden follow-up. Een hogere re-interventie percentage werd gevonden in 
patiënten na laparoscopische lavage (39%) vergeleken met sigmoidresectie (19%). 
Echter, 76% van de patiënten behoefde geen verdere chirurgische interventie tijdens 
hun primaire ziekenhuisopname. Er was geen verschil in behandel groepen wat betreft 
stoma vrije overleving in de levende patiënten na 12 maanden (78% lavage groep, 71% 
sigmoidectomie groepen), maar in de lavage groep had 74% nooit een stoma gehad. 
In hoofdstuk 7 werd een overzicht gepresenteerd met het beschikbare wetenschappelijke 
bewijs gecombineerd met expert mening in een richtlijn voor diagnose en behandeling van 
diverticulitis. De richtlijn werd geschreven onder leiding van de Nederlandse Vereniging 
voor Heelkunde. De werkgroep bestond uit vier chirurgen, een MDL arts, een radioloog, 
een internist, een diëtist en een epidemioloog en statitiscus. Het wetenschappelijke 
bewijs voor behandeling van sommige delen van diverticulitis is nog steeds spaarzaam, 
hierdoor wordt behandeling vooral beinvloed door de persoonlijke voorkeur van de 
dokter. Jongere patiënten hebben een hoger risico of terugkeer van klachten, maar geen 
hoger risico op complicaties dan oudere patiënten. 
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Aanwezigheid van pijn links onder in de buik bij lichamelijk onderzoek, de afwezigheid 
van braken en een C-reactive protein > 50 mg/ml heeft een hoge voorspellende waarde 
bij de diagnose van acute diverticulitis van het colon. Als deze 3 onderdelen samen 
aanwezig zijn en er zijn geen aanwijzingen voor gecompliceerde ziekte kan bij deze 
patiënten verder afbeeldend onderzoek achterwegen gelaten worden. Als afbeeldend 
onderzoek geindiceerd is, is echografie de modaliteit van eerste keus. Alleen na een 
negatieve of inconclusieve echo wordt een CT-scan geadviseerd. 
De optimale behandelstrategie is afhankelijk van de ernst van de peritonitis. In het 
algemeen kunnen patiënten met Hinchey 1 en 2 diverticulitis conservatief behandeld 
worden met toediening van intraveneuze vloeistof, pijnstilling en soms antibiotica met of 
zonder percutane drainage van abcessen. Er is geen indicatie voor routine endoscopisch 
onderzoek na een episode van ongecompliceerde diverticulitis. 
Er is geen bewijs voor routine toediening van antibiotica in patienten met klinisch 
mild verlopende ongecompliceerde diverticulitis. Abcessen pericolisch of in het kleine 
bekken kunnen initieel behandeld worden met antibiotische therapie of gecombineerd 
worden met percutane drainage. Als conservatieve therapie faalt is chirurgische spoed 
interventie geïndiceerd, waarbij resectie met primaire anastomose te prefereren is boven 
Hartmann’s procedure. De aanleg van een deviërend loop-ileostoma om de anastomose 
te beschermen moet overwogen worden, met name in patiënten met meerdere 
comorbiditeiten. 
In de laatste decaden is behandeling zonder resectie middels laparoscopische lavage 
populairder geworden voor behandeling van Hinchey 3 diverticulitis. Initiële resultaten 
toonden morbiditeit en mortaliteits percentages van minder dan 5%. De resultaten van 
gerandomiseerde klinische trials waarin laparoscopische lavage wordt vergeleken met 
resectie waren niet meegenomen in deze richtlijn omdat de trials niet waren afgerond en 
nog patiënten includeerden. 
In hoofdstuk 8 werd een diermodel in een gecontamineerde omgeving gepresenteerd. 
In 144 ratten vergeleken we zeven intraperitoneaal geplaatste meshes op infectieuze 
complicaties, adhesie vorming, ingroei en krimp na een follow-up van 28 of 90 dagen. 
Significant meer mesh infecties werden gevonden na implantatie van C-Qur (94%) en 
Dualmesh (47%). Sepramesh toonde een significante toename in bedekking van de mesh 
met adhesies van 12.5% na 28 dagen naar 60% na 90 dagen. Na 90 dagen was er geen 
verschil in adhesie vorming tussen de synthetische meshes (35-73%). Na 90 dagen was 
de bedekking van de mesh van de biologische Strattice mesh slechts 5%, maar ingroei 
(13%) was significant slechter dan andere meshes. Dualmesh toonde krimp van 63% na 
90 dagen. 
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Deze experimentele resultaten van synthetische mesh implantatie in gecontamineerde 
omgeving maken strikte contra-indicatie in mensen discutabel. Ondanks dat er geen 
meshes bestaan zonder nadelen, zekere synthetische meshes zijn mogelijk meer infectie-
resistent dan anderen en daarom nuttig bij gebruik van permanent hernia herstel in 
gecontamineerde omgeving. 
In hoofdstuk 9 werden infectieuze complicaties en functionele uitkomsten van 
vier biologische meshes onderzocht in 90 ratten. Meshes werden geïmplanteerd in 
gecontamineerde omgeving en uitkomsten werden gemeten na 90 of 180 dagen. Er 
kwamen meer mesh infecties voor in crosslinked meshes in vergelijking met non-
crosslinked meshes (70% vs 4%). Ingroei in de buikwand was slecht in alle meshes 
variërend van 0% tot 39%. Na 180 dagen kon geen residue worden aangetoond van non-
crosslinked Surgisis mesh. Na 180 dagen was krimp 0.8% in crosslinked Permacol en 20% 
in non-crosslinked Strattice. Strattice had de minste adhesie formatie (5%). 
Concluderend heeft dit experiment hoge infectie percentages en toegenomen adhesie 
vorming aangetoond in crosslinked biologische meshes. Weerstand tegen infectie zou 
implantatie van non-crosslinked Strattice mogelijk maken in gecontamineerde omgeving. 
Echter, de slechte ingroei van alle biologische meshes en complete verdwijning van 
Surgisis maken lange termijn biomechanische kracht van hernia herstel twijfelachtig. 
Implantatie van biologische protheses kunnen een goede keus zijn bij gecontamineerd 
buikwandherstel in meerdere fasen. De hoge kosten van een biologische mesh kunnen 
worden gerechtvaardigd door preventie van mesh infectie wat is geassocieerd met hoge 
kosten voor intensive care behandeling, reoperatie en verlengde opnameduur. 
In hoofdstuk 10 werden vier biologische meshes geïmplanteerd in niet-gecontamineerde 
omgeving en vergeleken na 90 of 180 dagen. In 64 ratten werden infectieuze complicaties, 
ingroei, krimp en adhesie vorming onderzocht. Er werden veel infectieuze complicaties 
aangetoond: 13% transcutane migratie van de prothese en 23% macroscopisch mesh 
infectie. Ingroei van de meshes was slecht (0% tot 37%) na 180 dagen. Krimp was niet 
verschillend tussen de meshes na 180 dagen. Na 90 dagen had Surgisis de hoogste 
adhesie score (90%). Strattice had de minste adhesies die de mesh bedekten (5%). 
We pleiten voor meer terughoudendheid bij implantatie van biologische meshes 
voor buikwand herstel. Er lijkt geen bewijs te zijn voor eerder geopperde hypotheses 
dat biologisch materiaal ingroei van cellen en bloedvaten mogelijk maakt leidend tot 
een duurzaam hernia herstel. Implantatie van biologische mesh reduceerd het infectie 
percentage niet wat een significante risicofactor is voor terugkeer van de buikwandbreuk. 
Biologische meshes bezitten mogelijk niet de benodigde karakteristieken voor implantatie 
in schone omgeving gezien het hoge infectie percentage en weinig ingroei van de mesh 
in het huidige experiment. 
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In hoofdstuk 11 onderzochten we de invloed van een nieuwe adhesie barrière op 
adhesie vorming in een peritonitis rat model in 40 ratten. Aanbrengen van de anti-
adhesie barrière, polyvinyl alcohol en carboxymethylcellulose hydrogel, resulteerde in 
minder adhesies dan in de controle groep. Daarbij was de sterkte van de adhesies minder 
wanneer de barrière gel was aangebracht. Er was geen verschil in aantal en grootte van 
intra-abdominale abcessen tussen de studie groepen. 
Polyvinyl alcohol en carboxymethylcellulose hydrogel toonde veelbelovende effectiviteit 
in dit experiment. Daarom is verder onderzoek van dit product nodig met aandacht voor 
de veiligheid bij aanbrenging rondom een intestinale anastomose en in de aanwezigheid 
van synthetisch materiaal zoals intra-abdominaal geplaatste meshes. 
Processed on: 22-2-2017
507513-L-bw-Mulder
221
Samenvatting
14
Processed on: 22-2-2017
507513-L-bw-Mulder
5ChAPTeR
Processed on: 22-2-2017
507513-L-bw-Mulder
List of Publications
Curriculum Vitae
PhD Portfolio
Dankwoord
Processed on: 22-2-2017
507513-L-bw-Mulder
224
Chapter 15
LIST OF PUBLICATIONS
Ladies Trial: laparoscopic peritoneal lavage or resection for purulent peritonitis and 
Hartmann’s procedure or resection with anastomosis for purulent or faecal peritonitis in 
perforated diverticulitis. 
Dutch Diverticular Disease (3D) Collaborative Study Group. 
BMC Surgery 2010 Oct 18; 10: 29
Treatment options for perforated colonic diverticular disease.
Irene M Mulder, Jefrey Vermeulen 
CML – Gastroenterology 2011; 30(3): 77–84.
‘Chapter 10: Laparoscopic Hernia Repair’.
EB Deerenberg, IM Mulder and JF Lange
Updated Topics in Minimally Invasive Abdominal Surgery (2011). Ed. ElGeidie. ISBN: 978-
953-307-773-4, InTech
‘Chapter 5: Peptic Ulcer Bleeding: Surgery and Radiology’. 
IM Mulder, EJ Kuipers, JF Lange
Gastrointestinal bleeding (2012). Ed. JJY Sung, ISBN 9781405195553, Wiley-Blackwell
Systematic review of trocar-site hernia.
HA Swank, IM Mulder, CF LaChapelle, JB Reitsma, JF Lange, WA Bemelman 
British Journal of Surgery 2012 Mar; 99(3): 315-323 
Postoperative adhesion prevention with a new barrier: an experimental study. 
M Ditzel, EB Deerenberg, N Komen, IM Mulder, J Jeekel, JF Lange. 
European Surgical Research 2012; 48(4): 187-193. 
Preoperative staging of perforated diverticulitis by computed tomography scanning. 
MP Gielens, IM Mulder, E van der Harst, MP Gosselink, KJ Kraal, HT Teng, JF Lange, J 
Vermeulen. 
Techniques in Coloproctology 2012 Oct; 16(5): 363-368. 
Polyvinyl alcohol hydrogel prevents formation of adhesions in a rat model of peritonitis .
IM Mulder, EB Deerenberg, M Ditzel, JC Slieker, WA Bemelman, J Jeekel, JF Lange. 
Surgical Infections 2012; 13(5): 321-325
Processed on: 22-2-2017
507513-L-bw-Mulder
225
List of publications
15
Experimental study on synthetic and biological mesh implantation in a contaminated 
environment. 
IM Mulder, EB Deerenberg, N Grotenhuis, M Ditzel, J Jeekel, JF Lange. 
British Journal of Surgery 2012 Dec; 99(12): 1734-1741
Effects of new anti-adhesion polyvinyl alcohol gel on healing of colon anastomoses in 
rats. 
JC Slieker, M Ditzel, JJ Harlaar, IM Mulder, EB Deerenberg, YM Bastiaansen-Jenniskens, 
GJ Kleinrensink, J Jeekel, JF Lange. 
Surgical Infections 2012 Dec; 13(6): 396-400. 
Systematic review of the technique of colorectal anastomosis. 
JC Slieker, F Daams, IM Mulder, J Jeekel, JF Lange.
JAMA Surgery 2013 Feb; 148(2): 190-201.
Early experience with laparoscopic lavage for perforated diverticulitis. 
HA Swank, IM Mulder, AG Hoofwijk, SW Nienhuijs, JF Lange, WA Bemelman; Dutch 
Diverticular Disease (3D) Collaborative Study Group. 
British Journal of Surgery 2013 Apr; 100(5): 704-710. 
Guidelines of diagnostics and treatment of acute left-sided colonic diverticulitis.
CS Andeweg, IM Mulder, RJ Felt-Bersma, A Verbon, GJ van der Wilt, H van Goor, JF 
Lange, J Stoker, MA Boermeester, RP Bleichrodt. 
Digestive Surgery 2013 Aug 20; 30(4-5): 278-292 
Routine histopathology for carcinoma in cholecystectomy specimens not evidence based: 
a systematic review. 
HA Swank, IM Mulder, WC Hop, MJ van de Vijver, JF Lange, WA Bemelman. 
Surgical Endoscopy 2013 Dec; 27(12): 4439-4448
In vitro model to study the biomaterial-dependent reaction of macrophages in an 
inflammatory environment.
N Grotenhuis, HF vd Toom, N Kops, Y Bayon, EB Deerenberg, IM Mulder, GJ van Osch, 
JF Lange, YM Bastiaansen-Jenniskens.
British Journal of Surgery 2014 Jul; 101(8): 983-992
Processed on: 22-2-2017
507513-L-bw-Mulder
226
Chapter 15
The prevention of colorectal anastomotic leakage with tissue adhesives in a contaminated 
environment is associated with the presence of anti-inflammatory macrophages. 
Z Wu, KA Vakalopoulos, GSA Boersema, LF Kroese, KH Lam, PH Van der Horst, IM 
Mulder, GJ Kleinrensink, J Jeekel, JF Lange. 
International Journal of Colorectal Disease 2014 Dec; 29(12): 1507-1516
Infection susceptibility of crosslinked and non-crosslinked biological meshes in an 
experimental contaminated environment.
IM Mulder, EB Deerenberg, WA Bemelman, J Jeekel, JF Lange. 
American Journal of Surgery 2015 Jul; 210 (1): 159-166
Laparoscopic peritoneal lavage or sigmoidectomy for perforated diverticulitis with 
purulent peritonitis: a multicentre, parallel-group, randomised, open-label trial.
S Vennix, GD Musters, IM Mulder, HA Swank, EC Consten, EJ Belgers, AA van Geloven, 
MF Gerhards, MJ Govaert, WM van Grevenstein, AG Hoofwijk, PM Kruyt, SW Nienhuijs, 
MA Boermeester, S van Dieren, JF Lange, WA Bemelman. 
The Lancet 2015 Sept 26; 386: 1269-1277
Problematic incorporation of biological meshes in ventral hernia repair during long-term 
follow-up
IM Mulder, EB Deerenberg, WA Bemelman, JF Lange. 
Submitted 
Biomaterial-specific inflammatory cell responses in a contaminated environment in vivo 
in rats.
N Grotenhuis, EB Deerenberg, IM Mulder, N Kops, GJVM Van Osch, YM Bastiaansen-
Jenniskens, JF Lange. 
Submitted 
Processed on: 22-2-2017
507513-L-bw-Mulder
227
List of publications
15
Processed on: 22-2-2017
507513-L-bw-Mulder
228
Chapter 15
Processed on: 22-2-2017
507513-L-bw-Mulder
229
Curriculum Vitae
15
CURRICULUM VITAe
Irene Maria Mulder werd op 14 Augustus 1984 geboren in Nieuwland. In 2002 begon 
zij met haar studie Geneeskunde aan de Erasmus Universiteit in Rotterdam. Tijdens haar 
studie ging zij 4 weken naar Finland voor keuzeonderwijs (Intensive care geneeskunde) 
aan de Univeristy Hospital of Turku. Voor haar keuzeonderzoek ging zij 7 maanden naar 
het Westmead’s Childrens Hospital in Sydney, Australië (Pediatric Intensive care). In 
mei 2009 behaalde zij haar artsdiploma en en begon als arts-assistent chirurgie in het 
Tweesteden ziekenhuis in Tilburg (opleider dr. S. Kranendonk). 
In maart 2010 startte zij als arts-onderzoeker in het Erasmus Medisch Centrum met de 
coördinatie van de Ladies trial onder begeleiding van professor J.F. Lange en professor 
W.A. Bemelman. De onderzoeken naar de optimale behandeling van diverticulitis en 
complicaties na abdominale infectie uitgevoerd tijdens deze periode hebben geleid tot 
dit proefschrift. Na haar tijd als fulltime onderzoeker heeft zij een jaar als arts-assistent 
chirurgie gewerkt in het Slotervaart Ziekenhuis in Amsterdam (opleider dr. B.J. Dwars). 
Daarna is zij januari 2014 begonnen aan haar opleiding tot chirurg in het Rode Kruis 
ziekenhuis in Beverwijk (opleiders dr. H.A. Cense en professor D.L. van der Peet).
Processed on: 22-2-2017
507513-L-bw-Mulder
230
Chapter 15
PhD PORTFOLIO
Name PhD student:  I.M. Mulder PhD period:  2010 – 2016
Erasmus MC Department:  Surgery  Promotors: Prof. Dr. J.F. Lange
                  Prof. Dr. W.A. Bemelman
1. PhD training      year  Workload
General courses         (eCTS)
Laboratory animal science     2010  3.0 
BROK (‘Basiscursus Regelgeving Klinisch Onderzoek’  2010  1.0
Seminars and workshops
Journal club      2010-2012 3.0
Teach the aios       2011   0.2
Ventrale hernia: open en laparoscopisch hernia herstel 2011   0.5
Round table Bard      2011   0.2
Precourse RICH 2012     2012  0.5
Presentations
Oral presentation Stafdag Heelkunde Erasmus MC  2010  1.0
Poster presentation SEOHS Rotterdam   2010  0.5
Oral presentations ESSR Aachen    2011  2.0
Oral presentation NVGIC dagen    2011  1.0
Oral presentation SEOHS Amsterdam   2011  1.0
Oral presentation RICH Rotterdam    2012  1.0
Oral presentation AHS New York    2012  1.0
Poster presentation AHS New York    2012  0.5
Oral presentations ‘voorjaarsvergadering’ NvVH Veldhoven 2012  2.0
(Inter)national conferences
SEOHS       2010-2015 1.5
NVGIC themadag     2010-2011 1.0
Chirurgendagen Veldhoven     2010-2016 3.0
EHS Gent      2011  0.5
ESSR Aachen      2011  1.0
RICH Rotterdam      2012  0.5
AHS New York      2012  1.0
Processed on: 22-2-2017
507513-L-bw-Mulder
231
PhD Portfolio
15
2. Teaching        
Lecturing
College Geneeskunde jaar 1: Casus “Dokter, ik ben zo moe…”2010-2012 1.0
College Ouderdag; anatomie van transplantatieorganen 2011  0.5
Supervising practicals and excursions, Tutoring
Examination of Basic Life Support (EHBO) of medical students 2010-2012 1.0
Processed on: 22-2-2017
507513-L-bw-Mulder
232
Chapter 15
DANkWOORD
Promotoren Johan Lange en Willem Bemelman, bedankt voor uw vertrouwen en vele 
onderzoeksideeën die geleid hebben tot dit proefschrift.
Copromotor hans Jeekel, bedankt voor al uw adviezen.
Promotiecommissie professor Bruno, professor Boermeester en professor van eijck, 
bedankt voor uw bereidheid om zitting te nemen in mijn promotiecommissie.
Rotterdamse laboratorium maatje eva Deerenberg, bedankt voor vele uren gezelligheid 
in het lab en dat je mij wilt bijstaan als paranimf.
Amsterdamse onderzoeks collega (a.k.a. ‘partner in trial’) hilko Swank, bedankt voor een 
fijne samenwerking en een vliegende onderzoeksstart.
Alle patiënten, chirurgen, arts-assistenten en verpleegkundigen, bedankt voor jullie 
participatie en inzet voor de Ladies-trial.
Mede-auteurs van de verrichte studies, bedankt voor jullie bijdrage aan dit proefschrift.
Onderzoekers in het Erasmus MC en het AMC, bedankt voor vele verjaardagstaartjes en 
uitwisselen van onderzoekservaringen.
Collega’s en chirurgen in het Slotervaart Ziekenhuis en het Rode Kruis Ziekenhuis, 
bedankt voor de leerzame tijd en gezellige uitjes.
Fantastische zus els Mulder, bedankt dat ik vaak in je voetstappen heb mogen volgen en 
dat je naast mij wil staan als paranimf.
Creatieve broer Roel Mulder, bedankt voor je hulp met de voorkant van mijn proefschrift. 
Papa en Mama, bedankt voor jullie motivering en liefdevolle steun.
Mijn allerliefste ewoud, bedankt voor de grapjes die het leven met jou zo leuk maken en 
af en toe een schop onder mijn kont om ‘dat boekje’ nu echt af te maken.
Processed on: 22-2-2017
507513-L-bw-Mulder
233
Dankwoord
15
Processed on: 22-2-2017
507513-L-bw-Mulder

Iren
e m
u
ld
er
New ApproAches to the  
surgicAl treAtmeNt of  
iNtrA-AbdomiNAl iNfectioN
Irene mulder
uitnodiging
voor het bijwonen van de
openbare verdediging van
het proefschrift:
new ApproAches 
to the surgicAl 
treAtment of  
intrA-AbdominAl 
infection
door
Irene Mulder
woensdag 29 maart 2017  
om 9.30 uur
Prof. Andries Queridozaal
Onderwijscentrum, Eg-370
Erasmus MC (faculteit)
Dr. Molewaterplein 50
3015 GE Rotterdam
Receptie ter plaatse na afloop 
van de plechtigheid
Paranimfen
Eva Deerenberg
Els Mulder
n
ew
 A
ppro
A
c
h
es to
 th
e su
rg
Ic
A
l treAtm
en
t o
f In
trA
-A
bd
o
m
In
A
l In
fec
tIo
n
Iren
e m
u
ld
er
e      
s r i l    
iNtrA- b i l i i
Irene ulder
i i i
voor het bij onen van de
openbare verdediging van
het proefschrift:
  
  i  
   
i - i  
i i
r
Ir  l
oens a   rt   
 .  r
Prof. ri s ri l
nder ijsc tr , -
Eras s  (f lt i
r. l t r l i  
301   tt r
Receptie t r l t   fl  
va   l ti i
r i f
Eva r r
Els l r
n
ew
 A
ppro
A
c
h
es to
 th
e su
rg
Ic
A
l treAtm
en
t o
f In
trA
-A
bd
o
m
In
A
l In
fec
tIo
n
